Congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
a	O
new	O
deletion	O
in	O
the	O
sodium	O
/	O
iodide	O
symporter	O
protein	O
.	O
	
OBJECTIVE	O
:	O
Iodide	B-Disease
transport	I-Disease
defect	I-Disease
(	O
ITD	B-Disease
)	O
is	O
a	O
rare	O
disorder	O
characterised	O
by	O
an	O
inability	B-Disease
of	I-Disease
the	I-Disease
thyroid	I-Disease
to	O
maintain	O
an	O
iodide	O
gradient	O
across	O
the	O
basolateral	O
membrane	O
of	O
thyroid	O
follicular	O
cells	O
","	O
that	O
often	O
results	O
in	O
congenital	B-Disease
hypothyroidism	I-Disease
.	O
	
When	O
present	O
the	O
defect	O
is	O
also	O
found	O
in	O
the	O
salivary	O
glands	O
and	O
gastric	O
mucosa	O
and	O
it	O
has	O
been	O
shown	O
to	O
arise	O
from	O
abnormalities	O
of	O
the	O
sodium	O
/	O
iodide	O
symporter	O
(	O
NIS	O
).	O
	
PATIENT	O
:	O
We	O
describe	O
a	O
woman	O
with	O
hypothyroidism	B-Disease
identified	O
at	O
the	O
3rd	O
month	O
of	O
life	O
.	O
	
The	O
diagnosis	O
of	O
ITD	B-Disease
was	O
suspected	O
because	O
of	O
nodular	B-Disease
goitre	I-Disease
","	O
and	O
little	O
if	O
any	O
iodide	O
uptake	O
by	O
the	O
thyroid	O
and	O
salivary	O
glands	O
.	O
	
Treatment	O
with	O
iodide	O
partially	O
corrected	O
the	O
hypothyroidism	B-Disease
;	O
however	O
","	O
long	O
-	O
term	O
substitution	O
therapy	O
with	O
L	O
-	O
thyroxine	O
was	O
started	O
.	O
	
MEASUREMENTS	O
:	O
Thyroid	O
radioiodide	O
uptake	O
was	O
only	O
1	O
.	O
4	O
%	O
and	O
0	O
.	O
3	O
%	O
at	O
1	O
and	O
24	O
h	O
after	O
the	O
administration	O
of	O
recombinant	O
human	O
TSH	O
.	O
	
The	O
saliva	O
to	O
plasma	O
I	O
-	O
ratio	O
was	O
1	O
.	O
1	O
indicating	O
that	O
the	O
inability	O
of	O
the	O
thyroid	O
gland	O
to	O
concentrate	O
I	O
-	O
was	O
also	O
present	O
in	O
the	O
salivary	O
glands	O
.	O
	
RESULTS	O
:	O
Analysis	O
of	O
the	O
patient	O
'	O
s	O
NIS	O
gene	O
revealed	O
a	O
15	O
nucleotide	O
(	O
nt	O
)	O
deletion	O
of	O
the	O
coding	O
sequence	O
(	O
nt	O
1314	O
through	O
nt	O
1328	O
)	O
and	O
the	O
insertion	O
of	O
15	O
nt	O
duplicating	O
the	O
first	O
15	O
nt	O
of	O
the	O
adjacent	O
intron	O
.	O
	
The	O
patient	O
was	O
homozygous	O
for	O
this	O
insertion	O
/	O
deletion	O
","	O
while	O
both	O
consanguineous	O
parents	O
were	O
heterozygous	O
.	O
	
This	O
deletion	O
predicts	O
the	O
production	O
of	O
a	O
protein	O
lacking	O
the	O
five	O
terminal	O
amino	O
acids	O
of	O
exon	O
XI	O
(	O
439	O
-	O
443	O
)	O
which	O
are	O
located	O
in	O
the	O
6th	O
intracellular	O
loop	O
.	O
	
COS	O
-	O
7	O
cells	O
transfected	O
with	O
a	O
vector	O
expressing	O
the	O
mutant	O
del	O
-(	O
439	O
-	O
443	O
)	O
NIS	O
failed	O
to	O
concentrate	O
iodide	O
","	O
suggesting	O
that	O
the	O
mutation	O
was	O
the	O
direct	O
cause	O
of	O
the	O
ITD	B-Disease
in	O
this	O
patient	O
.	O
	
CONCLUSION	O
:	O
In	O
conclusion	O
we	O
describe	O
the	O
first	O
Italian	O
case	O
of	O
congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
a	O
new	O
deletion	O
in	O
the	O
NIS	O
gene	O
.	O
	
Pallidal	O
stimulation	O
:	O
an	O
alternative	O
to	O
pallidotomy	O
?	O
	
A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	O
treatment	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	O
by	O
Laitinen	O
in	O
1985	O
.	O
	
Laitinen	O
'	O
s	O
procedure	O
improved	O
most	O
symptoms	O
in	O
drug	O
-	O
resistant	O
PD	B-Disease
","	O
which	O
engendered	O
wide	O
interest	O
in	O
the	O
neurosurgical	O
community	O
.	O
	
Another	O
lesioning	O
procedure	O
","	O
ventrolateral	O
thalamotomy	O
","	O
has	O
become	O
a	O
powerful	O
alternative	O
to	O
stimulate	O
the	O
nucleus	O
ventralis	O
intermedius	O
","	O
producing	O
high	O
long	O
-	O
term	O
success	O
rates	O
and	O
low	O
morbidity	O
rates	O
.	O
	
Pallidal	O
stimulation	O
has	O
not	O
met	O
with	O
the	O
same	O
success	O
.	O
	
According	O
to	O
the	O
literature	O
pallidotomy	O
improves	O
the	O
"	649	650	O	
on	O
"	652	653	O	
symptoms	O
of	O
PD	B-Disease
","	O
such	O
as	O
dyskinesias	B-Disease
","	O
as	O
well	O
as	O
the	O
"	706	707	O	
off	O
"	710	711	O	
symptoms	O
","	O
such	O
as	O
rigidity	B-Disease
","	O
bradykinesia	B-Disease
","	O
and	O
on	O
-	O
off	O
fluctuations	O
.	O
	
Pallidal	O
stimulation	O
improves	O
bradykinesia	B-Disease
and	O
rigidity	B-Disease
to	O
a	O
minor	O
extent	O
;	O
however	O
","	O
its	O
strength	O
seems	O
to	O
be	O
in	O
improving	O
levodopa	O
-	O
induced	O
dyskinesias	B-Disease
.	O
	
Stimulation	O
often	O
produces	O
an	O
improvement	O
in	O
the	O
hyper	B-Disease
-	I-Disease
or	I-Disease
dyskinetic	I-Disease
upper	O
limbs	O
","	O
but	O
increases	O
the	O
"	1032	1033	O	
freezing	O
"	1041	1042	O	
phenomenon	O
in	O
the	O
lower	O
limbs	O
at	O
the	O
same	O
time	O
.	O
	
Considering	O
the	O
small	O
increase	O
in	O
the	O
patient	O
'	O
s	O
independence	O
","	O
the	O
high	O
costs	O
of	O
bilateral	O
implants	O
","	O
and	O
the	O
difficulty	O
most	O
patients	O
experience	O
in	O
handling	O
the	O
devices	O
","	O
the	O
question	O
arises	O
as	O
to	O
whether	O
bilateral	O
pallidal	O
stimulation	O
is	O
a	O
real	O
alternative	O
to	O
pallidotomy	O
.	O
	
Carrier	O
frequency	O
of	O
mutation	O
657del5	O
in	O
the	O
NBS1	O
gene	O
in	O
a	O
population	O
of	O
Polish	O
pediatric	O
patients	O
with	O
sporadic	B-Disease
lymphoid	I-Disease
malignancies	I-Disease
.	O
	
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
NBS	B-Disease
)	O
is	O
a	O
human	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
characterized	O
by	O
genomic	O
instability	O
and	O
enhanced	O
cancer	B-Disease
predisposition	O
","	O
in	O
particular	O
to	O
lymphoma	B-Disease
and	O
leukemia	B-Disease
.	O
	
Recently	O
","	O
significantly	O
higher	O
frequencies	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Slavic	O
founder	O
NBS1	O
mutation	O
","	O
657del5	O
","	O
were	O
found	O
in	O
Russian	O
children	O
with	O
sporadic	B-Disease
lymphoid	I-Disease
malignancies	I-Disease
","	O
and	O
in	O
Polish	O
adults	O
with	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
lymphoma	I-Disease
(	O
NHL	B-Disease
).	O
	
In	O
addition	O
","	O
the	O
substitution	O
643C	O
>	O
T	O
(	O
R215W	O
)	O
has	O
also	O
been	O
found	O
in	O
excess	O
among	O
children	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
).	O
	
In	O
an	O
attempt	O
to	O
asses	O
the	O
contribution	O
of	O
both	O
mutations	O
to	O
the	O
development	O
of	O
sporadic	B-Disease
lymphoid	I-Disease
malignancies	I-Disease
","	O
we	O
analyzed	O
DNA	O
samples	O
from	O
a	O
large	O
group	O
of	O
Polish	O
pediatric	O
patients	O
.	O
	
The	O
NBS1	O
mutation	O
657del5	O
on	O
one	O
allele	O
was	O
found	O
in	O
3	O
of	O
270	O
patients	O
with	O
ALL	B-Disease
and	O
2	O
of	O
212	O
children	O
and	O
adolescents	O
with	O
NHL	B-Disease
;	O
no	O
carrier	O
was	O
found	O
among	O
63	O
patients	O
with	O
Hodgkin	B-Disease
lymphoma	I-Disease
(	O
HL	B-Disease
).	O
	
No	O
carriers	O
of	O
the	O
variant	O
R215W	O
were	O
detected	O
in	O
any	O
studied	O
group	O
.	O
	
The	O
relative	O
frequency	O
of	O
the	O
657del5	O
mutation	O
was	O
calculated	O
from	O
a	O
total	O
of	O
6	O
","	O
984	O
controls	O
matched	O
by	O
place	O
of	O
patient	O
residence	O
","	O
of	O
whom	O
42	O
were	O
found	O
to	O
be	O
carriers	O
(	O
frequency	O
=	O
0	O
.	O
6	O
).	O
	
In	O
the	O
analyzed	O
population	O
with	O
malignancies	B-Disease
","	O
an	O
increased	O
odds	O
ratio	O
for	O
the	O
occurrence	O
of	O
mutation	O
657del5	O
was	O
found	O
in	O
comparison	O
with	O
the	O
control	O
Polish	O
population	O
(	O
OR	O
range	O
1	O
.	O
48	O
-	O
1	O
.	O
85	O
","	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
18	O
-	O
2	O
.	O
65	O
).	O
	
This	O
finding	O
indicates	O
that	O
the	O
frequency	O
of	O
the	O
mutation	O
carriers	O
was	O
indeed	O
increased	O
in	O
patients	O
with	O
ALL	B-Disease
and	O
NHL	B-Disease
(	O
p	O
<	O
0	O
.	O
5	O
).	O
	
Nonetheless	O
","	O
NBS1	O
gene	O
heterozygosity	O
is	O
not	O
a	O
major	O
risk	O
factor	O
for	O
lymphoid	B-Disease
malignancies	I-Disease
in	O
childhood	O
and	O
adolescence	O
.	O
	
Segregation	O
of	O
a	O
M404V	O
mutation	O
of	O
the	O
p62	O
/	O
sequestosome	O
1	O
(	O
p62	O
/	O
SQSTM1	O
)	O
gene	O
with	O
polyostotic	O
Paget	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
of	I-Disease
bone	I-Disease
in	O
an	O
Italian	O
family	O
.	O
	
Mutations	O
of	O
the	O
p62	O
/	O
Sequestosome	O
1	O
gene	O
(	O
p62	O
/	O
SQSTM1	O
)	O
account	O
for	O
both	O
sporadic	O
and	O
familial	O
forms	O
of	O
Paget	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
of	I-Disease
bone	I-Disease
(	O
PDB	B-Disease
).	O
	
We	O
originally	O
described	O
a	O
methionine	O
-->	O
valine	O
substitution	O
at	O
codon	O
404	O
(	O
M404V	O
)	O
of	O
exon	O
8	O
","	O
in	O
the	O
ubiquitin	O
protein	O
-	O
binding	O
domain	O
of	O
p62	O
/	O
SQSTM1	O
gene	O
in	O
an	O
Italian	O
PDB	B-Disease
patient	O
.	O
	
The	O
collection	O
of	O
data	O
from	O
the	O
patient	O
'	O
s	O
pedigree	O
provided	O
evidence	O
for	O
a	O
familial	O
form	O
of	O
PDB	B-Disease
.	O
	
Extension	O
of	O
the	O
genetic	O
analysis	O
to	O
other	O
relatives	O
in	O
this	O
family	O
demonstrated	O
segregation	O
of	O
the	O
M404V	O
mutation	O
with	O
the	O
polyostotic	O
PDB	B-Disease
phenotype	O
and	O
provided	O
the	O
identification	O
of	O
six	O
asymptomatic	O
gene	O
carriers	O
.	O
	
DNA	O
for	O
mutational	O
analysis	O
of	O
the	O
exon	O
8	O
coding	O
sequence	O
was	O
obtained	O
from	O
22	O
subjects	O
","	O
4	O
PDB	B-Disease
patients	O
and	O
18	O
clinically	O
unaffected	O
members	O
.	O
	
Of	O
the	O
five	O
clinically	O
ascertained	O
affected	O
members	O
of	O
the	O
family	O
","	O
four	O
possessed	O
the	O
M404V	O
mutation	O
and	O
exhibited	O
the	O
polyostotic	O
form	O
of	O
PDB	B-Disease
","	O
except	O
one	O
patient	O
with	O
a	O
single	O
X	O
-	O
ray	O
-	O
assessed	O
skeletal	O
localization	O
and	O
one	O
with	O
a	O
polyostotic	B-Disease
disease	I-Disease
who	O
had	O
died	O
several	O
years	O
before	O
the	O
DNA	O
analysis	O
.	O
	
By	O
both	O
reconstitution	O
and	O
mutational	O
analysis	O
of	O
the	O
pedigree	O
","	O
six	O
unaffected	O
subjects	O
were	O
shown	O
to	O
bear	O
the	O
M404V	O
mutation	O
","	O
representing	O
potential	O
asymptomatic	O
gene	O
carriers	O
whose	O
circulating	O
levels	O
of	O
alkaline	O
phosphatase	O
were	O
recently	O
assessed	O
as	O
still	O
within	O
the	O
normal	O
range	O
.	O
	
Taken	O
together	O
","	O
these	O
results	O
support	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
the	O
M404V	O
mutation	O
in	O
the	O
p62	O
/	O
SQSTM1	O
gene	O
and	O
a	O
polyostotic	O
form	O
of	O
PDB	B-Disease
in	O
this	O
family	O
.	O
	
The	O
high	O
penetrance	O
of	O
the	O
PDB	B-Disease
trait	O
in	O
this	O
family	O
together	O
with	O
the	O
study	O
of	O
the	O
asymptomatic	O
gene	O
carriers	O
will	O
allow	O
us	O
to	O
confirm	O
the	O
proposed	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
to	O
evaluate	O
the	O
potential	O
use	O
of	O
mutational	O
analysis	O
of	O
the	O
p62	O
/	O
SQSTM1	O
gene	O
in	O
the	O
early	O
detection	O
of	O
relatives	O
at	O
risk	O
for	O
PDB	B-Disease
.	O
	
Two	O
distinct	O
mutations	O
at	O
a	O
single	O
BamHI	O
site	O
in	O
phenylketonuria	B-Disease
.	O
	
Classical	B-Disease
phenylketonuria	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	O
).	O
	
The	O
abolition	O
of	O
an	O
invariant	O
BamHI	O
site	O
located	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
PAH	O
gene	O
(	O
exon	O
7	O
)	O
led	O
to	O
the	O
recognition	O
of	O
two	O
new	O
point	O
mutations	O
at	O
codon	O
272	O
and	O
273	O
(	O
272gly	O
----	O
stop	O
and	O
273ser	O
----	O
phe	O
","	O
respectively	O
).	O
	
Both	O
mutations	O
were	O
detected	O
in	O
north	O
eastern	O
France	O
or	O
Belgium	O
and	O
occurred	O
on	O
the	O
background	O
of	O
RFLP	O
haplotype	O
7	O
alleles	O
.	O
	
The	O
present	O
study	O
supports	O
the	O
view	O
that	O
the	O
clinical	O
heterogeneity	O
in	O
PKU	B-Disease
is	O
accounted	O
for	O
by	O
the	O
large	O
variety	O
of	O
mutant	O
genotypes	O
associated	O
with	O
PAH	B-Disease
deficiencies	I-Disease
..	O
	
Association	O
of	O
DRD2	O
polymorphisms	O
and	O
chlorpromazine	O
-	O
induced	O
extrapyramidal	B-Disease
syndrome	I-Disease
in	O
Chinese	O
schizophrenic	B-Disease
patients	O
.	O
	
AIM	O
:	O
Extrapyramidal	B-Disease
syndrome	I-Disease
(	O
EPS	B-Disease
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	O
drugs	O
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	O
receptor	O
.	O
	
Recently	O
","	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	O
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	B-Disease
patients	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O
	
In	O
this	O
study	O
","	O
we	O
evaluate	O
the	O
role	O
DRD2	O
plays	O
in	O
chlorpromazine	O
-	O
induced	O
EPS	B-Disease
in	O
schizophrenic	B-Disease
patients	O
.	O
	
METHODS	O
:	O
We	O
identified	O
seven	O
SNP	O
(	O
single	O
nucleotide	O
polymorphism	O
)	O
(-	O
141Cins	O
>	O
del	O
","	O
TaqIB	O
","	O
TaqID	O
","	O
Ser311Cys	O
","	O
rs6275	O
","	O
rs6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	O
gene	O
in	O
146	O
schizophrenic	B-Disease
inpatients	O
(	O
59	O
with	O
EPS	B-Disease
and	O
87	O
without	O
EPS	B-Disease
according	O
to	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	O
after	O
8	O
weeks	O
.	O
	
The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
).	O
	
RESULTS	O
:	O
Polymorphisms	O
TaqID	O
","	O
Ser311Cys	O
and	O
rs6277	O
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study	O
.	O
	
No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-	O
141Cins	O
>	O
del	O
","	O
TaqIB	O
","	O
rs6275	O
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(	O
constituted	O
by	O
TaqIB	O
","	O
rs6275	O
and	O
TaqIA	O
)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups	O
.	O
	
CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	O
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	O
","	O
at	O
least	O
in	O
Chinese	O
patients	O
with	O
schizophrenia	B-Disease
.	O
	
Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	O
and	O
EPS	B-Disease
in	O
Caucasians	O
.	O
	
A	O
novel	O
IRF6	O
nonsense	O
mutation	O
(	O
Y67X	O
)	O
in	O
a	O
German	O
family	O
with	O
Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
.	O
	
Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
VWS	B-Disease
)	O
is	O
the	O
most	O
common	O
type	O
of	O
syndromic	B-Disease
orofacial	I-Disease
cleft	I-Disease
","	O
which	O
accounts	O
for	O
approximately	O
2	O
%	O
of	O
all	O
cleft	B-Disease
lip	I-Disease
and	I-Disease
palate	I-Disease
cases	O
.	O
	
It	O
is	O
characterised	O
by	O
variable	O
association	O
of	O
lower	O
lip	B-Disease
pits	I-Disease
","	O
cleft	B-Disease
lip	I-Disease
and	O
cleft	B-Disease
palate	I-Disease
","	O
and	O
hypodontia	B-Disease
.	O
	
VWS	B-Disease
arises	O
as	O
the	O
result	O
of	O
mutations	O
in	O
the	O
gene	O
encoding	O
interferon	O
regulatory	O
factor	O
6	O
(	O
IRF6	O
).	O
	
The	O
disorder	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
","	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
.	O
	
Very	O
recently	O
","	O
mutations	O
of	O
the	O
IRF6	O
gene	O
in	O
exons	O
2	O
-	O
9	O
have	O
been	O
found	O
in	O
VWS	B-Disease
patients	O
","	O
suggesting	O
that	O
this	O
gene	O
plays	O
an	O
important	O
role	O
in	O
orofacial	O
development	O
.	O
	
We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
IRF6	O
gene	O
in	O
a	O
German	O
family	O
.	O
	
Five	O
out	O
of	O
the	O
12	O
persons	O
affected	O
were	O
able	O
to	O
be	O
investigated	O
.	O
	
The	O
mutation	O
produced	O
a	O
stop	O
codon	O
within	O
exon	O
4	O
of	O
the	O
IRF6	O
gene	O
.	O
	
All	O
5	O
patients	O
were	O
heterozygous	O
for	O
a	O
base	O
substitution	O
c	O
.	O
201C	O
>	O
A	O
changing	O
the	O
tyrosine	O
codon	O
at	O
amino	O
acid	O
position	O
67	O
into	O
a	O
stop	O
codon	O
(	O
p	O
.	O
Y67X	O
)	O
in	O
exon	O
4	O
.	O
	
The	O
premature	O
stop	O
codon	O
was	O
responsible	O
for	O
a	O
truncated	O
protein	O
lacking	O
parts	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
and	O
the	O
complete	O
Smad	O
-	O
interferon	O
regulatory	O
factor	O
-	O
binding	O
domain	O
probably	O
essential	O
for	O
interactions	O
with	O
the	O
Smad	O
transcription	O
factors	O
.	O
	
Skewed	O
X	O
inactivation	O
in	O
an	O
X	B-Disease
linked	I-Disease
nystagmus	I-Disease
family	O
resulted	O
from	O
a	O
novel	O
","	O
p	O
.	O
R229G	O
","	O
missense	O
mutation	O
in	O
the	O
FRMD7	O
gene	O
.	O
	
AIMS	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
underlying	O
genetic	B-Disease
defect	I-Disease
of	O
a	O
large	O
Turkish	O
X	B-Disease
linked	I-Disease
nystagmus	I-Disease
(	O
NYS	B-Disease
)	O
family	O
.	O
	
METHODS	O
:	O
Both	O
Xp11	O
and	O
Xq26	O
loci	O
were	O
tested	O
by	O
linkage	O
analysis	O
.	O
	
The	O
12	O
exons	O
and	O
intron	O
-	O
exon	O
junctions	O
of	O
the	O
FRMD7	O
gene	O
were	O
screened	O
by	O
direct	O
sequencing	O
.	O
	
X	O
chromosome	O
inactivation	O
analysis	O
was	O
performed	O
by	O
enzymatic	O
predigestion	O
of	O
DNA	O
with	O
a	O
methylation	O
-	O
sensitive	O
enzyme	O
","	O
followed	O
by	O
PCR	O
of	O
the	O
polymorphic	O
CAG	O
repeat	O
of	O
the	O
androgen	O
receptor	O
gene	O
.	O
	
RESULTS	O
:	O
The	O
family	O
contained	O
162	O
individuals	O
","	O
among	O
whom	O
28	O
had	O
NYS	B-Disease
.	O
	
Linkage	O
analysis	O
confirmed	O
the	O
Xq26	O
locus	O
.	O
	
A	O
novel	O
missense	O
c	O
.	O
686C	O
>	O
G	O
mutation	O
","	O
which	O
causes	O
the	O
substitution	O
of	O
a	O
conserved	O
arginine	O
at	O
amino	O
acid	O
position	O
229	O
by	O
glycine	O
(	O
p	O
.	O
R229G	O
)	O
in	O
exon	O
8	O
of	O
the	O
FRMD7	O
gene	O
","	O
was	O
observed	O
.	O
	
This	O
change	O
was	O
not	O
documented	O
in	O
120	O
control	O
individuals	O
.	O
	
The	O
clinical	O
findings	O
in	O
a	O
female	O
who	O
was	O
homozygous	O
for	O
the	O
mutation	O
were	O
not	O
different	O
from	O
those	O
of	O
affected	O
heterozygous	O
females	O
.	O
	
Skewed	O
X	O
inactivation	O
was	O
remarkable	O
in	O
the	O
affected	O
females	O
of	O
the	O
family	O
.	O
	
CONCLUSIONS	O
:	O
A	O
novel	O
p	O
.	O
R229G	O
mutation	O
in	O
the	O
FRMD7	O
gene	O
causes	O
the	O
NYS	B-Disease
phenotype	O
","	O
and	O
skewed	O
X	O
inactivation	O
influences	O
the	O
manifestation	O
of	O
the	O
disease	O
in	O
X	B-Disease
linked	I-Disease
NYS	I-Disease
females	O
.	O
	
Identification	O
of	O
apolipoprotein	O
E	O
Guangzhou	O
(	O
arginine	O
150	O
proline	O
"),"	O
a	O
new	O
variant	O
associated	O
with	O
lipoprotein	B-Disease
glomerulopathy	I-Disease
.	O
	
BACKGROUND	O
/	O
AIMS	O
:	O
Lipoprotein	B-Disease
glomerulopathy	I-Disease
(	O
LPG	B-Disease
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
thrombus	B-Disease
-	O
like	O
substances	O
in	O
markedly	O
dilated	B-Disease
glomerular	I-Disease
capillaries	I-Disease
and	O
elevated	O
plasma	O
levels	O
of	O
apolipoprotein	O
E	O
(	O
apoE	O
).	O
	
Previous	O
studies	O
have	O
shown	O
that	O
genetic	O
disorders	O
of	O
apoE	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
LPG	B-Disease
","	O
but	O
LPG	B-Disease
may	O
not	O
be	O
caused	O
by	O
apoE	O
gene	O
mutations	O
in	O
Chinese	O
patients	O
.	O
	
This	O
study	O
investigated	O
the	O
association	O
of	O
a	O
new	O
variant	O
of	O
apoE	O
with	O
LPG	B-Disease
in	O
a	O
Chinese	O
family	O
.	O
	
METHODS	O
:	O
The	O
apoE	O
gene	O
in	O
a	O
family	O
with	O
4	O
LPG	B-Disease
patients	O
was	O
sequenced	O
.	O
	
The	O
polymerase	O
chain	O
reaction	O
product	O
of	O
coding	O
region	O
of	O
apoE	O
exon	O
4	O
was	O
cloned	O
into	O
pMD	O
18	O
-	O
T	O
vector	O
and	O
then	O
sequenced	O
.	O
	
RESULTS	O
:	O
A	O
novel	O
point	O
mutation	O
in	O
exon	O
4	O
of	O
the	O
apoE	O
gene	O
was	O
identified	O
in	O
all	O
4	O
LPG	B-Disease
patients	O
and	O
1	O
asymptomatic	O
family	O
member	O
.	O
	
Sequence	O
analysis	O
confirmed	O
a	O
nucleotide	O
G	O
to	O
C	O
point	O
mutation	O
in	O
exon	O
4	O
(	O
base	O
308	O
)	O
of	O
the	O
apoE	O
gene	O
in	O
all	O
patients	O
and	O
the	O
asymptomatic	O
family	O
member	O
.	O
	
This	O
missense	O
mutation	O
denotes	O
amino	O
acid	O
substitution	O
of	O
the	O
proline	O
residue	O
for	O
arginine	O
residue	O
at	O
position	O
150	O
of	O
apoE	O
.	O
	
Those	O
patients	O
were	O
all	O
heterozygotes	O
with	O
apoE	O
Guangzhou	O
.	O
	
One	O
of	O
2	O
grandsons	O
was	O
a	O
heterozygous	O
carrier	O
of	O
apoE	O
Guangzhou	O
","	O
although	O
he	O
did	O
not	O
have	O
proteinuria	B-Disease
.	O
	
CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
apoE	O
(	O
arginine	O
150	O
proline	O
)	O
is	O
a	O
novel	O
apoE	O
variant	O
that	O
etiologically	O
related	O
to	O
LPG	B-Disease
.	O
	
This	O
variant	O
(	O
apoE	O
Guangzhou	O
)	O
may	O
cause	O
a	O
marked	O
molecular	O
conformational	O
change	O
of	O
the	O
apoE	O
and	O
thus	O
impair	O
its	O
binding	O
ability	O
to	O
lipids	O
.	O
	
Mutational	O
analysis	O
of	O
CYP2C8	O
in	O
hypertensive	B-Disease
patients	O
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
.	O
	
WHAT	O
IS	O
KNOWN	O
AND	O
OBJECTIVE	O
:	O
CYP2C8	O
is	O
involved	O
in	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
epoxygenase	O
pathway	O
.	O
	
Arachidonic	O
acid	O
metabolites	O
such	O
as	O
epoxyeicosatrienenoic	O
acids	O
and	O
hydroxyeicosatetrenoic	O
acids	O
","	O
produced	O
may	O
have	O
a	O
role	O
in	O
hypertension	B-Disease
.	O
	
We	O
aimed	O
to	O
develop	O
a	O
medium	O
through	O
-	O
put	O
method	O
for	O
screening	O
samples	O
of	O
known	O
and	O
new	O
mutations	O
of	O
CYP2C8	O
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
).	O
	
METHODS	O
:	O
DNA	O
samples	O
from	O
200	O
subjects	O
(	O
hypertensive	B-Disease
patients	O
and	O
healthy	O
controls	O
)	O
were	O
screened	O
for	O
SNPs	O
in	O
CYP2C8	O
using	O
DHPLC	O
.	O
	
Genotypes	O
and	O
allelic	O
frequencies	O
of	O
CYP2C8	O
between	O
the	O
healthy	O
controls	O
and	O
patients	O
with	O
hypertension	B-Disease
were	O
compared	O
.	O
	
RESULTS	O
AND	O
DISCUSSIONS	O
:	O
Six	O
variants	O
were	O
detected	O
and	O
two	O
were	O
new	O
;	O
T	O
deletion	O
at	O
5063	O
and	O
substitution	O
of	O
C	O
to	O
T	O
at	O
33468	O
in	O
exon	O
8	O
.	O
	
Differences	O
in	O
variant	O
frequencies	O
were	O
detected	O
between	O
the	O
controls	O
and	O
hypertensive	B-Disease
patients	O
.	O
	
The	O
controls	O
have	O
significantly	O
higher	O
prevalence	O
of	O
C35322C	O
compared	O
to	O
the	O
patients	O
.	O
	
The	O
functional	O
significance	O
of	O
the	O
SNP	O
at	O
35322	O
requires	O
further	O
study	O
.	O
	
Having	O
homozygous	O
C35322C	O
could	O
be	O
a	O
protective	O
factor	O
for	O
hypertension	B-Disease
.	O
	
WHAT	O
IS	O
NEW	O
AND	O
CONCLUSION	O
:	O
Denaturing	O
high	O
performance	O
liquid	O
chromatography	O
is	O
useful	O
for	O
population	O
screening	O
to	O
identify	O
new	O
and	O
existing	O
SNPs	O
.	O
	
A	O
higher	O
frequency	O
of	O
the	O
C35322T	O
SNP	O
was	O
observed	O
among	O
hypertensive	B-Disease
patients	O
than	O
control	O
subjects	O
.	O
	
This	O
potentially	O
important	O
observation	O
requires	O
confirmation	O
and	O
the	O
clinical	O
significance	O
assessed	O
.	O
	
TNFR	O
-	O
associated	O
factor	O
2	O
deficiency	O
in	O
B	O
lymphocytes	O
predisposes	O
to	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
/	O
small	B-Disease
lymphocytic	I-Disease
lymphoma	I-Disease
in	O
mice	O
.	O
	
We	O
have	O
previously	O
shown	O
that	O
transgenic	O
(	O
tg	O
)	O
mice	O
expressing	O
in	O
B	O
lymphocytes	O
both	O
BCL	O
-	O
2	O
and	O
a	O
TNFR	O
-	O
associated	O
factor	O
2	O
(	O
TRAF2	O
)	O
mutant	O
lacking	O
the	O
really	O
interesting	O
new	O
gene	O
and	O
zinc	O
finger	O
domains	O
(	O
TRAF2DN	O
)	O
develop	O
small	B-Disease
lymphocytic	I-Disease
lymphoma	I-Disease
and	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
with	O
high	O
incidence	O
(	O
Zapata	O
et	O
al	O
.	O
	
2004	O
.	O
	
Proc	O
.	O
	
Nat	O
.	O
	
Acad	O
.	O
	
Sci	O
.	O
	
USA	O
101	O
:	O
16600	O
-	O
16605	O
).	O
	
Further	O
analysis	O
of	O
the	O
expression	O
of	O
TRAF2	O
and	O
TRAF2DN	O
in	O
purified	O
B	O
cells	O
demonstrated	O
that	O
expression	O
of	O
both	O
endogenous	O
TRAF2	O
and	O
tg	O
TRAF2DN	O
was	O
negligible	O
in	O
Traf2DN	O
-	O
tg	O
B	O
cells	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O
	
This	O
was	O
the	O
result	O
of	O
proteasome	O
-	O
dependent	O
degradation	O
","	O
and	O
rendered	O
TRAF2DN	O
B	O
cells	O
as	O
bona	O
fide	O
TRAF2	O
-	O
deficient	O
B	O
cells	O
.	O
	
Similar	O
to	O
B	O
cells	O
with	O
targeted	O
Traf2	O
deletion	O
","	O
Traf2DN	O
-	O
tg	O
mice	O
show	O
expanded	O
marginal	O
zone	O
B	O
cell	O
population	O
and	O
have	O
constitutive	O
p100	O
NF	O
-	O
kappaB2	O
processing	O
.	O
	
Also	O
","	O
TRAF3	O
","	O
X	O
-	O
linked	O
inhibitor	O
of	O
apoptosis	O
","	O
and	O
Bcl	O
-	O
X	O
(	O
L	O
)	O
expression	O
levels	O
were	O
increased	O
","	O
whereas	O
cellular	O
inhibitors	O
of	O
apoptosis	O
1	O
and	O
2	O
levels	O
were	O
drastically	O
reduced	O
compared	O
with	O
those	O
found	O
in	O
wild	O
-	O
type	O
B	O
cells	O
.	O
	
Moreover	O
","	O
consistent	O
with	O
previous	O
results	O
","	O
we	O
also	O
show	O
that	O
TRAF2	O
was	O
required	O
for	O
efficient	O
JNK	O
and	O
ERK	O
activation	O
in	O
response	O
to	O
CD40	O
engagement	O
.	O
	
However	O
","	O
TRAF2	O
was	O
deleterious	O
for	O
BCR	O
-	O
mediated	O
activation	O
of	O
these	O
kinases	O
.	O
	
In	O
contrast	O
","	O
TRAF2	O
deficiency	O
had	O
no	O
effect	O
on	O
CD40	O
-	O
mediated	O
p38	O
MAPK	O
activation	O
but	O
significantly	O
reduced	O
BCR	O
-	O
mediated	O
p38	O
activation	O
.	O
	
Finally	O
","	O
we	O
further	O
confirm	O
that	O
TRAF2	O
was	O
required	O
for	O
CD40	O
-	O
mediated	O
proliferation	O
","	O
but	O
its	O
absence	O
relieved	O
B	O
cells	O
of	O
the	O
need	O
for	O
B	O
cell	O
activating	O
factor	O
for	O
survival	O
.	O
	
Altogether	O
","	O
our	O
results	O
suggest	O
that	O
TRAF2	O
deficiency	O
cooperates	O
with	O
BCL	O
-	O
2	O
in	O
promoting	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
/	O
small	B-Disease
lymphocytic	I-Disease
lymphoma	I-Disease
in	O
mice	O
","	O
possibly	O
by	O
specifically	O
enforcing	O
marginal	O
zone	O
B	O
cell	O
accumulation	O
","	O
increasing	O
X	O
-	O
linked	O
inhibitor	O
of	O
apoptosis	O
expression	O
","	O
and	O
rendering	O
B	O
cells	O
independent	O
of	O
B	O
cell	O
activating	O
factor	O
for	O
survival	O
.	O
	
CTR9	O
/	O
PAF1c	O
regulates	O
molecular	O
lineage	O
identity	O
","	O
histone	O
H3K36	O
trimethylation	O
and	O
genomic	O
imprinting	O
during	O
preimplantation	O
development	O
.	O
	
Genome	O
-	O
wide	O
epigenetic	O
reprogramming	O
is	O
required	O
for	O
successful	O
preimplantation	O
development	O
.	O
	
Inappropriate	O
or	O
deficient	O
chromatin	O
regulation	O
can	O
result	O
in	O
defective	O
lineage	O
specification	O
and	O
loss	O
of	O
genomic	O
imprinting	O
","	O
compromising	O
normal	O
development	O
.	O
	
Here	O
we	O
report	O
that	O
two	O
members	O
of	O
the	O
RNA	O
polymerase	O
II	O
associated	O
factor	O
","	O
homolog	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
complex	O
(	O
PAF1	O
complex	O
)	O
components	O
","	O
Ctr9	O
and	O
Rtf1	O
","	O
are	O
required	O
during	O
mammalian	O
preimplantation	O
development	O
.	O
	
We	O
demonstrate	O
that	O
Ctr9	O
-	O
deficient	O
embryos	O
fail	O
to	O
correctly	O
specify	O
lineages	O
at	O
the	O
blastocyst	O
stage	O
.	O
	
Expression	O
of	O
some	O
lineage	O
specific	O
factors	O
is	O
markedly	O
reduced	O
in	O
Ctr9	O
knockdown	O
embryos	O
","	O
including	O
Eomes	O
","	O
Elf5	O
and	O
Sox2	O
","	O
while	O
others	O
are	O
inappropriately	O
expressed	O
(	O
4-Oct	O
","	O
Nanog	O
","	O
Gata6	O
","	O
Fgf4	O
and	O
Sox17	O
).	O
	
We	O
also	O
show	O
that	O
several	O
imprinted	O
genes	O
(	O
Mest	O
","	O
Peg3	O
","	O
Snrpn	O
and	O
Meg3	O
)	O
are	O
aberrantly	O
expressed	O
although	O
allele	O
specific	O
DNA	O
methylation	O
is	O
not	O
altered	O
.	O
	
We	O
document	O
a	O
loss	O
of	O
histone	O
H3	O
lysine	O
36	O
trimethylation	O
(	O
H3K36me3	O
)	O
in	O
Ctr9	O
-	O
deficient	O
embryos	O
and	O
confirm	O
that	O
knockdown	O
of	O
either	O
Setd2	O
or	O
Rtf1	O
results	O
in	O
similar	O
phenotypes	O
.	O
	
These	O
findings	O
show	O
that	O
the	O
PAF1	O
complex	O
is	O
required	O
for	O
mammalian	O
development	O
","	O
likely	O
through	O
regulation	O
of	O
H3K36me3	O
","	O
and	O
indicate	O
functional	O
conservation	O
of	O
the	O
PAF1	O
complex	O
from	O
yeast	O
to	O
mammals	O
in	O
vivo	O
.	O
	
Regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
and	O
apoptotic	O
pathways	O
by	O
betaine	O
attenuates	O
isoproterenol	O
-	O
induced	O
acute	O
myocardial	B-Disease
injury	I-Disease
in	O
rats	O
.	O
	
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cardioprotective	O
effects	O
of	O
betaine	O
on	O
acute	O
myocardial	B-Disease
ischemia	I-Disease
induced	O
experimentally	O
in	O
rats	O
focusing	O
on	O
regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
and	O
apoptotic	O
pathways	O
as	O
the	O
potential	O
mechanism	O
underlying	O
the	O
drug	O
effect	O
.	O
	
Male	O
Sprague	O
Dawley	O
rats	O
were	O
treated	O
with	O
betaine	O
(	O
100	O
","	O
200	O
","	O
and	O
400	O
mg	O
/	O
kg	O
)	O
orally	O
for	O
40	O
days	O
.	O
	
Acute	O
myocardial	B-Disease
ischemic	I-Disease
injury	I-Disease
was	O
induced	O
in	O
rats	O
by	O
subcutaneous	O
injection	O
of	O
isoproterenol	O
(	O
85	O
mg	O
/	O
kg	O
"),"	O
for	O
two	O
consecutive	O
days	O
.	O
	
Serum	O
cardiac	O
marker	O
enzyme	O
","	O
histopathological	O
variables	O
and	O
expression	O
of	O
protein	O
levels	O
were	O
analyzed	O
.	O
	
Oral	O
administration	O
of	O
betaine	O
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	O
ventricular	B-Disease
remodeling	I-Disease
.	O
	
Western	O
blot	O
analysis	O
showed	O
that	O
isoproterenol	O
-	O
induced	O
phosphorylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhanced	O
by	O
betaine	O
treatment	O
in	O
myocardium	O
.	O
	
Furthermore	O
","	O
betaine	O
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
treatment	O
increased	O
the	O
ventricular	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
reduced	O
the	O
level	O
of	O
Bax	O
","	O
therefore	O
causing	O
a	O
significant	O
increase	O
in	O
the	O
ratio	O
of	O
Bcl	O
-	O
2	O
/	O
Bax	O
.	O
	
The	O
protective	O
role	O
of	O
betaine	O
on	O
myocardial	B-Disease
damage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O
	
In	O
summary	O
","	O
our	O
results	O
showed	O
that	O
betaine	O
pretreatment	O
attenuated	O
isoproterenol	O
-	O
induced	O
acute	O
myocardial	B-Disease
ischemia	I-Disease
via	O
the	O
regulation	O
of	O
STAT3	O
and	O
apoptotic	O
pathways	O
.	O
	
Combination	O
of	O
the	O
histone	O
deacetylase	O
inhibitor	O
depsipeptide	O
and	O
5	O
-	O
fluorouracil	O
upregulates	O
major	O
histocompatibility	O
complex	O
class	O
II	O
and	O
p21	O
genes	O
and	O
activates	O
caspase	O
-	O
3	O
/	O
7	O
in	O
human	O
colon	B-Disease
cancer	I-Disease
HCT	O
-	O
116	O
cells	O
.	O
	
Epigenetic	O
anticancer	O
drugs	O
such	O
as	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitors	O
have	O
been	O
combined	O
with	O
existing	O
anticancer	O
drugs	O
for	O
synergistic	O
or	O
additive	O
effects	O
.	O
	
In	O
the	O
present	O
study	O
","	O
we	O
found	O
that	O
a	O
very	O
low	O
concentration	O
of	O
depsipeptide	O
","	O
an	O
HDAC	O
inhibitor	O
","	O
potentiated	O
the	O
antitumor	O
activity	O
of	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
in	O
a	O
human	O
colon	B-Disease
cancer	I-Disease
cell	O
model	O
using	O
HCT	O
-	O
116	O
","	O
HT29	O
","	O
and	O
SW48	O
cells	O
via	O
the	O
inhibition	O
of	O
colony	O
formation	O
ability	O
or	O
cellular	O
viability	O
.	O
	
Exposure	O
to	O
a	O
combination	O
of	O
5	O
-	O
FU	O
(	O
1	O
.	O
75	O
uM	O
)	O
and	O
1	O
nM	O
depsipeptide	O
for	O
24	O
and	O
48	O
h	O
resulted	O
in	O
a	O
3	O
-	O
to	O
4	O
-	O
fold	O
increase	O
in	O
activated	O
caspase	O
-	O
3	O
/	O
7	O
","	O
while	O
5	O
-	O
FU	O
alone	O
failed	O
to	O
activate	O
caspase	O
-	O
3	O
/	O
7	O
.	O
	
Microarray	O
and	O
subsequent	O
gene	O
ontology	O
analyses	O
revealed	O
that	O
compared	O
to	O
5	O
-	O
FU	O
or	O
depsipeptide	O
alone	O
","	O
the	O
combination	O
treatment	O
of	O
5	O
-	O
FU	O
and	O
depsipeptide	O
upregulated	O
genes	O
related	O
to	O
cell	O
death	O
and	O
the	O
apoptotic	O
process	O
consistent	O
with	O
the	O
inhibition	O
of	O
colony	O
formation	O
and	O
caspase	O
-	O
3	O
/	O
7	O
activation	O
.	O
	
These	O
analyses	O
indicated	O
marked	O
upregulation	O
of	O
antigen	O
processing	O
and	O
presentation	O
of	O
peptide	O
or	O
polysaccharide	O
antigen	O
via	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
(	O
GO	O
:	O
2504	O
)	O
and	O
MHC	O
protein	O
complex	O
(	O
GO	O
:	O
42611	O
).	O
	
Compared	O
with	O
vehicle	O
controls	O
","	O
the	O
cells	O
treated	O
with	O
the	O
combination	O
of	O
5	O
-	O
FU	O
and	O
depsipeptide	O
showed	O
marked	O
induction	O
(	O
3	O
-	O
to	O
8	O
.	O
5	O
-	O
fold	O
)	O
of	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
","	O
but	O
not	O
of	O
MHC	O
class	O
I	O
genes	O
.	O
	
Furthermore	O
","	O
our	O
global	O
analysis	O
of	O
gene	O
expression	O
","	O
which	O
was	O
focused	O
on	O
genes	O
involved	O
in	O
the	O
molecular	O
regulation	O
of	O
MHC	O
class	O
II	O
genes	O
","	O
showed	O
enhancement	O
of	O
pro	O
-	O
apoptotic	O
PCAF	O
and	O
CIITA	O
after	O
the	O
combination	O
of	O
5	O
-	O
FU	O
and	O
depsipeptide	O
.	O
	
These	O
results	O
may	O
indicate	O
a	O
closer	O
relationship	O
between	O
elevation	O
of	O
MHC	O
class	O
II	O
expression	O
and	O
cellular	O
apoptosis	O
induced	O
by	O
the	O
combination	O
of	O
depsipeptide	O
and	O
5	O
-	O
FU	O
.	O
	
To	O
the	O
best	O
of	O
our	O
knowledge	O
","	O
this	O
is	O
the	O
first	O
study	O
to	O
report	O
that	O
the	O
combination	O
of	O
5	O
-	O
FU	O
and	O
depsipeptide	O
induces	O
human	O
colon	B-Disease
cancer	I-Disease
cell	O
apoptosis	O
in	O
a	O
concerted	O
manner	O
with	O
the	O
induction	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O
	
Seven	O
novel	O
and	O
six	O
de	O
novo	O
PHEX	O
gene	O
mutations	O
in	O
patients	O
with	O
hypophosphatemic	B-Disease
rickets	I-Disease
.	O
	
Inactivating	O
mutations	O
in	O
phosphate	O
-	O
regulating	O
gene	O
with	O
homologies	O
to	O
endopeptidase	O
on	O
the	O
X	O
chromosome	O
(	O
PHEX	O
)	O
have	O
been	O
identified	O
as	O
a	O
cause	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
hypophosphatemic	I-Disease
rickets	I-Disease
(	O
XLH	B-Disease
;	O
OMIM	B-Disease
307800	I-Disease
).	O
	
In	O
the	O
present	O
study	O
","	O
we	O
enrolled	O
43	O
patients	O
from	O
18	O
unrelated	O
families	O
clinically	O
diagnosed	O
with	O
hypophosphatemic	B-Disease
rickets	I-Disease
and	O
250	O
healthy	O
controls	O
.	O
	
For	O
each	O
available	O
individual	O
","	O
all	O
22	O
exons	O
with	O
their	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
PHEX	O
gene	O
were	O
directly	O
sequenced	O
.	O
	
The	O
levels	O
of	O
serum	O
fibroblast	O
growth	O
factor	O
23	O
(	O
FGF23	O
)	O
were	O
measured	O
as	O
well	O
.	O
	
Sequencing	O
analysis	O
detected	O
17	O
different	O
PHEX	O
gene	O
mutations	O
","	O
and	O
7	O
of	O
these	O
were	O
identified	O
as	O
novel	O
:	O
3	O
missense	O
mutations	O
","	O
including	O
c	O
.	O
304G	O
>	O
A	O
(	O
p	O
.	O
Gly102Arg	O
)	O
in	O
exon	O
3	O
","	O
c	O
.	O
229T	O
>	O
C	O
(	O
p	O
.	O
Cys77Arg	O
)	O
in	O
exon	O
3	O
and	O
c	O
.	O
824T	O
>	O
C	O
(	O
p	O
.	O
Leu275Pro	O
)	O
in	O
exon	O
7	O
;	O
2	O
deletion	O
mutations	O
","	O
including	O
c	O
.	O
528delT	O
(	O
p	O
.	O
Glu177LysfsX44	O
)	O
in	O
exon	O
5	O
and	O
c	O
.	O
1234delA	O
(	O
p	O
.	O
Ser412ValfsX12	O
)	O
in	O
exon	O
11	O
;	O
and	O
2	O
alternative	O
splicing	O
mutations	O
","	O
including	O
c	O
.	O
436_436	O
+	O
1delAG	O
in	O
intron	O
4	O
at	O
splicing	O
donor	O
sites	O
and	O
c	O
.	O
1483	O
-	O
1G	O
>	O
C	O
in	O
intron	O
13	O
at	O
splicing	O
acceptor	O
sites	O
.	O
	
Moreover	O
","	O
6	O
mutations	O
were	O
proven	O
to	O
be	O
de	O
novo	O
in	O
6	O
sporadic	O
cases	O
and	O
the	O
probands	O
were	O
all	O
females	O
.	O
	
No	O
mutations	O
were	O
found	O
in	O
the	O
250	O
healthy	O
controls	O
.	O
	
The	O
serum	O
levels	O
of	O
FGF23	O
varied	O
widely	O
among	O
the	O
patients	O
with	O
XLH	B-Disease
","	O
and	O
no	O
significant	O
difference	O
was	O
found	O
when	O
compared	O
with	O
those	O
of	O
the	O
healthy	O
controls	O
.	O
	
On	O
the	O
whole	O
","	O
the	O
findings	O
of	O
this	O
study	O
provide	O
new	O
insight	O
into	O
the	O
spectrum	O
of	O
PHEX	O
mutations	O
and	O
provide	O
potential	O
evidence	O
of	O
a	O
critical	O
domain	O
in	O
PHEX	O
protein	O
.	O
	
In	O
addition	O
","	O
the	O
finding	O
of	O
an	O
overlap	O
of	O
the	O
serum	O
FGF23	O
levels	O
between	O
the	O
patients	O
with	O
XLH	B-Disease
and	O
the	O
healthy	O
controls	O
indicates	O
its	O
limited	O
diagnostic	O
value	O
in	O
XLH	B-Disease
.	O
	
Localisation	O
of	O
the	O
Becker	O
muscular	O
dystrophy	O
gene	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
by	O
linkage	O
to	O
cloned	O
DNA	O
sequences	O
.	O
	
A	O
linkage	O
study	O
in	O
30	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	B-Disease
)	O
kindreds	O
using	O
three	O
cloned	O
DNA	O
sequences	O
from	O
the	O
X	O
chromosome	O
which	O
demonstrate	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
"),"	O
suggests	O
that	O
the	O
BMD	O
gene	O
is	O
located	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
","	O
in	O
the	O
p21	O
region	O
.	O
	
The	O
genes	O
for	O
Becker	B-Disease
and	I-Disease
Duchenne	I-Disease
dystrophies	I-Disease
must	O
therefore	O
be	O
closely	O
linked	O
","	O
if	O
not	O
allelic	O
","	O
and	O
any	O
future	O
DNA	O
probes	O
found	O
to	O
be	O
of	O
practical	O
use	O
in	O
one	O
disorder	O
should	O
be	O
equally	O
applicable	O
to	O
the	O
other	O
.	O
	
The	O
linkage	O
analysis	O
also	O
provides	O
data	O
on	O
the	O
frequency	O
of	O
recombination	O
along	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
","	O
and	O
across	O
the	O
centromeric	O
region	O
..	O
	
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
):	O
a	O
novel	O
mutation	O
of	O
the	O
ALD	O
gene	O
in	O
6	O
members	O
of	O
a	O
family	O
presenting	O
with	O
5	O
different	O
phenotypes	O
.	O
	
Fragments	O
of	O
the	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
cDNA	O
from	O
a	O
patient	O
with	O
adolescent	O
ALD	B-Disease
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
subcloned	O
.	O
	
Bidirectional	O
sequencing	O
of	O
the	O
entire	O
coding	O
ALD	O
gene	O
disclosed	O
a	O
cytosine	O
to	O
guanine	O
transversion	O
at	O
nucleotide	O
1451	O
in	O
exon	O
five	O
","	O
resulting	O
in	O
substitution	O
of	O
proline	O
484	O
by	O
arginine	O
.	O
	
Five	O
of	O
nine	O
siblings	O
of	O
the	O
patient	O
","	O
comprising	O
two	O
cerebral	O
ALD	B-Disease
","	O
one	O
adrenomyeloneuropathy	B-Disease
","	O
one	O
Addison	B-Disease
only	O
as	O
well	O
as	O
the	O
symptomatic	O
mother	O
(	O
all	O
accumulating	O
very	O
long	O
chain	O
fatty	O
acids	O
)	O
carried	O
this	O
mutation	O
","	O
which	O
was	O
not	O
found	O
in	O
the	O
unaffected	O
persons	O
","	O
in	O
five	O
unrelated	O
ALD	B-Disease
patients	O
","	O
and	O
in	O
twenty	O
controls	O
.	O
	
We	O
propose	O
that	O
this	O
missense	O
mutation	O
generated	O
the	O
disease	O
per	O
se	O
as	O
well	O
as	O
the	O
metabolic	O
defect	O
;	O
the	O
different	O
phenotypes	O
","	O
however	O
","	O
must	O
have	O
originated	O
by	O
means	O
of	O
additional	O
pathogenetic	O
factors	O
..	O
	
Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
.	O
	
The	O
ability	O
to	O
scan	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O
.	O
	
We	O
have	O
designed	O
high	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
96	O
","	O
600	O
oligonucleotides	O
20	O
-	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
to	O
screen	O
for	O
a	O
wide	O
range	O
of	O
heterozygous	O
mutations	O
in	O
the	O
3	O
.	O
	
45	O
-	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	O
breast	O
and	O
ovarian	O
cancer	O
gene	O
BRCA1	O
.	O
	
Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
two	O
-	O
colour	O
analysis	O
.	O
	
Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
","	O
and	O
no	O
FALSE	O
positive	O
mutations	O
were	O
identified	O
in	O
20	O
control	O
samples	O
.	O
	
Eight	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
.	O
	
DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
detection	O
of	O
genetic	O
alterations	O
.	O
	
Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
HNF4alpha	O
gene	O
are	O
associated	O
with	O
the	O
conversion	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
:	O
the	O
STOP	O
-	O
NIDDM	O
trial	O
.	O
	
Hepatocyte	O
nuclear	O
factor	O
4alpha	O
(	O
HNF4alpha	O
)	O
is	O
a	O
transcription	O
factor	O
","	O
which	O
is	O
necessary	O
for	O
normal	O
function	O
of	O
human	O
liver	O
and	O
pancreatic	O
islets	O
.	O
	
We	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
HNF4A	O
","	O
encoding	O
HNF4alpha	O
","	O
influenced	O
the	O
conversion	O
from	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
IGT	B-Disease
)	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
in	O
subjects	O
of	O
the	O
STOP	O
-	O
NIDDM	O
trial	O
.	O
	
This	O
trial	O
aimed	O
at	O
evaluating	O
the	O
effect	O
of	O
acarbose	O
compared	O
to	O
placebo	O
in	O
the	O
prevention	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
.	O
	
Eight	O
SNPs	O
covering	O
the	O
intragenic	O
and	O
alternate	O
P2	O
promoter	O
regions	O
of	O
HNF4A	O
were	O
genotyped	O
in	O
study	O
samples	O
using	O
the	O
TaqMan	O
Allelic	O
Discrimination	O
Assays	O
.	O
	
Three	O
SNPs	O
in	O
the	O
P2	O
promoter	O
region	O
(	O
rs4810424	O
","	O
rs1884614	O
","	O
and	O
rs2144908	O
)	O
were	O
in	O
almost	O
complete	O
association	O
(	O
D	O
'>	O
0	O
.	O
97	O
","	O
r	O
(	O
2	O
)>	O
0	O
.	O
95	O
)	O
and	O
","	O
therefore	O
","	O
only	O
rs4810424	O
was	O
included	O
in	O
further	O
analyses	O
.	O
	
Female	O
carriers	O
of	O
the	O
less	O
frequent	O
C	O
allele	O
of	O
rs4810424	O
had	O
a	O
1	O
.	O
7	O
-	O
fold	O
elevated	O
risk	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
9	O
-	O
2	O
.	O
66	O
;	O
P	O
=	O
0	O
.	O
20	O
]	O
for	O
the	O
conversion	O
to	O
diabetes	B-Disease
compared	O
to	O
women	O
with	O
the	O
common	O
genotype	O
after	O
the	O
adjustment	O
for	O
age	O
","	O
treatment	O
group	O
(	O
placebo	O
or	O
acarbose	O
"),"	O
smoking	O
","	O
weight	O
at	O
baseline	O
","	O
and	O
weight	O
change	O
.	O
	
No	O
association	O
was	O
found	O
in	O
men	O
.	O
	
Haplotype	O
analysis	O
based	O
on	O
three	O
SNPs	O
(	O
rs4810424	O
","	O
rs2071197	O
","	O
and	O
rs3818247	O
)	O
representing	O
the	O
linkage	O
disequilibrium	O
blocks	O
in	O
our	O
study	O
population	O
indicated	O
that	O
the	O
conversion	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
was	O
dependent	O
on	O
the	O
number	O
of	O
risk	O
alleles	O
in	O
different	O
haplotypes	O
in	O
women	O
.	O
	
Our	O
results	O
suggest	O
that	O
SNPs	O
of	O
HNF4A	O
and	O
their	O
haplotypes	O
predispose	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
in	O
female	O
subjects	O
of	O
the	O
STOP	O
-	O
NIDDM	O
study	O
population	O
.	O
	
Hepatic	O
but	O
not	O
brain	O
iron	O
is	O
rapidly	O
chelated	O
by	O
deferasirox	O
in	O
aceruloplasminemia	B-Disease
due	O
to	O
a	O
novel	O
gene	O
mutation	O
.	O
	
BACKGROUND	O
_	O
#	O
38	O
;	O
AIMS	O
:	O
Aceruloplasminemia	B-Disease
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disease	I-Disease
associated	O
with	O
brain	O
and	O
liver	O
iron	O
accumulation	O
which	O
typically	O
presents	O
with	O
movement	B-Disease
disorders	I-Disease
","	O
retinal	B-Disease
degeneration	I-Disease
","	O
and	O
diabetes	B-Disease
mellitus	I-Disease
.	O
	
Ceruloplasmin	O
is	O
a	O
multi	O
-	O
copper	O
ferroxidase	O
that	O
is	O
secreted	O
into	O
plasma	O
and	O
facilitates	O
cellular	O
iron	O
export	O
and	O
iron	O
binding	O
to	O
transferrin	O
.	O
	
RESULTS	O
:	O
A	O
novel	O
homozygous	O
ceruloplasmin	O
gene	O
mutation	O
","	O
c	O
.	O
2554	O
+	O
1G	O
>	O
T	O
","	O
was	O
identified	O
as	O
the	O
cause	O
of	O
aceruloplasminemia	B-Disease
in	O
three	O
affected	O
siblings	O
.	O
	
Two	O
siblings	O
presented	O
with	O
movement	B-Disease
disorders	I-Disease
and	O
diabetes	B-Disease
.	O
	
Complementary	O
DNA	O
sequencing	O
showed	O
that	O
this	O
mutation	O
causes	O
skipping	O
of	O
exon	O
14	O
and	O
deletion	O
of	O
amino	O
acids	O
809	O
-	O
852	O
while	O
preserving	O
the	O
open	O
reading	O
frame	O
.	O
	
Western	O
blotting	O
of	O
liver	O
extracts	O
and	O
sera	O
of	O
affected	O
patients	O
showed	O
retention	O
of	O
the	O
abnormal	O
protein	O
in	O
the	O
liver	O
.	O
	
Aceruloplasminemia	B-Disease
was	O
associated	O
with	O
severe	O
brain	O
and	O
liver	O
iron	B-Disease
overload	I-Disease
","	O
where	O
hepatic	O
mRNA	O
expression	O
of	O
the	O
iron	O
hormone	O
hepcidin	O
was	O
increased	O
","	O
corresponding	O
to	O
the	O
degree	O
of	O
iron	B-Disease
overload	I-Disease
.	O
	
Hepatic	O
iron	O
concentration	O
normalized	O
after	O
3	O
and	O
5months	O
of	O
iron	O
chelation	O
therapy	O
with	O
deferasirox	O
","	O
which	O
was	O
also	O
associated	O
with	O
reduced	O
insulin	O
demands	O
.	O
	
During	O
short	O
term	O
treatment	O
there	O
was	O
no	O
clinical	O
or	O
imaging	O
evidence	O
for	O
significant	O
effects	O
on	O
brain	O
iron	B-Disease
overload	I-Disease
.	O
	
CONCLUSIONS	O
:	O
Aceruloplasminemia	B-Disease
can	O
show	O
an	O
incomplete	O
clinical	O
penetrance	O
but	O
is	O
invariably	O
associated	O
with	O
iron	O
accumulation	O
in	O
the	O
liver	O
and	O
in	O
the	O
brain	O
.	O
	
Iron	O
accumulation	O
in	O
aceruloplasminemia	B-Disease
is	O
a	O
result	O
of	O
defective	O
cellular	O
iron	O
export	O
","	O
where	O
hepcidin	O
regulation	O
is	O
appropriate	O
for	O
the	O
degree	O
of	O
iron	B-Disease
overload	I-Disease
.	O
	
Iron	O
chelation	O
with	O
deferasirox	O
was	O
effective	O
in	O
mobilizing	O
hepatic	O
iron	O
but	O
has	O
no	O
effect	O
on	O
brain	O
iron	O
.	O
	
The	O
androgen	O
receptor	O
confers	O
protection	O
against	O
diet	O
-	O
induced	O
atherosclerosis	B-Disease
","	O
obesity	B-Disease
","	O
and	O
dyslipidemia	B-Disease
in	O
female	O
mice	O
.	O
	
Androgens	O
have	O
important	O
cardiometabolic	O
actions	O
in	O
males	O
","	O
but	O
their	O
metabolic	O
role	O
in	O
females	O
is	O
unclear	O
.	O
	
To	O
determine	O
the	O
physiologic	O
androgen	O
receptor	O
(	O
AR	O
)-	O
dependent	O
actions	O
of	O
androgens	O
on	O
atherogenesis	B-Disease
in	O
female	O
mice	O
","	O
we	O
generated	O
female	O
AR	O
-	O
knockout	O
(	O
ARKO	O
)	O
mice	O
on	O
an	O
atherosclerosis	B-Disease
-	O
prone	O
apolipoprotein	O
E	O
(	O
apoE	O
)-	O
deficient	O
background	O
.	O
	
After	O
8	O
weeks	O
on	O
a	O
high	O
-	O
fat	O
diet	O
","	O
but	O
not	O
on	O
a	O
normal	O
chow	O
diet	O
","	O
atherosclerosis	B-Disease
in	O
aorta	O
was	O
increased	O
in	O
ARKO	O
females	O
(+	O
59	O
%	O
vs	O
.	O
	
control	O
apoE	O
-	O
deficient	O
mice	O
with	O
intact	O
AR	O
gene	O
).	O
	
They	O
also	O
displayed	O
increased	O
body	O
weight	O
(+	O
18	O
"%),"	O
body	O
fat	O
percentage	O
(+	O
62	O
"%),"	O
and	O
hepatic	O
triglyceride	O
levels	O
","	O
reduced	O
insulin	O
sensitivity	O
","	O
and	O
a	O
marked	O
atherogenic	B-Disease
dyslipidemia	I-Disease
(	O
serum	O
cholesterol	O
","	O
+	O
52	O
%).	O
	
Differences	O
in	O
atherosclerosis	B-Disease
","	O
body	O
weight	O
","	O
and	O
lipid	O
levels	O
between	O
ARKO	O
and	O
control	O
mice	O
were	O
abolished	O
in	O
mice	O
that	O
were	O
ovariectomized	O
before	O
puberty	O
","	O
consistent	O
with	O
a	O
protective	O
action	O
of	O
ovarian	O
androgens	O
mediated	O
via	O
the	O
AR	O
.	O
	
Furthermore	O
","	O
the	O
AR	O
agonist	O
dihydrotestosterone	O
reduced	O
atherosclerosis	B-Disease
(-	O
41	O
%;	O
thoracic	O
aorta	O
"),"	O
subcutaneous	O
fat	O
mass	O
(-	O
44	O
"%),"	O
and	O
cholesterol	O
levels	O
(-	O
35	O
%)	O
in	O
ovariectomized	O
mice	O
","	O
reduced	O
hepatocyte	O
lipid	O
accumulation	O
in	O
hepatoma	B-Disease
cells	O
in	O
vitro	O
","	O
and	O
regulated	O
mRNA	O
expression	O
of	O
hepatic	O
genes	O
pivotal	O
for	O
lipid	O
homeostasis	O
.	O
	
In	O
conclusion	O
","	O
we	O
demonstrate	O
that	O
the	O
AR	O
protects	O
against	O
diet	O
-	O
induced	O
atherosclerosis	B-Disease
in	O
female	O
mice	O
and	O
propose	O
that	O
this	O
is	O
mediated	O
by	O
modulation	O
of	O
body	O
composition	O
and	O
lipid	O
metabolism	O
.	O
	
Circulating	O
Fatty	O
Acid	O
Synthase	O
in	O
pregnant	O
women	O
:	O
Relationship	O
to	O
blood	O
pressure	O
","	O
maternal	O
metabolism	O
and	O
newborn	O
parameters	O
.	O
	
The	O
enzyme	O
FASN	O
(	O
fatty	O
acid	O
synthase	O
)	O
is	O
potentially	O
related	O
with	O
hypertension	B-Disease
and	O
metabolic	B-Disease
dysfunction	I-Disease
.	O
	
FASN	O
is	O
highly	O
expressed	O
in	O
the	O
human	O
placenta	O
.	O
	
We	O
aimed	O
to	O
investigate	O
the	O
relationship	O
circulating	O
FASN	O
has	O
with	O
blood	O
pressure	O
","	O
maternal	O
metabolism	O
and	O
newborn	O
parameters	O
in	O
healthy	O
pregnant	O
women	O
.	O
	
Circulating	O
FASN	O
was	O
assessed	O
in	O
115	O
asymptomatic	O
pregnant	O
women	O
in	O
the	O
second	O
trimester	O
of	O
gestation	O
along	O
with	O
C	O
-	O
peptide	O
","	O
fasting	O
glucose	O
and	O
insulin	O
","	O
post	O
-	O
load	O
glucose	O
lipids	O
","	O
HMW	O
-	O
adiponectin	O
and	O
blood	O
pressure	O
(	O
the	O
latter	O
was	O
assessed	O
in	O
each	O
trimester	O
of	O
gestation	O
).	O
	
At	O
birth	O
","	O
newborns	O
and	O
placentas	O
were	O
weighed	O
.	O
	
FASN	O
expression	O
was	O
also	O
able	O
to	O
be	O
assessed	O
in	O
80	O
placentas	O
.	O
	
Higher	O
circulating	O
FASN	O
was	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
"),"	O
with	O
a	O
more	O
favourable	O
metabolic	O
phenotype	O
(	O
lower	O
fasting	O
glucose	O
and	O
insulin	O
","	O
post	O
load	O
glucose	O
","	O
HbAc1	O
","	O
HOMA	O
-	O
IR	O
and	O
C	O
-	O
peptide	O
"),"	O
and	O
with	O
lower	O
placental	O
and	O
birth	O
weight	O
(	O
all	O
p	O
<	O
0	O
.	O
5	O
to	O
p	O
<	O
0	O
.	O
1	O
).	O
	
Placental	O
FASN	O
expression	O
related	O
positively	O
to	O
circulating	O
FASN	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
and	O
negatively	O
to	O
placental	O
weight	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
	
Our	O
observations	O
suggest	O
a	O
physiological	O
role	O
of	O
placental	O
FASN	O
in	O
human	O
pregnancy	O
.	O
	
Future	O
studies	O
will	O
clarify	O
whether	O
circulating	O
FASN	O
of	O
placental	O
origin	O
does	O
actually	O
regulate	O
placental	O
and	O
fetal	O
growth	O
","	O
and	O
(	O
thereby	O
)	O
has	O
a	O
favourable	O
influence	O
on	O
the	O
pregnant	O
mother	O
'	O
s	O
insulin	O
sensitivity	O
and	O
blood	O
pressure	O
.	O
	
Sildenafil	O
attenuates	O
hypoxic	B-Disease
pulmonary	I-Disease
remodelling	I-Disease
by	O
inhibiting	O
bone	O
marrow	O
progenitor	O
cells	O
.	O
	
The	O
recruitment	O
of	O
bone	O
marrow	O
(	O
BM	O
)-	O
derived	O
progenitor	O
cells	O
to	O
the	O
lung	O
is	O
related	O
to	O
pulmonary	B-Disease
remodelling	I-Disease
and	O
the	O
pathogenesis	O
of	O
pulmonary	B-Disease
hypertension	I-Disease
(	O
PH	B-Disease
).	O
	
Although	O
sildenafil	O
is	O
a	O
known	O
target	O
in	O
PH	B-Disease
treatment	O
","	O
the	O
underlying	O
molecular	O
mechanism	O
is	O
still	O
elusive	O
.	O
	
To	O
test	O
the	O
hypothesis	O
that	O
the	O
therapeutic	O
effect	O
of	O
sildenafil	O
is	O
linked	O
to	O
the	O
reduced	O
recruitment	O
of	O
BM	O
-	O
derived	O
progenitor	O
cells	O
","	O
we	O
induced	O
pulmonary	B-Disease
remodelling	I-Disease
in	O
rats	O
by	O
two	O
-	O
week	O
exposure	O
to	O
chronic	O
hypoxia	B-Disease
(	O
CH	B-Disease
","	O
10	O
%	O
oxygen	O
"),"	O
a	O
trigger	O
of	O
BM	O
-	O
derived	O
progenitor	O
cells	O
.	O
	
Rats	O
were	O
treated	O
with	O
either	O
placebo	O
(	O
saline	O
)	O
or	O
sildenafil	O
(	O
1	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
ip	O
)	O
during	O
CH	B-Disease
.	O
	
Control	O
rats	O
were	O
kept	O
in	O
room	O
air	O
(	O
21	O
%	O
oxygen	O
)	O
with	O
no	O
treatment	O
.	O
	
As	O
expected	O
","	O
sildenafil	O
attenuated	O
the	O
CH	B-Disease
-	O
induced	O
increase	O
in	O
right	O
ventricular	O
systolic	O
pressure	O
and	O
right	B-Disease
ventricular	I-Disease
hypertrophy	I-Disease
.	O
	
However	O
","	O
sildenafil	O
suppressed	O
the	O
CH	B-Disease
-	O
induced	O
increase	O
in	O
c	O
-	O
kit	O
(+)	O
cells	O
in	O
the	O
adventitia	O
of	O
pulmonary	O
arteries	O
.	O
	
Moreover	O
","	O
sildenafil	O
reduced	O
the	O
number	O
of	O
c	O
-	O
kit	O
(+)	O
cells	O
that	O
colocalize	O
with	O
tyrosine	O
kinase	O
receptor	O
2	O
(	O
VEGF	O
-	O
R2	O
)	O
and	O
CD68	O
(	O
a	O
marker	O
for	O
macrophages	O
"),"	O
indicating	O
a	O
positive	O
effect	O
on	O
moderating	O
hypoxia	B-Disease
-	O
induced	O
smooth	O
muscle	O
cell	O
proliferation	O
and	O
inflammation	B-Disease
without	O
affecting	O
the	O
pulmonary	O
levels	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)-	O
1a	O
.	O
	
Furthermore	O
","	O
sildenafil	O
depressed	O
the	O
number	O
of	O
CXCR4	O
(+)	O
cells	O
.	O
	
Collectively	O
","	O
these	O
findings	O
indicate	O
that	O
the	O
improvement	O
in	O
pulmonary	O
haemodynamic	O
by	O
sildenafil	O
is	O
linked	O
to	O
decreased	O
recruitment	O
of	O
BM	O
-	O
derived	O
c	O
-	O
kit	O
(+)	O
cells	O
in	O
the	O
pulmonary	O
tissue	O
.	O
	
The	O
attenuation	O
of	O
the	O
recruitment	O
of	O
BM	O
-	O
derived	O
c	O
-	O
kit	O
(+)	O
cells	O
by	O
sildenafil	O
may	O
provide	O
novel	O
therapeutic	O
insights	O
into	O
the	O
control	O
of	O
pulmonary	B-Disease
remodelling	I-Disease
.	O
	
Genetic	O
variants	O
of	O
the	O
T	O
-	O
cell	O
immunoglobulin	O
mucin	O
1	O
but	O
not	O
the	O
T	O
-	O
cell	O
immunoglobulin	O
mucin	O
3	O
gene	O
are	O
associated	O
with	O
asthma	B-Disease
in	O
an	O
African	O
American	O
population	O
.	O
	
BACKGROUND	O
:	O
The	O
T	O
-	O
cell	O
immunoglobulin	O
mucin	O
(	O
TIM	O
)	O
proteins	O
and	O
their	O
genetic	O
variants	O
have	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
regulating	O
allergic	B-Disease
diseases	I-Disease
.	O
	
OBJECTIVE	O
:	O
Genetic	O
association	O
of	O
the	O
sequence	O
variants	O
for	O
TIM	O
-	O
1	O
and	O
TIM	O
-	O
3	O
genes	O
with	O
asthma	B-Disease
in	O
an	O
African	O
American	O
population	O
was	O
investigated	O
.	O
	
METHODS	O
:	O
Both	O
case	O
-	O
control	O
and	O
family	O
-	O
based	O
association	O
analyses	O
were	O
performed	O
for	O
a	O
total	O
of	O
7	O
polymorphisms	O
","	O
including	O
3	O
single	O
nucleotide	O
polymorphism	O
(	O
SNPs	O
)	O
and	O
1	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
TIM	O
-	O
1	O
and	O
3	O
SNPs	O
in	O
the	O
TIM	O
-	O
3	O
genes	O
.	O
	
The	O
exposure	O
to	O
hepatitis	O
A	O
virus	O
as	O
judged	O
by	O
seropositivity	O
was	O
also	O
examined	O
.	O
	
RESULTS	O
:	O
In	O
the	O
case	O
-	O
control	O
design	O
","	O
the	O
frequencies	O
of	O
the	O
TT	O
genotype	O
for	O
SNP	O
rs2277025	O
and	O
the	O
homozygous	O
deletion	O
variant	O
(	O
157delMTTTVP	O
)	O
in	O
the	O
fourth	O
exon	O
of	O
the	O
TIM	O
-	O
1	O
gene	O
were	O
higher	O
among	O
patients	O
with	O
patients	O
with	O
asthma	B-Disease
compared	O
with	O
the	O
controls	O
(	O
odds	O
ratio	O
[	O
OR	O
"],"	O
2	O
.	O
779	O
","	O
P	O
=	O
.	O
16	O
;	O
and	O
OR	O
","	O
3	O
.	O
9	O
","	O
P	O
=	O
.	O
22	O
","	O
respectively	O
).	O
	
This	O
association	O
was	O
substantiated	O
by	O
haplotype	O
analysis	O
of	O
these	O
and	O
2	O
additional	O
SNPs	O
(	O
OR	O
","	O
2	O
.	O
48	O
;	O
P	O
=	O
.	O
4	O
"),"	O
and	O
also	O
by	O
family	O
-	O
based	O
tests	O
for	O
the	O
allele	O
and	O
haplotype	O
carrying	O
157delMTTTVP	O
(	O
P	O
=	O
.	O
9	O
and	O
P	O
=	O
.	O
48	O
","	O
respectively	O
).	O
	
Furthermore	O
","	O
this	O
association	O
seems	O
to	O
exist	O
even	O
in	O
the	O
hepatitis	O
A	O
virus	O
-	O
seronegative	O
subjects	O
in	O
our	O
data	O
.	O
	
None	O
of	O
the	O
3	O
variants	O
in	O
TIM	O
-	O
3	O
genes	O
yielded	O
significant	O
association	O
with	O
either	O
asthma	B-Disease
or	O
asthma	B-Disease
-	O
related	O
phenotypes	O
.	O
	
CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
the	O
genetic	O
variants	O
of	O
the	O
TIM	O
-	O
1	O
but	O
not	O
the	O
TIM	O
-	O
3	O
gene	O
contribute	O
to	O
asthma	B-Disease
susceptibility	O
in	O
this	O
African	O
-	O
American	O
population	O
.	O
	
Identification	O
of	O
the	O
BRAF	O
V600E	O
mutation	O
in	O
gastroenteropancreatic	B-Disease
neuroendocrine	I-Disease
tumors	I-Disease
.	O
	
Genomic	O
profiles	O
of	O
gastroenteropancreatic	B-Disease
neuroendocrine	I-Disease
tumors	I-Disease
(	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
)	O
are	O
still	O
insufficiently	O
understood	O
","	O
and	O
the	O
genetic	O
alterations	O
associated	O
with	O
drug	O
responses	O
have	O
not	O
been	O
studied	O
.	O
	
Here	O
","	O
we	O
performed	O
whole	O
exome	O
sequencing	O
of	O
12	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
from	O
patients	O
enrolled	O
in	O
a	O
nonrandomized	O
","	O
open	O
-	O
labeled	O
","	O
single	O
-	O
center	O
phase	O
II	O
study	O
for	O
pazopanib	O
","	O
and	O
integrated	O
our	O
results	O
with	O
previously	O
published	O
results	O
on	O
pancreas	O
(	O
n	O
=	O
12	O
)	O
and	O
small	O
intestine	B-Disease
NETs	I-Disease
(	O
n	O
=	O
50	O
).	O
	
The	O
mean	O
numbers	O
of	O
somatic	O
mutations	O
in	O
each	O
case	O
varied	O
widely	O
from	O
20	O
to	O
4682	O
.	O
	
Among	O
12	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
","	O
eight	O
showed	O
mutations	O
of	O
more	O
than	O
one	O
cancer	B-Disease
-	O
related	O
gene	O
","	O
including	O
TP53	O
","	O
CNBD1	O
","	O
RB1	O
","	O
APC	O
","	O
BCOR	O
","	O
BRAF	O
","	O
CTNNB1	O
","	O
EGFR	O
","	O
EP300	O
","	O
ERBB3	O
","	O
KDM6A	O
","	O
KRAS	O
","	O
MGA	O
","	O
MLL3	O
","	O
PTEN	O
","	O
RASA1	O
","	O
SMARCB1	O
","	O
SPEN	O
","	O
TBC1D12	O
","	O
and	O
VHL	O
.	O
	
TP53	O
was	O
recurrently	O
mutated	O
in	O
three	O
cases	O
","	O
whereas	O
CNBD1	O
and	O
RB1	O
mutations	O
were	O
identified	O
in	O
two	O
cases	O
.	O
	
Three	O
GEP	B-Disease
-	I-Disease
NET	I-Disease
patients	O
with	O
TP53	O
mutations	O
demonstrated	O
a	O
durable	O
response	O
and	O
one	O
small	O
intestinal	B-Disease
grade	I-Disease
(	I-Disease
G	I-Disease
)	I-Disease
1	I-Disease
NET	I-Disease
patient	O
with	O
BRAF	O
V600E	O
mutation	O
showed	O
progression	O
after	O
pazopanib	O
treatment	O
.	O
	
We	O
found	O
BRAF	O
V600E	O
(	O
G1	O
NET	B-Disease
from	O
rectum	O
and	O
two	O
G3	O
NETs	B-Disease
from	O
colon	O
)	O
and	O
BRAF	O
G593S	O
(	O
G2	O
NET	B-Disease
from	O
pancreas	O
)	O
missense	O
mutations	O
(	O
9	O
.	O
1	O
%)	O
in	O
an	O
independent	O
cohort	O
of	O
44	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
from	O
the	O
rectum	O
(	O
n	O
=	O
26	O
"),"	O
colon	O
(	O
n	O
=	O
7	O
"),"	O
pancreas	O
(	O
n	O
=	O
4	O
"),"	O
small	O
intestine	O
(	O
n	O
=	O
3	O
"),"	O
stomach	O
(	O
n	O
=	O
3	O
)	O
and	O
appendix	O
(	O
n	O
=	O
1	O
)	O
by	O
Sanger	O
sequencing	O
.	O
	
All	O
tumor	B-Disease
specimens	O
were	O
obtained	O
before	O
chemotherapy	O
.	O
	
In	O
conclusion	O
","	O
BRAF	O
V600E	O
mutation	O
is	O
likely	O
to	O
result	O
in	O
resistance	O
to	O
pazopanib	O
but	O
may	O
be	O
a	O
potentianally	O
actionable	O
mutation	O
in	O
metastatic	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
patients	O
.	O
	
MicroRNA	O
deep	O
sequencing	O
in	O
two	O
adult	O
stem	O
cell	O
populations	O
identifies	O
miR	O
-	O
501	O
as	O
a	O
novel	O
regulator	O
of	O
myosin	O
heavy	O
chain	O
during	O
muscle	O
regeneration	O
.	O
	
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
important	O
regulators	O
of	O
skeletal	O
muscle	O
regeneration	O
","	O
but	O
the	O
underlying	O
mechanisms	O
are	O
still	O
incompletely	O
understood	O
.	O
	
Here	O
","	O
comparative	O
miRNA	O
sequencing	O
analysis	O
of	O
myogenic	O
progenitor	O
cells	O
(	O
MPs	O
)	O
and	O
non	O
-	O
myogenic	O
fibroblast	O
-	O
adipocyte	O
progenitors	O
(	O
FAPs	O
)	O
during	O
cardiotoxin	O
(	O
CTX	O
)-	O
induced	O
muscle	B-Disease
injury	I-Disease
uncovered	O
miR	O
-	O
501	O
as	O
a	O
novel	O
muscle	O
-	O
specific	O
miRNA	O
.	O
	
miR	O
-	O
501	O
is	O
an	O
intronic	O
miRNA	O
and	O
its	O
expression	O
levels	O
in	O
MPs	O
correlated	O
with	O
its	O
host	O
gene	O
","	O
chloride	O
channel	O
","	O
voltage	O
-	O
sensitive	O
5	O
(	O
Clcn5	O
).	O
	
Pharmacological	O
inhibition	O
of	O
miR	O
-	O
501	O
dramatically	O
blunted	O
the	O
induction	O
of	O
embryonic	O
myosin	O
heavy	O
chain	O
(	O
MYH3	O
)	O
and	O
","	O
to	O
a	O
lesser	O
extent	O
","	O
adult	O
myosin	O
isoforms	O
during	O
muscle	O
regeneration	O
","	O
and	O
promoted	O
small	O
-	O
diameter	O
neofibers	O
.	O
	
An	O
unbiased	O
target	O
identification	O
approach	O
in	O
primary	O
myoblasts	O
validated	O
gigaxonin	O
as	O
a	O
target	O
of	O
miR	O
-	O
501	O
that	O
mimicked	O
the	O
effect	O
of	O
miR	O
-	O
501	O
inhibition	O
on	O
MYH3	O
expression	O
.	O
	
In	O
the	O
mdx	O
mouse	O
model	O
","	O
which	O
models	O
a	O
pathological	O
disease	O
state	O
","	O
not	O
only	O
was	O
miR	O
-	O
501	O
induced	O
in	O
regenerating	O
skeletal	O
muscle	O
","	O
but	O
also	O
its	O
serum	O
levels	O
were	O
increased	O
","	O
which	O
correlated	O
with	O
the	O
disease	O
state	O
of	O
the	O
animals	O
.	O
	
Our	O
results	O
suggest	O
that	O
miR	O
-	O
501	O
plays	O
a	O
key	O
role	O
in	O
adult	O
muscle	O
regeneration	O
and	O
might	O
serve	O
as	O
a	O
novel	O
serum	O
biomarker	O
for	O
the	O
activation	O
of	O
adult	O
muscle	O
stem	O
cells	O
.	O
	
Strong	O
association	O
of	O
677	O
C	O
>	O
T	O
substitution	O
in	O
the	O
MTHFR	O
gene	O
with	O
male	B-Disease
infertility	I-Disease
--	O
a	O
study	O
on	O
an	O
indian	O
population	O
and	O
a	O
meta	O
-	O
analysis	O
.	O
	
BACKGROUND	O
:	O
Methylenetetrahydrofolate	O
reductase	O
(	O
MTHFR	O
)	O
is	O
an	O
important	O
enzyme	O
of	O
folate	O
and	O
methionine	O
metabolism	O
","	O
making	O
it	O
crucial	O
for	O
DNA	O
synthesis	O
and	O
methylation	O
.	O
	
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
MTHFR	O
gene	O
677C	O
>	O
T	O
polymorphism	O
in	O
infertile	O
male	O
individuals	O
from	O
North	O
India	O
","	O
followed	O
by	O
a	O
meta	O
-	O
analysis	O
on	O
our	O
data	O
and	O
published	O
studies	O
.	O
	
METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
undertook	O
genotyping	O
on	O
a	O
total	O
of	O
837	O
individuals	O
including	O
well	O
characterized	O
infertile	O
(	O
N	O
=	O
522	O
)	O
and	O
confirmed	O
fertile	O
(	O
N	O
=	O
315	O
)	O
individuals	O
.	O
	
The	O
SNP	O
was	O
typed	O
by	O
direct	O
DNA	O
sequencing	O
.	O
	
Chi	O
square	O
test	O
was	O
done	O
for	O
statistical	O
analysis	O
.	O
	
Published	O
studies	O
were	O
searched	O
using	O
appropriate	O
keywords	O
.	O
	
Source	O
of	O
data	O
collection	O
for	O
meta	O
-	O
analysis	O
included	O
'	O
Pubmed	O
"',"	O
'	O
Ovid	O
'	O
and	O
'	O
Google	O
Scholar	O
'.	O
	
Those	O
studies	O
analyzing	O
677C	O
>	O
T	O
polymorphism	O
in	O
male	B-Disease
infertility	I-Disease
and	O
presenting	O
all	O
relevant	O
data	O
were	O
included	O
in	O
meta	O
-	O
analysis	O
.	O
	
The	O
genotype	O
data	O
for	O
infertile	O
subjects	O
and	O
fertile	O
controls	O
was	O
extracted	O
from	O
each	O
study	O
.	O
	
Chi	O
square	O
test	O
was	O
done	O
to	O
obtain	O
odds	O
ratio	O
(	O
OR	O
)	O
and	O
p	O
-	O
value	O
.	O
	
Meta	O
-	O
analysis	O
was	O
performed	O
using	O
Comprehensive	O
Meta	O
-	O
analysis	O
software	O
(	O
Version	O
2	O
).	O
	
The	O
frequency	O
of	O
mutant	O
(	O
T	O
)	O
allele	O
(	O
p	O
=	O
0	O
.	O
25	O
)	O
and	O
genotypes	O
(	O
CT	O
+	O
TT	O
)	O
(	O
p	O
=	O
0	O
.	O
187	O
)	O
was	O
significantly	O
higher	O
in	O
infertile	O
individuals	O
in	O
comparison	O
to	O
fertile	O
controls	O
in	O
our	O
case	O
-	O
control	O
study	O
.	O
	
The	O
overall	O
summary	O
estimate	O
(	O
OR	O
)	O
for	O
allele	O
and	O
genotype	O
meta	O
-	O
analysis	O
were	O
1	O
.	O
304	O
(	O
p	O
=	O
0	O
.	O
0	O
"),"	O
1	O
.	O
310	O
(	O
p	O
=	O
0	O
.	O
0	O
"),"	O
respectively	O
","	O
establishing	O
significant	O
association	O
of	O
677C	O
>	O
T	O
polymorphism	O
with	O
male	B-Disease
infertility	I-Disease
.	O
	
CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
677C	O
>	O
T	O
substitution	O
associated	O
strongly	O
with	O
male	B-Disease
infertility	I-Disease
in	O
Indian	O
population	O
.	O
	
Allele	O
and	O
genotype	O
meta	O
-	O
analysis	O
also	O
supported	O
its	O
strong	O
correlation	O
with	O
male	B-Disease
infertility	I-Disease
","	O
thus	O
establishing	O
it	O
as	O
a	O
risk	O
factor	O
.	O
	
Screening	O
for	O
exonic	O
copy	O
number	O
mutations	O
at	O
MSH2	O
and	O
MLH1	O
by	O
MAPH	O
.	O
	
BACKGROUND	O
:	O
Exonic	O
deletions	O
in	O
MSH2	O
and	O
MLH1	O
are	O
significant	O
contributors	O
to	O
the	O
mutation	O
spectrum	O
in	O
HNPCC	B-Disease
","	O
and	O
heterozygous	O
changes	O
in	O
exon	O
copy	O
number	O
are	O
not	O
detected	O
by	O
conventional	O
mutation	O
screening	O
methods	O
.	O
	
AIMS	O
:	O
We	O
aimed	O
to	O
develop	O
methods	O
for	O
screening	O
copy	O
number	O
changes	O
in	O
all	O
the	O
exons	O
of	O
the	O
MLH1	O
and	O
MSH2	O
genes	O
using	O
a	O
single	O
multiplex	O
amplifiable	O
probe	O
hybridisation	O
(	O
MAPH	O
)	O
assay	O
.	O
	
METHODS	O
:	O
We	O
developed	O
a	O
probe	O
set	O
consisting	O
of	O
probes	O
from	O
the	O
19	O
exons	O
of	O
MLH1	O
and	O
16	O
exons	O
of	O
MSH2	O
","	O
and	O
3	O
control	O
probes	O
","	O
and	O
applied	O
it	O
to	O
screening	O
for	O
deletions	O
and	O
duplications	O
using	O
fluorescent	O
detection	O
of	O
amplified	O
fragments	O
.	O
	
RESULTS	O
:	O
We	O
tested	O
73	O
DNA	O
samples	O
from	O
controls	O
and	O
50	O
from	O
HNPCC	B-Disease
patients	O
in	O
whom	O
no	O
point	O
mutations	O
had	O
been	O
found	O
","	O
and	O
detected	O
10	O
copy	O
number	O
changes	O
among	O
the	O
patient	O
samples	O
.	O
	
A	O
deletion	O
of	O
about	O
1	O
.	O
4	O
kb	O
including	O
exon	O
3	O
of	O
MSH2	O
was	O
confirmed	O
by	O
amplification	O
of	O
a	O
junction	O
fragment	O
","	O
and	O
was	O
shown	O
to	O
be	O
the	O
result	O
of	O
an	O
unequal	O
recombination	O
between	O
intronic	O
Alu	O
elements	O
.	O
	
CONCLUSIONS	O
:	O
MAPH	O
can	O
detect	O
exonic	O
copy	O
number	O
changes	O
in	O
MLH1	O
and	O
MSH2	O
in	O
DNA	O
from	O
HNPCC	B-Disease
patients	O
.	O
	
Since	O
finding	O
an	O
exonic	O
deletion	O
or	O
duplication	O
makes	O
full	O
sequence	O
analysis	O
unnecessary	O
","	O
it	O
may	O
be	O
most	O
cost	O
-	O
effective	O
to	O
pre	O
-	O
screen	O
samples	O
by	O
MAPH	O
or	O
MLPA	O
before	O
screening	O
for	O
point	O
mutations	O
.	O
	
Analysis	O
of	O
-	O
1082	O
IL	O
-	O
10	O
gene	O
polymorphism	O
in	O
Iranian	O
patients	O
with	O
generalized	O
aggressive	B-Disease
periodontitis	I-Disease
.	O
	
BACKGROUND	O
:	O
Periodontitis	B-Disease
is	O
a	O
multifactorial	O
disease	O
and	O
its	O
severe	O
forms	O
","	O
such	O
as	O
aggressive	B-Disease
periodontitis	I-Disease
","	O
are	O
suggested	O
to	O
have	O
a	O
genetic	O
basis	O
.	O
	
Among	O
the	O
genetic	O
factors	O
","	O
polymorphisms	O
in	O
cytokine	O
genes	O
have	O
recently	O
been	O
described	O
in	O
susceptibility	O
to	O
periodontitis	B-Disease
.	O
	
IL	O
-	O
10	O
is	O
a	O
multi	O
-	O
functional	O
cytokine	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
periodontitis	B-Disease
.	O
	
A	O
substitution	O
G	O
/	O
A	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL	O
-	O
10	O
gene	O
at	O
position	O
-	O
1082	O
has	O
been	O
associated	O
with	O
different	O
amounts	O
of	O
IL	O
-	O
10	O
production	O
.	O
	
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
links	O
between	O
-	O
1082	O
(	O
G	O
/	O
A	O
)	O
polymorphism	O
of	O
the	O
IL	O
-	O
10	O
gene	O
and	O
the	O
generalized	O
form	O
of	O
aggressive	B-Disease
periodontitis	I-Disease
.	O
	
MATERIAL	O
/	O
METHODS	O
:	O
This	O
study	O
included	O
52	O
Iranian	O
Khorasanian	O
(	O
north	O
-	O
east	O
province	O
of	O
Iran	O
)	O
subjects	O
suffering	O
from	O
generalized	O
aggressive	B-Disease
periodontitis	I-Disease
referred	O
to	O
the	O
Periodontology	O
Department	O
of	O
Mashhad	O
Dental	O
School	O
.	O
	
They	O
were	O
compared	O
to	O
61	O
age	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
of	O
the	O
same	O
race	O
.	O
	
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
cells	O
and	O
genotyping	O
was	O
performed	O
by	O
means	O
of	O
the	O
amplification	O
refractory	O
mutation	O
system	O
polymerase	O
chain	O
reaction	O
(	O
ARMS	O
-	O
PCR	O
)	O
method	O
.	O
	
Data	O
were	O
analyzed	O
using	O
the	O
chi	O
-	O
squared	O
test	O
.	O
	
RESULTS	O
:	O
There	O
was	O
no	O
marked	O
difference	O
in	O
genotype	O
frequencies	O
between	O
the	O
controls	O
and	O
generalized	O
aggressive	B-Disease
periodontitis	I-Disease
patients	O
(	O
p	O
=	O
0	O
.	O
585	O
).	O
	
Moreover	O
","	O
no	O
association	O
between	O
patients	O
and	O
normal	O
subjects	O
was	O
found	O
in	O
their	O
allele	O
frequency	O
(	O
p	O
=	O
0	O
.	O
329	O
).	O
	
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
the	O
polymorphic	O
nucleotide	O
A	O
at	O
position	O
-	O
1082	O
of	O
the	O
IL	O
-	O
10	O
gene	O
is	O
not	O
associated	O
with	O
generalized	O
aggressive	B-Disease
periodontitis	I-Disease
in	O
the	O
Iranian	O
population	O
.	O
	
U87MG	O
decoded	O
:	O
the	O
genomic	O
sequence	O
of	O
a	O
cytogenetically	O
aberrant	O
human	O
cancer	B-Disease
cell	O
line	O
.	O
	
U87MG	O
is	O
a	O
commonly	O
studied	O
grade	B-Disease
IV	I-Disease
glioma	I-Disease
cell	O
line	O
that	O
has	O
been	O
analyzed	O
in	O
at	O
least	O
1	O
","	O
700	O
publications	O
over	O
four	O
decades	O
.	O
	
In	O
order	O
to	O
comprehensively	O
characterize	O
the	O
genome	O
of	O
this	O
cell	O
line	O
and	O
to	O
serve	O
as	O
a	O
model	O
of	O
broad	O
cancer	B-Disease
genome	O
sequencing	O
","	O
we	O
have	O
generated	O
greater	O
than	O
30x	O
genomic	O
sequence	O
coverage	O
using	O
a	O
novel	O
50	O
-	O
base	O
mate	O
paired	O
strategy	O
with	O
a	O
1	O
.	O
4kb	O
mean	O
insert	O
library	O
.	O
	
A	O
total	O
of	O
1	O
","	O
14	O
","	O
984	O
","	O
286	O
mate	O
-	O
end	O
and	O
120	O
","	O
691	O
","	O
623	O
single	O
-	O
end	O
two	O
-	O
base	O
encoded	O
reads	O
were	O
generated	O
from	O
five	O
slides	O
.	O
	
All	O
data	O
were	O
aligned	O
using	O
a	O
custom	O
designed	O
tool	O
called	O
BFAST	O
","	O
allowing	O
optimal	O
color	O
space	O
read	O
alignment	O
and	O
accurate	O
identification	O
of	O
DNA	O
variants	O
.	O
	
The	O
aligned	O
sequence	O
reads	O
and	O
mate	O
-	O
pair	O
information	O
identified	O
35	O
interchromosomal	O
translocation	O
events	O
","	O
1	O
","	O
315	O
structural	O
variations	O
(>	O
100	O
bp	O
"),"	O
191	O
","	O
743	O
small	O
(<	O
21	O
bp	O
)	O
insertions	O
and	O
deletions	O
(	O
indels	O
"),"	O
and	O
2	O
","	O
384	O
","	O
470	O
single	O
nucleotide	O
variations	O
(	O
SNVs	O
).	O
	
Among	O
these	O
observations	O
","	O
the	O
known	O
homozygous	O
mutation	O
in	O
PTEN	O
was	O
robustly	O
identified	O
","	O
and	O
genes	O
involved	O
in	O
cell	O
adhesion	O
were	O
overrepresented	O
in	O
the	O
mutated	O
gene	O
list	O
.	O
	
Data	O
were	O
compared	O
to	O
219	O
","	O
187	O
heterozygous	O
single	O
nucleotide	O
polymorphisms	O
assayed	O
by	O
Illumina	O
1M	O
Duo	O
genotyping	O
array	O
to	O
assess	O
accuracy	O
:	O
93	O
.	O
83	O
%	O
of	O
all	O
SNPs	O
were	O
reliably	O
detected	O
at	O
filtering	O
thresholds	O
that	O
yield	O
greater	O
than	O
99	O
.	O
99	O
%	O
sequence	O
accuracy	O
.	O
	
Protein	O
coding	O
sequences	O
were	O
disrupted	O
predominantly	O
in	O
this	O
cancer	B-Disease
cell	O
line	O
due	O
to	O
small	O
indels	O
","	O
large	O
deletions	O
","	O
and	O
translocations	O
.	O
	
In	O
total	O
","	O
512	O
genes	O
were	O
homozygously	O
mutated	O
","	O
including	O
154	O
by	O
SNVs	O
","	O
178	O
by	O
small	O
indels	O
","	O
145	O
by	O
large	O
microdeletions	O
","	O
and	O
35	O
by	O
interchromosomal	O
translocations	O
to	O
reveal	O
a	O
highly	O
mutated	O
cell	O
line	O
genome	O
.	O
	
Of	O
the	O
small	O
homozygously	O
mutated	O
variants	O
","	O
8	O
SNVs	O
and	O
99	O
indels	O
were	O
novel	O
events	O
not	O
present	O
in	O
dbSNP	O
.	O
	
These	O
data	O
demonstrate	O
that	O
routine	O
generation	O
of	O
broad	O
cancer	B-Disease
genome	O
sequence	O
is	O
possible	O
outside	O
of	O
genome	O
centers	O
.	O
	
The	O
sequence	O
analysis	O
of	O
U87MG	O
provides	O
an	O
unparalleled	O
level	O
of	O
mutational	O
resolution	O
compared	O
to	O
any	O
cell	O
line	O
to	O
date	O
.	O
	
Repeated	O
otilonium	O
bromide	O
administration	O
prevents	O
neurotransmitter	O
changes	O
in	O
colon	O
of	O
rats	O
underwent	O
to	O
wrap	O
restraint	O
stress	O
.	O
	
Otilonium	O
bromide	O
(	O
OB	O
)	O
is	O
a	O
spasmolytic	O
drug	O
successfully	O
used	O
for	O
the	O
treatment	O
of	O
irritable	B-Disease
bowel	I-Disease
syndrome	I-Disease
(	O
IBS	B-Disease
).	O
	
Its	O
efficacy	O
has	O
been	O
attributed	O
to	O
the	O
block	O
of	O
L	O
-	O
and	O
T	O
-	O
type	O
Ca	O
(	O
2	O
+)	O
channels	O
and	O
muscarinic	O
and	O
tachykinin	O
receptors	O
in	O
the	O
smooth	O
muscle	O
.	O
	
Furthermore	O
","	O
in	O
healthy	O
rats	O
","	O
repeated	O
OB	O
administration	O
modified	O
neurotransmitter	O
expression	O
and	O
function	O
suggesting	O
other	O
mechanisms	O
of	O
action	O
.	O
	
On	O
this	O
basis	O
","	O
we	O
investigated	O
whether	O
repeated	O
OB	O
treatment	O
prevented	O
the	O
functional	O
and	O
neurochemical	O
changes	O
observed	O
in	O
the	O
colon	O
of	O
rats	O
underwent	O
to	O
wrap	O
restrain	O
stress	O
(	O
WRS	O
)	O
a	O
psychosocial	O
stressor	O
considered	O
suitable	O
to	O
reproduce	O
the	O
main	O
IBS	B-Disease
signs	O
and	O
symptoms	O
.	O
	
In	O
control	O
","	O
WRS	O
and	O
OB	O
/	O
WRS	O
rats	O
functional	O
parameters	O
were	O
measured	O
in	O
vivo	O
and	O
morphological	O
investigations	O
were	O
done	O
ex	O
vivo	O
in	O
the	O
colon	O
.	O
	
The	O
results	O
showed	O
that	O
OB	O
counteracts	O
most	O
of	O
the	O
neurotransmitters	O
changes	O
caused	O
by	O
WRS	O
.	O
	
In	O
particular	O
","	O
the	O
drug	O
prevents	O
the	O
decrease	O
in	O
SP	O
"-,"	O
NK1r	O
"-,"	O
nNOS	O
"-,"	O
VIP	O
"-,"	O
and	O
S100b	O
-	O
immunoreactivity	O
(	O
IR	O
)	O
and	O
the	O
increase	O
in	O
CGRP	O
"-,"	O
and	O
CRF1r	O
-	O
IR	O
.	O
	
On	O
the	O
contrary	O
","	O
OB	O
does	O
not	O
affect	O
the	O
increase	O
in	O
CRF2r	O
-	O
IR	O
neurons	O
observed	O
in	O
WRS	O
rats	O
and	O
does	O
not	O
interfere	O
with	O
the	O
mild	O
mucosal	B-Disease
inflammation	I-Disease
due	O
to	O
WRS	O
.	O
	
Finally	O
","	O
OB	O
per	O
se	O
increases	O
the	O
Mr2	O
expression	O
in	O
the	O
muscle	O
wall	O
and	O
decreases	O
the	O
number	O
of	O
the	O
myenteric	O
ChAT	O
-	O
IR	O
neurons	O
.	O
	
Functional	O
findings	O
show	O
a	O
significantly	O
reduction	O
in	O
the	O
number	O
of	O
spontaneous	O
abdominal	O
contraction	O
in	O
OB	O
treated	O
rats	O
.	O
	
The	O
ability	O
of	O
OB	O
to	O
block	O
L	O
-	O
type	O
Ca	O
(	O
2	O
+)	O
channels	O
","	O
also	O
expressed	O
by	O
enteric	O
neurons	O
","	O
might	O
represent	O
a	O
possible	O
mechanism	O
through	O
which	O
OB	O
exerts	O
its	O
actions	O
.	O
	
Clusters	O
of	O
multidrug	O
-	O
resistant	O
Mycobacterium	O
tuberculosis	O
cases	O
","	O
Europe	O
.	O
	
Molecular	O
surveillance	O
of	O
multidrug	B-Disease
-	I-Disease
resistant	I-Disease
tuberculosis	I-Disease
(	O
MDR	B-Disease
TB	I-Disease
)	O
was	O
implemented	O
in	O
Europe	O
as	O
case	O
reporting	O
in	O
2005	O
.	O
	
For	O
all	O
new	O
MDR	B-Disease
TB	I-Disease
cases	O
detected	O
from	O
January	O
2003	O
through	O
June	O
2007	O
","	O
countries	O
reported	O
case	O
-	O
based	O
epidemiologic	O
data	O
and	O
DNA	O
fingerprint	O
patterns	O
of	O
MDR	B-Disease
TB	I-Disease
strains	O
when	O
available	O
.	O
	
International	O
clusters	O
were	O
detected	O
and	O
analyzed	O
.	O
	
From	O
2003	O
through	O
mid	O
-	O
2007	O
in	O
Europe	O
","	O
2	O
","	O
494	O
cases	O
of	O
MDR	B-Disease
TB	I-Disease
were	O
reported	O
from	O
24	O
European	O
countries	O
.	O
	
Epidemiologic	O
and	O
molecular	O
data	O
were	O
linked	O
for	O
593	O
(	O
39	O
%)	O
cases	O
","	O
and	O
672	O
insertion	O
sequence	O
6110	O
DNA	O
fingerprint	O
patterns	O
were	O
reported	O
from	O
19	O
countries	O
.	O
	
Of	O
these	O
patterns	O
","	O
288	O
(	O
43	O
%)	O
belonged	O
to	O
18	O
European	O
clusters	O
;	O
7	O
clusters	O
(	O
242	O
/	O
288	O
cases	O
","	O
84	O
%)	O
were	O
characterized	O
by	O
strains	O
of	O
the	O
Beijing	O
genotype	O
family	O
","	O
including	O
the	O
largest	O
cluster	O
(	O
175	O
/	O
288	O
cases	O
","	O
61	O
%).	O
	
Both	O
clustering	O
and	O
the	O
Beijing	O
genotype	O
were	O
associated	O
with	O
strains	O
originating	O
in	O
eastern	O
European	O
countries	O
.	O
	
Molecular	O
cluster	O
detection	O
contributes	O
to	O
identification	O
of	O
transmission	O
profile	O
","	O
risk	O
factors	O
","	O
and	O
control	O
measures	O
.	O
	
An	O
inducible	O
mouse	O
model	O
of	O
podocin	O
-	O
mutation	O
-	O
related	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
Mutations	O
in	O
the	O
NPHS2	O
gene	O
","	O
encoding	O
podocin	O
","	O
cause	O
hereditary	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
The	O
most	O
common	O
podocin	O
mutation	O
","	O
R138Q	O
","	O
is	O
associated	O
with	O
early	O
disease	O
onset	O
and	O
rapid	O
progression	O
to	O
end	O
-	O
stage	O
renal	B-Disease
disease	I-Disease
.	O
	
Knock	O
-	O
in	O
mice	O
carrying	O
a	O
R140Q	O
mutation	O
","	O
the	O
mouse	O
analogue	O
of	O
human	O
R138Q	O
","	O
show	O
developmental	O
arrest	O
of	O
podocytes	O
and	O
lethal	O
renal	B-Disease
failure	I-Disease
at	O
neonatal	O
age	O
.	O
	
Here	O
we	O
created	O
a	O
conditional	O
podocin	O
knock	O
-	O
in	O
model	O
named	O
NPHS2	O
R140Q	O
"/-,"	O
using	O
a	O
tamoxifen	O
-	O
inducible	O
Cre	O
recombinase	O
","	O
which	O
permits	O
to	O
study	O
the	O
effects	O
of	O
the	O
mutation	O
in	O
postnatal	O
life	O
.	O
	
Within	O
the	O
first	O
week	O
of	O
R140Q	O
hemizygosity	O
induction	O
the	O
animals	O
developed	O
proteinuria	B-Disease
","	O
which	O
peaked	O
after	O
4	O
-	O
5	O
weeks	O
.	O
	
Subsequently	O
the	O
animals	O
developed	O
progressive	O
renal	B-Disease
failure	I-Disease
","	O
with	O
a	O
median	O
survival	O
time	O
of	O
12	O
(	O
95	O
%	O
CI	O
:	O
11	O
-	O
13	O
)	O
weeks	O
.	O
	
Foot	O
process	O
fusion	O
was	O
observed	O
within	O
one	O
week	O
","	O
progressing	O
to	O
severe	O
and	O
global	O
effacement	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O
	
The	O
number	O
of	O
podocytes	O
per	O
glomerulus	O
gradually	O
diminished	O
to	O
18	O
%	O
compared	O
to	O
healthy	O
controls	O
12	O
-	O
16	O
weeks	O
after	O
induction	O
.	O
	
The	O
fraction	O
of	O
segmentally	O
sclerosed	O
glomeruli	O
was	O
25	O
"%,"	O
85	O
%	O
and	O
97	O
%	O
at	O
2	O
","	O
4	O
and	O
8	O
weeks	O
","	O
respectively	O
.	O
	
Severe	O
tubulointerstitial	B-Disease
fibrosis	I-Disease
was	O
present	O
at	O
later	O
disease	O
stage	O
and	O
was	O
correlated	O
quantitatively	O
with	O
the	O
level	O
of	O
proteinuria	B-Disease
at	O
early	O
disease	O
stages	O
.	O
	
While	O
R140Q	O
podocin	O
mRNA	O
expression	O
was	O
elevated	O
","	O
protein	O
abundance	O
was	O
reduced	O
by	O
more	O
than	O
50	O
%	O
within	O
one	O
week	O
following	O
induction	O
.	O
	
Whereas	O
miRNA21	O
expression	O
persistently	O
increased	O
during	O
the	O
first	O
4	O
weeks	O
","	O
miRNA	O
-	O
193a	O
expression	O
peaked	O
2	O
weeks	O
after	O
induction	O
.	O
	
In	O
conclusion	O
","	O
the	O
inducible	O
R140Q	O
-	O
podocin	O
mouse	O
model	O
is	O
an	O
auspicious	O
model	O
of	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
human	O
nephrotic	B-Disease
syndrome	I-Disease
","	O
with	O
a	O
spontaneous	O
disease	O
course	O
strongly	O
reminiscent	O
of	O
the	O
human	O
disorder	O
.	O
	
This	O
model	O
constitutes	O
a	O
valuable	O
tool	O
to	O
test	O
the	O
efficacy	O
of	O
novel	O
pharmacological	O
interventions	O
aimed	O
to	O
improve	O
podocyte	O
function	O
and	O
viability	O
and	O
attenuate	O
proteinuria	B-Disease
","	O
glomerulosclerosis	B-Disease
and	O
progressive	O
renal	B-Disease
failure	I-Disease
.	O
	
Over	O
-	O
expression	O
of	O
BMP4	O
and	O
BMP5	O
in	O
a	O
child	O
with	O
axial	B-Disease
skeletal	I-Disease
malformations	I-Disease
and	O
heterotopic	B-Disease
ossification	I-Disease
:	O
a	O
new	O
syndrome	O
.	O
	
Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
are	O
a	O
highly	O
conserved	O
class	O
of	O
signaling	O
molecules	O
that	O
induce	O
ectopic	B-Disease
cartilage	I-Disease
and	I-Disease
bone	I-Disease
formation	I-Disease
in	O
vivo	O
.	O
	
Dysregulated	O
expression	O
of	O
bone	O
morphogenetic	O
protein	O
4	O
(	O
BMP4	O
)	O
is	O
found	O
in	O
the	O
cells	O
of	O
patients	O
who	O
have	O
fibrodysplasia	B-Disease
ossificans	I-Disease
progressiva	I-Disease
(	O
FOP	B-Disease
"),"	O
a	O
genetic	O
disorder	O
of	O
axial	B-Disease
and	I-Disease
appendicular	I-Disease
skeletal	I-Disease
malformation	I-Disease
and	O
progressive	O
heterotopic	B-Disease
ossification	I-Disease
.	O
	
Loss	O
of	O
function	O
mutations	O
in	O
the	O
bone	O
morphogenetic	O
protein	O
5	O
(	O
bmp5	O
)	O
gene	O
leading	O
to	O
under	O
-	O
expression	O
of	O
BMP5	O
cause	O
the	O
murine	O
short	B-Disease
ear	I-Disease
syndrome	I-Disease
","	O
characterized	O
by	O
small	O
malformed	O
ears	O
and	O
a	O
broad	O
range	O
of	O
axial	B-Disease
skeletal	I-Disease
malformations	I-Disease
.	O
	
We	O
found	O
features	O
reminiscent	O
of	O
both	O
the	O
short	O
ear	O
mouse	O
and	O
FOP	B-Disease
in	O
a	O
child	O
with	O
malformed	B-Disease
external	I-Disease
ears	I-Disease
","	O
multiple	B-Disease
malformations	I-Disease
of	I-Disease
the	I-Disease
axial	I-Disease
skeleton	I-Disease
","	O
and	O
progressive	O
heterotopic	B-Disease
ossification	I-Disease
in	O
the	O
neck	O
and	O
back	O
.	O
	
We	O
examined	O
BMP	O
mRNA	O
expression	O
in	O
transformed	O
lymphocytes	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
and	O
protein	O
expression	O
by	O
ELISA	O
assays	O
and	O
immunohistochemistry	O
.	O
	
Elevated	O
levels	O
of	O
BMP4	O
and	O
BMP5	O
mRNA	O
and	O
protein	O
were	O
detected	O
in	O
the	O
patient	O
'	O
s	O
cells	O
while	O
levels	O
of	O
BMP2	O
mRNA	O
were	O
unchanged	O
.	O
	
Our	O
data	O
suggest	O
that	O
dysregulated	O
expression	O
of	O
BMP4	O
and	O
BMP5	O
genes	O
is	O
associated	O
with	O
an	O
array	O
of	O
human	O
axial	B-Disease
skeletal	I-Disease
abnormalities	I-Disease
similar	O
to	O
the	O
short	O
ear	O
mouse	O
and	O
FOP	B-Disease
.	O
	
Sex	O
-	O
differential	O
genetic	O
effect	O
of	O
phosphodiesterase	O
4D	O
(	O
PDE4D	O
)	O
on	O
carotid	B-Disease
atherosclerosis	I-Disease
.	O
	
BACKGROUND	O
:	O
The	O
phosphodiesterase	O
4D	O
(	O
PDE4D	O
)	O
gene	O
was	O
reported	O
as	O
a	O
susceptibility	O
gene	O
to	O
stroke	B-Disease
.	O
	
The	O
genetic	O
effect	O
might	O
be	O
attributed	O
to	O
its	O
role	O
in	O
modulating	O
the	O
atherogenic	B-Disease
process	O
in	O
the	O
carotid	O
arteries	O
.	O
	
Using	O
carotid	O
intima	O
-	O
media	O
thickness	O
(	O
IMT	O
)	O
and	O
plaque	O
index	O
as	O
phenotypes	O
","	O
the	O
present	O
study	O
sought	O
to	O
determine	O
the	O
influence	O
of	O
this	O
gene	O
on	O
subclinical	O
atherosclerosis	B-Disease
.	O
	
METHODS	O
:	O
Carotid	O
ultrasonography	O
was	O
performed	O
on	O
1013	O
stroke	B-Disease
-	O
free	O
subjects	O
who	O
participated	O
in	O
the	O
health	O
screening	O
programs	O
(	O
age	O
52	O
.	O
6	O
+/-	O
12	O
.	O
2	O
;	O
47	O
.	O
6	O
%	O
men	O
).	O
	
Genotype	O
distribution	O
was	O
compared	O
among	O
the	O
high	O
-	O
risk	O
(	O
plaque	O
index	O
>	O
or	O
=	O
4	O
"),"	O
low	O
-	O
risk	O
(	O
index	O
=	O
1	O
-	O
3	O
"),"	O
and	O
reference	O
(	O
index	O
=	O
0	O
)	O
groups	O
.	O
	
We	O
analyzed	O
continuous	O
IMT	O
data	O
and	O
further	O
dichotomized	O
IMT	O
data	O
using	O
mean	O
plus	O
one	O
standard	O
deviation	O
as	O
the	O
cutoff	O
level	O
.	O
	
Because	O
the	O
plaque	O
prevalence	O
and	O
IMT	O
values	O
displayed	O
a	O
notable	O
difference	O
between	O
men	O
and	O
women	O
","	O
we	O
carried	O
out	O
sex	O
-	O
specific	O
analyses	O
in	O
addition	O
to	O
analyzing	O
the	O
overall	O
data	O
.	O
	
Rs702553	O
at	O
the	O
PDE4D	O
gene	O
was	O
selected	O
because	O
it	O
conferred	O
a	O
risk	O
for	O
young	O
stroke	B-Disease
in	O
our	O
previous	O
report	O
.	O
	
Previous	O
young	O
stroke	B-Disease
data	O
(	O
190	O
cases	O
and	O
211	O
controls	O
)	O
with	O
an	O
additional	O
532	O
control	O
subjects	O
without	O
ultrasonic	O
data	O
were	O
shown	O
as	O
a	O
cross	O
-	O
validation	O
for	O
the	O
genetic	O
effect	O
.	O
	
RESULTS	O
:	O
In	O
the	O
overall	O
analyses	O
","	O
the	O
rare	O
homozygote	O
of	O
rs702553	O
led	O
to	O
an	O
OR	O
of	O
3	O
.	O
1	O
(	O
p	O
=	O
0	O
.	O
34	O
)	O
for	O
a	O
plaque	O
index	O
>	O
or	O
=	O
4	O
.	O
	
When	O
subjects	O
were	O
stratified	O
by	O
sex	O
","	O
the	O
genetic	O
effect	O
was	O
only	O
evident	O
in	O
men	O
but	O
not	O
in	O
women	O
.	O
	
Comparing	O
male	O
subjects	O
with	O
plaque	O
index	O
>	O
or	O
=	O
4	O
and	O
those	O
with	O
plaque	O
index	O
=	O
0	O
","	O
the	O
TT	O
genotype	O
was	O
over	O
-	O
represented	O
(	O
27	O
.	O
6	O
%	O
vs	O
.	O
	
13	O
.	O
4	O
"%,"	O
p	O
=	O
0	O
.	O
8	O
).	O
	
For	O
dichotomized	O
IMT	O
data	O
in	O
men	O
","	O
the	O
TT	O
genotype	O
had	O
an	O
OR	O
of	O
2	O
.	O
1	O
(	O
p	O
=	O
0	O
.	O
32	O
)	O
for	O
a	O
thicker	O
IMT	O
at	O
the	O
common	O
carotid	O
artery	O
compared	O
with	O
the	O
(	O
AA	O
+	O
AT	O
)	O
genotypes	O
.	O
	
In	O
women	O
","	O
neither	O
IMT	O
nor	O
plaque	O
index	O
was	O
associated	O
with	O
rs702553	O
.	O
	
Similarly	O
","	O
SNP	O
rs702553	O
was	O
only	O
significant	O
in	O
young	O
stroke	B-Disease
men	O
(	O
OR	O
=	O
1	O
.	O
8	O
","	O
p	O
=	O
0	O
.	O
25	O
)	O
but	O
not	O
in	O
women	O
(	O
p	O
=	O
0	O
.	O
27	O
).	O
	
CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrates	O
a	O
sex	O
-	O
differential	O
effect	O
of	O
PDE4D	O
on	O
IMT	O
","	O
plaque	O
index	O
and	O
stroke	B-Disease
","	O
which	O
highlights	O
its	O
influence	O
on	O
various	O
aspects	O
of	O
atherogenesis	B-Disease
.	O
	
Detection	O
of	O
EGFR	O
mutations	O
in	O
plasma	O
DNA	O
from	O
lung	B-Disease
cancer	I-Disease
patients	O
by	O
mass	O
spectrometry	O
genotyping	O
is	O
predictive	O
of	O
tumor	B-Disease
EGFR	O
status	O
and	O
response	O
to	O
EGFR	O
inhibitors	O
.	O
	
AIMS	O
:	O
EGFR	O
mutations	O
now	O
guide	O
the	O
clinical	O
use	O
of	O
EGFR	O
-	O
targeted	O
therapy	O
in	O
lung	B-Disease
cancer	I-Disease
.	O
	
However	O
","	O
standard	O
EGFR	O
mutation	O
analysis	O
requires	O
a	O
minimum	O
amount	O
of	O
tumor	B-Disease
tissue	O
","	O
which	O
may	O
not	O
be	O
available	O
in	O
certain	O
situations	O
.	O
	
In	O
this	O
study	O
","	O
we	O
combined	O
a	O
mass	O
spectrometry	O
genotyping	O
assay	O
(	O
Sequenom	O
)	O
with	O
a	O
mutant	O
-	O
enriched	O
PCR	O
(	O
ME	O
-	O
PCR	O
)	O
to	O
detect	O
EGFR	O
mutations	O
in	O
free	O
plasma	O
DNA	O
from	O
patients	O
with	O
lung	B-Disease
cancer	I-Disease
.	O
	
METHOD	O
:	O
DNAs	O
were	O
extracted	O
from	O
31	O
plasma	O
samples	O
from	O
31	O
patients	O
and	O
analyzed	O
by	O
both	O
methods	O
for	O
EGFR	O
Exon	O
19	O
deletion	O
and	O
EGFR	O
L858R	O
mutation	O
.	O
	
Results	O
in	O
plasma	O
DNA	O
samples	O
were	O
compared	O
with	O
EGFR	O
mutation	O
status	O
obtained	O
in	O
tumor	B-Disease
DNA	O
(	O
18	O
/	O
31	O
EGFR	O
mutant	O
).	O
	
The	O
relationship	O
of	O
EGFR	O
mutation	O
status	O
in	O
tumor	B-Disease
and	O
/	O
or	O
plasma	O
samples	O
to	O
overall	O
survival	O
was	O
assessed	O
.	O
	
RESULTS	O
:	O
The	O
EGFR	O
mutation	O
status	O
in	O
plasma	O
DNA	O
was	O
identical	O
to	O
the	O
primary	O
tumor	B-Disease
in	O
61	O
%	O
of	O
patients	O
(	O
19	O
/	O
31	O
).	O
	
By	O
mass	O
spectrometry	O
genotyping	O
","	O
the	O
plasma	O
samples	O
contained	O
mutant	O
DNA	O
corresponding	O
to	O
5	O
/	O
14	O
EGFR	O
Exon	O
19	O
deletions	O
and	O
3	O
/	O
4	O
EGFR	O
L858R	O
mutations	O
previously	O
diagnosed	O
in	O
the	O
matched	O
tumors	B-Disease
.	O
	
Two	O
samples	O
were	O
positive	O
in	O
plasma	O
DNA	O
but	O
negative	O
in	O
primary	O
tumor	B-Disease
tissue	O
.	O
	
Results	O
were	O
similar	O
for	O
samples	O
studied	O
by	O
ME	O
-	O
PCR	O
.	O
	
For	O
patients	O
treated	O
with	O
erlotinib	O
","	O
overall	O
survival	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
EGFR	O
mutation	O
in	O
plasma	O
and	O
/	O
or	O
tumor	B-Disease
tissue	O
(	O
p	O
=	O
0	O
.	O
2	O
"),"	O
with	O
the	O
two	O
patients	O
positive	O
only	O
in	O
plasma	O
DNA	O
showing	O
responses	O
and	O
favorable	O
outcomes	O
.	O
	
CONCLUSION	O
:	O
The	O
detection	O
of	O
EGFR	O
mutations	O
in	O
plasma	O
DNA	O
samples	O
by	O
mass	O
spectrometry	O
genotyping	O
and	O
ME	O
-	O
PCR	O
is	O
feasible	O
.	O
	
A	O
positive	O
EGFR	O
result	O
in	O
plasma	O
DNA	O
has	O
a	O
high	O
predictive	O
value	O
for	O
tumor	B-Disease
EGFR	O
status	O
and	O
for	O
favorable	O
clinical	O
course	O
on	O
EGFR	O
-	O
targeted	O
therapy	O
and	O
could	O
therefore	O
be	O
useful	O
in	O
guiding	O
clinical	O
decisions	O
in	O
patients	O
with	O
insufficient	O
or	O
unavailable	O
tumor	B-Disease
specimens	O
.	O
	
Psoriasin	O
promotes	O
invasion	O
","	O
aggregation	O
and	O
survival	O
of	O
pancreatic	B-Disease
cancer	I-Disease
cells	O
;	O
association	O
with	O
disease	O
progression	O
.	O
	
Psoriasin	O
(	O
S100A7	O
)	O
is	O
an	O
11	O
-	O
kDa	O
small	O
calcium	O
binding	O
protein	O
initially	O
isolated	O
from	O
psoriatic	B-Disease
skin	I-Disease
lesions	I-Disease
.	O
	
It	O
belongs	O
to	O
the	O
S100	O
family	O
of	O
proteins	O
which	O
play	O
an	O
important	O
role	O
in	O
a	O
range	O
of	O
cell	O
functions	O
including	O
proliferation	O
","	O
differentiation	O
","	O
migration	O
and	O
apoptosis	O
.	O
	
Aberrant	O
Psoriasin	O
expression	O
has	O
been	O
implicated	O
in	O
a	O
range	O
of	O
cancers	B-Disease
and	O
is	O
often	O
associated	O
with	O
poor	O
prognosis	O
.	O
	
This	O
study	O
examined	O
the	O
role	O
of	O
Psoriasin	O
on	O
pancreatic	B-Disease
cancer	I-Disease
cell	O
functions	O
and	O
the	O
implication	O
in	O
progression	O
of	O
the	O
disease	O
.	O
	
Expression	O
of	O
Psoriasin	O
was	O
determined	O
in	O
a	O
cohort	O
of	O
pancreatic	O
tissues	O
comprised	O
of	O
126	O
pancreatic	B-Disease
tumours	I-Disease
and	O
114	O
adjacent	O
non	O
-	O
tumour	O
pancreatic	O
tissues	O
.	O
	
Knockdown	O
and	O
overexpression	O
of	O
Psoriasin	O
in	O
pancreatic	B-Disease
cancer	I-Disease
cells	O
was	O
performed	O
using	O
specifically	O
constructed	O
plasmids	O
","	O
which	O
either	O
had	O
anti	O
-	O
Psoriasin	O
ribozyme	O
transgene	O
or	O
the	O
full	O
length	O
human	O
Psoriasin	O
coding	O
sequence	O
.	O
	
Psoriasin	O
knockdown	O
and	O
overexpression	O
was	O
verified	O
using	O
conventional	O
RT	O
-	O
PCR	O
and	O
qPCR	O
.	O
	
The	O
effect	O
of	O
manipulating	O
Psoriasin	O
expression	O
on	O
pancreatic	B-Disease
cancer	I-Disease
cell	O
functions	O
was	O
assessed	O
using	O
several	O
in	O
vitro	O
cell	O
function	O
assays	O
.	O
	
Local	O
invasive	O
pancreatic	B-Disease
cancers	I-Disease
extended	O
beyond	O
the	O
pancreas	O
expressed	O
higher	O
levels	O
of	O
Psoriasin	O
transcripts	O
compared	O
with	O
the	O
cancers	B-Disease
confined	O
to	O
the	O
pancreas	O
.	O
	
Primary	B-Disease
tumours	I-Disease
with	O
distant	O
metastases	B-Disease
exhibited	O
a	O
reduced	O
expression	O
of	O
Psoriasin	O
.	O
	
Psoriasin	O
overexpression	O
cell	O
lines	O
exhibited	O
significantly	O
increased	O
growth	O
and	O
migration	O
compared	O
to	O
control	O
cells	O
.	O
	
In	O
addition	O
","	O
Psoriasin	O
overexpression	O
resulted	O
in	O
increased	O
pancreatic	B-Disease
cancer	I-Disease
cell	O
invasion	O
which	O
was	O
associated	O
with	O
upregulation	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
(	O
MMP	O
-	O
2	O
)	O
and	O
MMP	O
-	O
9	O
.	O
	
Overexpression	O
of	O
Psoriasin	O
also	O
promoted	O
aggregation	O
and	O
survival	O
of	O
pancreatic	B-Disease
cancer	I-Disease
cells	O
when	O
they	O
lost	O
anchorage	O
.	O
	
Taken	O
together	O
","	O
higher	O
expression	O
of	O
Psoriasin	O
was	O
associated	O
with	O
local	O
invasion	O
in	O
pancreatic	B-Disease
cancers	I-Disease
.	O
	
Psoriasin	O
expression	O
is	O
associated	O
with	O
pancreatic	B-Disease
cancer	I-Disease
cell	O
growth	O
","	O
migration	O
","	O
cell	O
-	O
matrix	O
adhesion	O
","	O
and	O
invasion	O
via	O
regulation	O
of	O
MMPs	O
.	O
	
As	O
such	O
","	O
the	O
proposed	O
implications	O
of	O
Psoriasin	O
in	O
invasion	O
","	O
disease	O
progression	O
and	O
as	O
a	O
potential	O
therapeutic	O
target	O
warrant	O
further	O
investigation	O
.	O
	
Two	O
novel	O
mutations	O
in	O
SRY	O
gene	O
form	O
Chinese	O
sex	B-Disease
reversal	I-Disease
XY	I-Disease
females	O
.	O
	
The	O
SRY	O
gene	O
(	O
sex	O
determining	O
region	O
on	O
Y	O
chromosome	O
)	O
acts	O
as	O
TDF	O
and	O
is	O
required	O
for	O
regulating	O
male	O
sex	O
determination	O
.	O
	
SRY	O
represents	O
a	O
transcription	O
factor	O
belonging	O
to	O
the	O
superfamily	O
of	O
genes	O
sharing	O
the	O
HMG	O
-	O
box	O
motif	O
(	O
high	O
-	O
mobility	O
group	O
-	O
box	O
"),"	O
which	O
acts	O
as	O
DNA	O
binding	O
region	O
.	O
	
Deletion	O
and	O
inactivating	O
mutations	O
of	O
SRY	O
are	O
among	O
the	O
known	O
causes	O
of	O
XY	B-Disease
sex	I-Disease
reversal	I-Disease
.	O
	
Here	O
","	O
we	O
described	O
the	O
screening	O
of	O
10	O
patients	O
who	O
presented	O
with	O
46	B-Disease
","	I-Disease
XY	I-Disease
sex	I-Disease
reversal	I-Disease
for	O
mutations	O
in	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
SRY	O
gene	O
.	O
	
DNA	O
was	O
isolated	O
from	O
blood	O
samples	O
using	O
standard	O
techniques	O
.	O
	
A	O
609	O
bp	O
fragment	O
from	O
the	O
central	O
portion	O
of	O
the	O
SRY	O
gene	O
was	O
amplified	O
","	O
using	O
primers	O
XES	O
-	O
2	O
and	O
XES	O
-	O
7	O
.	O
	
The	O
amplified	O
PCR	O
fragments	O
were	O
cloned	O
into	O
the	O
pUCm	O
-	O
T	O
vectors	O
","	O
and	O
direct	O
sequencing	O
were	O
carried	O
out	O
on	O
an	O
ABI	O
377	O
-	O
3	O
automated	O
DNA	O
sequencer	O
to	O
detect	O
the	O
mutation	O
.	O
	
PCR	O
-	O
restriction	O
enzyme	O
digestion	O
was	O
applied	O
to	O
detect	O
the	O
results	O
of	O
DNA	O
sequencing	O
.	O
	
In	O
two	O
patients	O
","	O
de	O
novo	O
mutations	O
led	O
to	O
an	O
amino	O
acid	O
substitution	O
.	O
	
An	O
A	O
was	O
replaced	O
by	O
a	O
G	O
in	O
codon	O
38	O
upstream	O
of	O
the	O
5	O
'	O
border	O
outside	O
the	O
HMG	O
box	O
of	O
the	O
SRY	O
gene	O
","	O
resulting	O
in	O
the	O
replacement	O
of	O
the	O
amino	O
acid	O
glutamate	O
by	O
glycine	O
.	O
	
Another	O
heterozygous	O
T	O
to	O
A	O
transition	O
at	O
the	O
nucleotide	O
position	O
+	O
387	O
which	O
encodes	O
for	O
a	O
Tyrosine	O
(	O
Tyr	O
)	O
instead	O
of	O
a	O
Term	O
","	O
whereas	O
her	O
father	O
was	O
proven	O
to	O
have	O
the	O
wild	O
-	O
type	O
sequence	O
.	O
	
These	O
point	O
mutations	O
have	O
been	O
confirmed	O
with	O
PCR	O
-	O
restrict	O
enzyme	O
method	O
.	O
	
As	O
demonstrated	O
by	O
the	O
Human	O
Gene	O
Mutation	O
Database	O
analysis	O
","	O
homology	O
search	O
","	O
and	O
review	O
of	O
the	O
literature	O
","	O
these	O
two	O
mutations	O
were	O
not	O
described	O
previously	O
and	O
brought	O
the	O
total	O
number	O
of	O
SRY	O
gene	O
nucleotide	O
substitutions	O
(	O
missense	O
/	O
nonsense	O
)	O
to	O
45	O
.	O
	
These	O
findings	O
indicated	O
that	O
these	O
amino	O
acid	O
substitutions	O
may	O
be	O
responsible	O
for	O
the	O
sex	B-Disease
reversal	I-Disease
","	O
not	O
only	O
inside	O
the	O
HMG	O
-	O
box	O
but	O
also	O
outside	O
the	O
HMG	O
-	O
box	O
.	O
	
The	O
two	O
novel	O
mutations	O
in	O
SRY	O
gene	O
provided	O
valuable	O
information	O
for	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
the	O
patient	O
with	O
46	B-Disease
","	I-Disease
XY	I-Disease
female	I-Disease
sex	I-Disease
reversal	I-Disease
.	O
	
A	O
novel	O
missense	O
mutation	O
","	O
F826Y	O
","	O
in	O
the	O
mineralocorticoid	O
receptor	O
gene	O
in	O
Japanese	O
hypertensives	B-Disease
:	O
its	O
implications	O
for	O
clinical	O
phenotypes	O
.	O
	
A	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
resulting	O
in	O
the	O
S810L	O
amino	O
acid	O
substitution	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
","	O
locus	O
symbol	O
NR3C2	O
)	O
is	O
responsible	O
for	O
early	O
-	O
onset	O
hypertension	B-Disease
that	O
is	O
exacerbated	O
in	O
pregnancy	O
.	O
	
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
other	O
types	O
of	O
missense	O
mutations	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
could	O
be	O
implicated	O
in	O
hypertension	B-Disease
in	O
Japanese	O
.	O
	
Here	O
","	O
we	O
screened	O
942	O
Japanese	O
patients	O
with	O
hypertension	B-Disease
for	O
the	O
S810L	O
mutation	O
in	O
exon	O
6	O
in	O
the	O
MR	O
.	O
	
We	O
did	O
not	O
identify	O
the	O
S810L	O
mutation	O
in	O
our	O
hypertensive	B-Disease
population	O
","	O
indicating	O
that	O
S810L	O
does	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
etiology	O
of	O
essential	B-Disease
hypertension	I-Disease
in	O
Japanese	O
.	O
	
However	O
","	O
we	O
identified	O
a	O
novel	O
missense	O
mutation	O
","	O
F826Y	O
","	O
in	O
three	O
patients	O
in	O
a	O
heterozygous	O
state	O
","	O
in	O
addition	O
to	O
four	O
single	O
nucleotide	O
polymorphisms	O
","	O
including	O
one	O
synonymous	O
mutation	O
(	O
L809L	O
).	O
	
The	O
F826Y	O
mutation	O
is	O
present	O
in	O
the	O
MR	O
hormone	O
-	O
binding	O
domain	O
and	O
might	O
affect	O
the	O
ligand	O
affinity	O
.	O
	
The	O
F826Y	O
mutation	O
was	O
also	O
identified	O
in	O
13	O
individuals	O
(	O
5	O
hypertensives	B-Disease
and	O
8	O
normotensives	O
)	O
in	O
a	O
Japanese	O
general	O
population	O
(	O
n	O
=	O
3	O
","	O
655	O
).	O
	
The	O
allele	O
frequency	O
was	O
0	O
.	O
178	O
.	O
	
The	O
frequencies	O
of	O
the	O
F826Y	O
mutation	O
in	O
the	O
hypertensive	B-Disease
population	O
(	O
3	O
/	O
942	O
)	O
and	O
in	O
the	O
hypertensive	B-Disease
group	O
(	O
5	O
/	O
1	O
","	O
480	O
)	O
and	O
the	O
normotensive	O
group	O
(	O
8	O
/	O
2	O
","	O
175	O
)	O
in	O
the	O
general	O
population	O
were	O
not	O
significantly	O
different	O
","	O
suggesting	O
that	O
this	O
mutation	O
does	O
not	O
greatly	O
affect	O
hypertension	B-Disease
.	O
	
Although	O
it	O
is	O
unclear	O
at	O
present	O
whether	O
or	O
not	O
the	O
F826Y	O
mutation	O
makes	O
a	O
substantial	O
contribution	O
to	O
the	O
mineralocorticoid	O
receptor	O
activity	O
","	O
this	O
missense	O
mutation	O
may	O
contribute	O
","	O
to	O
some	O
extent	O
","	O
to	O
clinical	O
phenotypes	O
through	O
its	O
effects	O
on	O
MR	O
.	O
	
Myocardial	O
Fas	O
ligand	O
expression	O
increases	O
susceptibility	O
to	O
AZT	O
-	O
induced	O
cardiomyopathy	B-Disease
.	O
	
BACKGROUND	O
:	O
Dilated	B-Disease
cardiomyopathy	I-Disease
(	O
DCM	B-Disease
)	O
and	O
myocarditis	B-Disease
occur	O
in	O
many	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
","	O
resulting	O
in	O
symptomatic	O
heart	B-Disease
failure	I-Disease
in	O
up	O
to	O
5	O
%	O
of	O
patients	O
.	O
	
Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
significantly	O
reduced	O
morbidity	O
and	O
mortality	O
of	O
acquired	B-Disease
immunodeficiency	I-Disease
syndrome	I-Disease
(	O
AIDS	B-Disease
"),"	O
but	O
has	O
resulted	O
in	O
an	O
increase	O
in	O
cardiac	B-Disease
and	I-Disease
skeletal	I-Disease
myopathies	I-Disease
.	O
	
METHODS	O
AND	O
RESULTS	O
:	O
In	O
order	O
to	O
investigate	O
whether	O
the	O
HAART	O
component	O
zidovudine	O
(	O
3	O
'-	O
azido	O
-	O
2	O
"',"	O
3	O
'-	O
deoxythymidine	O
;	O
AZT	O
)	O
triggers	O
the	O
Fas	O
-	O
dependent	O
cell	O
-	O
death	O
pathway	O
and	O
cause	O
cytoskeletal	O
disruption	O
in	O
a	O
murine	O
model	O
of	O
DCM	B-Disease
","	O
8	O
-	O
week	O
-	O
old	O
transgenic	O
(	O
expressing	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
:	O
FasL	O
Tg	O
)	O
and	O
non	O
-	O
transgenic	O
(	O
NTg	O
)	O
mice	O
received	O
water	O
ad	O
libitum	O
containing	O
different	O
concentrations	O
of	O
AZT	O
(	O
0	O
","	O
0	O
.	O
7	O
","	O
0	O
.	O
2	O
","	O
and	O
0	O
.	O
7	O
mg	O
/	O
ml	O
).	O
	
After	O
6	O
weeks	O
","	O
cardiac	O
function	O
was	O
assessed	O
by	O
echocardiography	O
and	O
morphology	O
was	O
assessed	O
by	O
histopathologic	O
and	O
immunohistochemical	O
methods	O
.	O
	
NTg	O
and	O
untreated	O
FasL	O
Tg	O
mice	O
showed	O
little	O
or	O
no	O
change	O
in	O
cardiac	O
structure	O
or	O
function	O
.	O
	
In	O
contrast	O
","	O
AZT	O
-	O
treated	O
FasL	O
Tg	O
mice	O
developed	O
cardiac	B-Disease
dilation	I-Disease
and	O
depressed	B-Disease
cardiac	I-Disease
function	I-Disease
in	O
a	O
dose	O
-	O
dependent	O
manner	O
","	O
with	O
concomitant	O
inflammatory	B-Disease
infiltration	O
of	O
both	O
ventricles	O
.	O
	
These	O
changes	O
were	O
associated	O
with	O
an	O
increased	O
sarcolemmal	O
expression	O
of	O
Fas	O
and	O
FasL	O
","	O
as	O
well	O
as	O
increased	O
activation	O
of	O
caspase	O
3	O
","	O
translocation	O
of	O
calpain	O
1	O
to	O
the	O
sarcolemma	O
and	O
sarcomere	O
","	O
and	O
increased	O
numbers	O
of	O
cells	O
undergoing	O
apoptosis	O
.	O
	
These	O
were	O
associated	O
with	O
changes	O
in	O
dystrophin	O
and	O
cardiac	O
troponin	O
I	O
localization	O
","	O
as	O
well	O
as	O
loss	O
of	O
sarcolemmal	O
integrity	O
.	O
	
CONCLUSIONS	O
:	O
The	O
expression	O
of	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
","	O
as	O
identified	O
in	O
HIV	O
-	O
positive	O
patients	O
","	O
might	O
increase	O
the	O
susceptibility	O
to	O
HAART	O
-	O
induced	O
cardiomyopathy	B-Disease
due	O
to	O
activation	O
of	O
apoptotic	O
pathways	O
","	O
resulting	O
in	O
cardiac	B-Disease
dilation	I-Disease
and	I-Disease
dysfunction	I-Disease
.	O
	
Familial	O
glucocorticoid	O
receptor	O
haploinsufficiency	O
by	O
non	O
-	O
sense	O
mediated	O
mRNA	O
decay	O
","	O
adrenal	B-Disease
hyperplasia	I-Disease
and	O
apparent	B-Disease
mineralocorticoid	I-Disease
excess	I-Disease
.	O
	
Primary	O
glucocorticoid	B-Disease
resistance	I-Disease
(	O
OMIM	B-Disease
138040	I-Disease
)	O
is	O
a	O
rare	O
hereditary	B-Disease
disease	I-Disease
that	O
causes	O
a	O
generalized	O
partial	O
insensitivity	O
to	O
glucocorticoid	O
action	O
","	O
due	O
to	O
genetic	O
alterations	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
).	O
	
Investigation	O
of	O
adrenal	B-Disease
incidentalomas	I-Disease
led	O
to	O
the	O
discovery	O
of	O
a	O
family	O
(	O
eight	O
affected	O
individuals	O
spanning	O
three	O
generations	O
"),"	O
prone	O
to	O
cortisol	B-Disease
resistance	I-Disease
","	O
bilateral	B-Disease
adrenal	I-Disease
hyperplasia	I-Disease
","	O
arterial	O
hypertension	B-Disease
and	O
hypokalemia	B-Disease
.	O
	
This	O
phenotype	O
exacerbated	O
over	O
time	O
","	O
cosegregates	O
with	O
the	O
first	O
heterozygous	O
nonsense	O
mutation	O
p	O
.	O
R469	O
[	O
R	O
","	O
X	O
]	O
reported	O
to	O
date	O
for	O
the	O
GR	O
","	O
replacing	O
an	O
arginine	O
(	O
CGA	O
)	O
by	O
a	O
stop	O
(	O
TGA	O
)	O
at	O
amino	O
-	O
acid	O
469	O
in	O
the	O
second	O
zinc	O
finger	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
receptor	O
.	O
	
In	O
vitro	O
","	O
this	O
mutation	O
leads	O
to	O
a	O
truncated	O
50	O
-	O
kDa	O
GR	O
lacking	O
hormone	O
and	O
DNA	O
binding	O
capacity	O
","	O
devoid	O
of	O
hormone	O
-	O
dependent	O
nuclear	O
translocation	O
and	O
transactivation	O
properties	O
.	O
	
In	O
the	O
proband	O
'	O
s	O
fibroblasts	O
","	O
we	O
provided	O
evidence	O
for	O
the	O
lack	O
of	O
expression	O
of	O
the	O
defective	O
allele	O
in	O
vivo	O
.	O
	
The	O
absence	O
of	O
detectable	O
mutated	O
GR	O
mRNA	O
was	O
accompanied	O
by	O
a	O
50	O
%	O
reduction	O
in	O
wild	O
type	O
GR	O
transcript	O
and	O
protein	O
.	O
	
This	O
reduced	O
GR	O
expression	O
leads	O
to	O
a	O
significantly	O
below	O
-	O
normal	O
induction	O
of	O
glucocorticoid	O
-	O
induced	O
target	O
genes	O
","	O
FKBP5	O
in	O
fibroblasts	O
.	O
	
We	O
demonstrated	O
that	O
the	O
molecular	O
mechanisms	O
of	O
glucocorticoid	O
signaling	O
dysfunction	O
involved	O
GR	O
haploinsufficiency	O
due	O
to	O
the	O
selective	O
degradation	O
of	O
the	O
mutated	O
GR	O
transcript	O
through	O
a	O
nonsense	O
-	O
mediated	O
mRNA	O
Decay	O
that	O
was	O
experimentally	O
validated	O
on	O
emetine	O
-	O
treated	O
propositus	O
'	O
fibroblasts	O
.	O
	
GR	O
haploinsufficiency	O
leads	O
to	O
hypertension	B-Disease
due	O
to	O
illicit	O
occupation	O
of	O
renal	O
mineralocorticoid	O
receptor	O
by	O
elevated	O
cortisol	O
rather	O
than	O
to	O
increased	O
mineralocorticoid	O
production	O
reported	O
in	O
primary	O
glucocorticoid	B-Disease
resistance	I-Disease
.	O
	
Indeed	O
","	O
apparent	B-Disease
mineralocorticoid	I-Disease
excess	I-Disease
was	O
demonstrated	O
by	O
a	O
decrease	O
in	O
urinary	O
tetrahydrocortisone	O
-	O
tetrahydrocortisol	O
ratio	O
in	O
affected	O
patients	O
","	O
revealing	O
reduced	O
glucocorticoid	O
degradation	O
by	O
renal	O
activity	O
of	O
the	O
11b	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
2	O
","	O
a	O
GR	O
regulated	O
gene	O
.	O
	
We	O
propose	O
thus	O
that	O
GR	O
haploinsufficiency	O
compromises	O
glucocorticoid	O
sensitivity	O
and	O
may	O
represent	O
a	O
novel	O
genetic	O
cause	O
of	O
subclinical	O
hypercortisolism	B-Disease
","	O
incidentally	O
revealed	O
bilateral	B-Disease
adrenal	I-Disease
hyperplasia	I-Disease
and	O
mineralocorticoid	O
-	O
independent	O
hypertension	B-Disease
.	O
	
Polymorphism	O
of	O
the	O
PEMT	O
gene	O
and	O
susceptibility	O
to	O
nonalcoholic	B-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
(	O
NAFLD	B-Disease
).	O
	
Phosphatidylethanolamine	O
N	O
-	O
methyltransferase	O
(	O
PEMT	O
)	O
catalyzes	O
phosphatidylcholine	O
synthesis	O
.	O
	
PEMT	O
knockout	O
mice	O
have	O
fatty	B-Disease
livers	I-Disease
","	O
and	O
it	O
is	O
possible	O
that	O
","	O
in	O
humans	O
","	O
nonalcoholic	B-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
(	O
NAFLD	B-Disease
)	O
might	O
be	O
associated	O
with	O
PEMT	O
gene	O
polymorphisms	O
.	O
	
DNA	O
samples	O
from	O
59	O
humans	O
without	O
fatty	B-Disease
liver	I-Disease
and	O
from	O
28	O
humans	O
with	O
NAFLD	B-Disease
were	O
genotyped	O
for	O
a	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
8	O
of	O
PEMT	O
","	O
which	O
leads	O
to	O
a	O
V175M	O
substitution	O
.	O
	
V175M	O
is	O
a	O
loss	O
of	O
function	O
mutation	O
","	O
as	O
determined	O
by	O
transiently	O
transfecting	O
McArdle	O
-	O
RH7777	O
cells	O
with	O
constructs	O
of	O
wild	O
-	O
type	O
PEMT	O
open	O
reading	O
frame	O
or	O
the	O
V175M	O
mutant	O
.	O
	
Met	O
/	O
Met	O
at	O
residue	O
175	O
(	O
loss	O
of	O
function	O
SNP	O
)	O
occurred	O
in	O
67	O
.	O
9	O
%	O
of	O
the	O
NAFLD	B-Disease
subjects	O
and	O
in	O
only	O
40	O
.	O
7	O
%	O
of	O
control	O
subjects	O
(	O
P	O
<	O
0	O
.	O
3	O
).	O
	
For	O
the	O
first	O
time	O
we	O
report	O
that	O
a	O
polymorphism	O
of	O
the	O
human	O
PEMT	O
gene	O
(	O
V175M	O
)	O
is	O
associated	O
with	O
diminished	O
activity	O
and	O
may	O
confer	O
susceptibility	O
to	O
NAFLD	B-Disease
.	O
	
Polymorphisms	O
in	O
the	O
FOXP3	O
gene	O
in	O
Han	O
Chinese	O
psoriasis	B-Disease
patients	O
.	O
	
BACKGROUND	O
:	O
Psoriasis	B-Disease
is	O
a	O
common	O
dermatological	B-Disease
disorder	I-Disease
","	O
in	O
which	O
autoimmunity	O
plays	O
an	O
important	O
role	O
.	O
	
CD4	O
(+)	O
CD25	O
(+)	O
regulatory	O
T	O
cells	O
(	O
T	O
-	O
regs	O
)	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
some	O
autoimmune	B-Disease
diseases	I-Disease
.	O
	
T	O
-	O
regs	O
express	O
the	O
fork	O
head	O
/	O
winged	O
helix	O
transcription	O
factor	O
","	O
FOXP3	O
","	O
which	O
appears	O
to	O
be	O
of	O
key	O
importance	O
in	O
the	O
development	O
and	O
function	O
of	O
T	O
-	O
regs	O
.	O
	
Studies	O
have	O
found	O
that	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
FOXP3	O
gene	O
contribute	O
to	O
susceptibility	O
to	O
some	O
autoimmune	B-Disease
disorders	I-Disease
.	O
	
However	O
","	O
information	O
about	O
FOXP3	O
gene	O
in	O
psoriasis	B-Disease
is	O
limited	O
.	O
	
OBJECTIVE	O
:	O
This	O
study	O
evaluated	O
the	O
association	O
between	O
FOXP3	O
gene	O
SNPs	O
and	O
susceptibility	O
to	O
psoriasis	B-Disease
in	O
a	O
Han	O
Chinese	O
population	O
.	O
	
METHODS	O
:	O
In	O
a	O
hospital	O
-	O
based	O
case	O
-	O
control	O
study	O
","	O
524	O
patients	O
with	O
psoriasis	B-Disease
and	O
549	O
psoriasis	B-Disease
-	O
free	O
controls	O
were	O
recruited	O
according	O
to	O
age	O
and	O
gender	O
.	O
	
We	O
investigated	O
four	O
SNPs	O
in	O
the	O
FOXP3	O
gene	O
(-	O
6054	O
","	O
deletion	O
/	O
ATT	O
;	O
-	O
3279	O
","	O
A	O
/	O
C	O
;	O
-	O
924	O
","	O
A	O
/	O
G	O
;	O
IVS9	O
+	O
459	O
","	O
A	O
/	O
G	O
)	O
in	O
psoriatic	B-Disease
patients	O
","	O
and	O
assessed	O
allele	O
and	O
genotype	O
frequencies	O
in	O
psoriatic	B-Disease
patients	O
(	O
237	O
females	O
","	O
287	O
males	O
)	O
and	O
normal	O
controls	O
(	O
272	O
females	O
","	O
277	O
males	O
).	O
	
The	O
polymorphisms	O
were	O
genotyped	O
using	O
the	O
PCR	O
sequence	O
-	O
specific	O
primer	O
(	O
PCR	O
-	O
SSP	O
)	O
technique	O
and	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O
	
RESULTS	O
:	O
We	O
found	O
that	O
increased	O
risk	O
of	O
psoriasis	B-Disease
was	O
associated	O
with	O
the	O
FOXP3	O
-	O
3279	O
AC	O
genotype	O
(	O
adjusted	O
OR	O
","	O
1	O
.	O
32	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
1	O
-	O
1	O
.	O
74	O
)	O
and	O
the	O
combined	O
AC	O
+	O
AA	O
genotype	O
(	O
adjusted	O
OR	O
","	O
1	O
.	O
38	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
7	O
-	O
1	O
.	O
78	O
"),"	O
compared	O
with	O
the	O
-	O
3279	O
CC	O
genotype	O
.	O
	
We	O
also	O
found	O
that	O
an	O
increased	O
risk	O
of	O
psoriasis	B-Disease
was	O
associated	O
with	O
the	O
FOXP3	O
IVS9	O
+	O
459	O
GG	O
genotype	O
(	O
adjusted	O
OR	O
","	O
2	O
.	O
24	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
41	O
-	O
3	O
.	O
58	O
).	O
	
However	O
","	O
the	O
combined	O
GA	O
+	O
GG	O
genotype	O
showed	O
no	O
such	O
tendency	O
(	O
adjusted	O
OR	O
=	O
1	O
.	O
28	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
0	O
-	O
1	O
.	O
64	O
"),"	O
compared	O
with	O
the	O
IVS9	O
+	O
459	O
AA	O
genotype	O
.	O
	
There	O
was	O
no	O
evidence	O
of	O
an	O
increased	O
risk	O
associated	O
with	O
the	O
FOXP3	O
-	O
6054	O
deletion	O
/	O
ATT	O
or	O
FOXP3	O
-	O
924	O
A	O
/	O
G	O
genotype	O
.	O
	
In	O
combined	O
genotype	O
analyses	O
","	O
the	O
FOXP3	O
-	O
3279	O
AC	O
+	O
AA	O
genotype	O
was	O
more	O
obviously	O
associated	O
in	O
males	O
(	O
adjusted	O
OR	O
=	O
1	O
.	O
60	O
","	O
95	O
%	O
CI	O
=	O
1	O
.	O
11	O
-	O
2	O
.	O
31	O
)	O
and	O
severe	O
psoriasis	B-Disease
patients	O
(	O
PASI	O
score	O
>	O
20	O
;	O
adjusted	O
OR	O
=	O
1	O
.	O
97	O
","	O
95	O
%	O
CI	O
=	O
1	O
.	O
41	O
-	O
2	O
.	O
75	O
).	O
	
Meanwhile	O
","	O
the	O
FOXP3	O
IVS9	O
+	O
459	O
GA	O
+	O
GG	O
genotype	O
was	O
also	O
associated	O
with	O
severe	O
psoriasis	B-Disease
patients	O
(	O
adjusted	O
OR	O
=	O
1	O
.	O
69	O
","	O
95	O
%	O
CI	O
=	O
1	O
.	O
21	O
-	O
2	O
.	O
36	O
).	O
	
CONCLUSIONS	O
:	O
FOXP3	O
polymorphisms	O
appear	O
to	O
contribute	O
to	O
the	O
risk	O
of	O
psoriasis	B-Disease
in	O
a	O
Han	O
Chinese	O
population	O
.	O
	
Larger	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
findings	O
.	O
	
21903317	
Autosomal	O
dominant	O
mutation	O
in	O
the	O
signal	O
peptide	O
of	O
renin	O
in	O
a	O
kindred	O
with	O
anemia	B-Disease
","	O
hyperuricemia	B-Disease
","	O
and	O
CKD	B-Disease
.	O
	
Homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
renin	O
(	O
REN	O
)	O
cause	O
renal	B-Disease
tubular	I-Disease
dysgenesis	I-Disease
","	O
which	O
is	O
characterized	O
by	O
death	B-Disease
in	O
utero	O
due	O
to	O
kidney	B-Disease
failure	I-Disease
and	O
pulmonary	B-Disease
hypoplasia	I-Disease
.	O
	
The	O
phenotype	O
resembles	O
the	O
fetopathy	B-Disease
caused	O
by	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
or	O
angiotensin	O
receptor	O
blocker	O
intake	O
during	O
pregnancy	O
.	O
	
Recently	O
","	O
heterozygous	O
REN	O
mutations	O
were	O
shown	O
to	O
result	O
in	O
early	O
-	O
onset	O
hyperuricemia	B-Disease
","	O
anemia	B-Disease
","	O
and	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
(	O
CKD	B-Disease
).	O
	
To	O
date	O
","	O
only	O
3	O
different	O
heterozygous	O
REN	O
mutations	O
have	O
been	O
published	O
.	O
	
We	O
report	O
mutation	O
analysis	O
of	O
the	O
REN	O
gene	O
in	O
39	O
kindreds	O
with	O
hyperuricemia	B-Disease
and	O
CKD	B-Disease
who	O
previously	O
tested	O
negative	O
for	O
mutations	O
in	O
the	O
UMOD	O
(	O
uromodulin	O
)	O
and	O
HNF1B	O
(	O
hepatocyte	O
nuclear	O
factor	O
1b	O
)	O
genes	O
.	O
	
We	O
identified	O
one	O
kindred	O
with	O
a	O
novel	O
thymidine	O
to	O
cytosine	O
mutation	O
at	O
position	O
28	O
in	O
the	O
REN	O
complementary	O
DNA	O
","	O
corresponding	O
to	O
a	O
tryptophan	O
to	O
arginine	O
substitution	O
at	O
amino	O
acid	O
10	O
","	O
which	O
is	O
found	O
within	O
the	O
signal	O
sequence	O
(	O
c	O
.	O
28T	O
>	O
C	O
;	O
p	O
.	O
W10R	O
).	O
	
On	O
this	O
basis	O
","	O
we	O
conclude	O
that	O
REN	O
mutations	O
are	O
rare	O
events	O
in	O
patients	O
with	O
CKD	B-Disease
.	O
	
Within	O
the	O
kindred	O
","	O
we	O
found	O
affected	O
individuals	O
over	O
4	O
generations	O
who	O
carried	O
the	O
novel	O
REN	O
mutation	O
and	O
were	O
characterized	O
by	O
significant	O
anemia	B-Disease
","	O
hyperuricemia	B-Disease
","	O
and	O
CKD	B-Disease
.	O
	
Anemia	B-Disease
was	O
severe	O
and	O
disproportional	O
to	O
the	O
degree	O
of	O
decreased	O
kidney	O
function	O
.	O
	
Because	O
all	O
heterozygous	O
REN	O
mutations	O
that	O
have	O
been	O
described	O
are	O
localized	O
in	O
the	O
signal	O
sequence	O
","	O
screening	O
of	O
the	O
REN	O
gene	O
for	O
patients	O
with	O
CKD	B-Disease
with	O
hyperuricemia	B-Disease
and	O
anemia	B-Disease
may	O
best	O
be	O
focused	O
on	O
sequencing	O
of	O
exon	O
1	O
","	O
which	O
encodes	O
the	O
signal	O
peptide	O
.	O
	
27103577	
On	O
the	O
pivotal	O
role	O
of	O
PPARa	O
in	O
adaptation	O
of	O
the	O
heart	O
to	O
hypoxia	B-Disease
and	O
why	O
fat	O
in	O
the	O
diet	O
increases	O
hypoxic	B-Disease
injury	O
.	O
	
The	O
role	O
of	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
a	O
(	O
PPARa	O
)-	O
mediated	O
metabolic	O
remodeling	O
in	O
cardiac	O
adaptation	O
to	O
hypoxia	B-Disease
has	O
yet	O
to	O
be	O
defined	O
.	O
	
Here	O
","	O
mice	O
were	O
housed	O
in	O
hypoxia	B-Disease
for	O
3	O
wk	O
before	O
in	O
vivo	O
contractile	O
function	O
was	O
measured	O
using	O
cine	O
MRI	O
.	O
	
In	O
isolated	O
","	O
perfused	O
hearts	O
","	O
energetics	O
were	O
measured	O
using	O
(	O
31	O
)	O
P	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
"),"	O
and	O
glycolysis	O
and	O
fatty	O
acid	O
oxidation	O
were	O
measured	O
using	O
[(	O
3	O
)	O
H	O
]	O
labeling	O
.	O
	
Compared	O
with	O
a	O
normoxic	O
","	O
chow	O
-	O
fed	O
control	O
mouse	O
heart	O
","	O
hypoxia	B-Disease
decreased	O
PPARa	O
expression	O
","	O
fatty	O
acid	O
oxidation	O
","	O
and	O
mitochondrial	O
uncoupling	O
protein	O
3	O
(	O
UCP3	O
)	O
levels	O
","	O
while	O
increasing	O
glycolysis	O
","	O
all	O
of	O
which	O
served	O
to	O
maintain	O
normal	O
ATP	O
concentrations	O
([	O
ATP	O
])	O
and	O
thereby	O
","	O
ejection	O
fractions	O
.	O
	
A	O
high	O
-	O
fat	O
diet	O
increased	O
cardiac	O
PPARa	O
expression	O
","	O
fatty	O
acid	O
oxidation	O
","	O
and	O
UCP3	O
levels	O
with	O
decreased	O
glycolysis	O
.	O
	
Hypoxia	B-Disease
was	O
unable	O
to	O
alter	O
the	O
high	O
PPARa	O
expression	O
or	O
reverse	O
the	O
metabolic	O
changes	O
caused	O
by	O
the	O
high	O
-	O
fat	O
diet	O
","	O
with	O
the	O
result	O
that	O
[	O
ATP	O
]	O
and	O
contractile	O
function	O
decreased	O
significantly	O
.	O
	
The	O
adaptive	O
metabolic	O
changes	O
caused	O
by	O
hypoxia	B-Disease
in	O
control	O
mouse	O
hearts	O
were	O
found	O
to	O
have	O
occurred	O
already	O
in	O
PPARa	O
-	O
deficient	O
(	O
PPARa	O
(-/-))	O
mouse	O
hearts	O
and	O
sustained	O
function	O
in	O
hypoxia	B-Disease
despite	O
an	O
inability	O
for	O
further	O
metabolic	O
remodeling	O
.	O
	
We	O
conclude	O
that	O
decreased	O
cardiac	O
PPARa	O
expression	O
is	O
essential	O
for	O
adaptive	O
metabolic	O
remodeling	O
in	O
hypoxia	B-Disease
","	O
but	O
is	O
prevented	O
by	O
dietary	O
fat	O
.-	O
Cole	O
","	O
M	O
.	O
A	O
".,"	O
Abd	O
Jamil	O
","	O
A	O
.	O
H	O
".,"	O
Heather	O
","	O
L	O
.	O
C	O
".,"	O
Murray	O
","	O
A	O
.	O
J	O
".,"	O
Sutton	O
","	O
E	O
.	O
R	O
".,"	O
Slingo	O
","	O
M	O
".,"	O
Sebag	O
-	O
Montefiore	O
","	O
L	O
".,"	O
Tan	O
","	O
S	O
.	O
C	O
".,"	O
Aksentijevic	O
","	O
D	O
".,"	O
Gildea	O
","	O
O	O
.	O
S	O
".,"	O
Stuckey	O
","	O
D	O
.	O
J	O
".,"	O
Yeoh	O
","	O
K	O
.	O
K	O
".,"	O
Carr	O
","	O
C	O
.	O
A	O
".,"	O
Evans	O
","	O
R	O
.	O
D	O
".,"	O
Aasum	O
","	O
E	O
".,"	O
Schofield	O
","	O
C	O
.	O
J	O
".,"	O
Ratcliffe	O
","	O
P	O
.	O
J	O
".,"	O
Neubauer	O
","	O
S	O
".,"	O
Robbins	O
","	O
P	O
.	O
A	O
".,"	O
Clarke	O
","	O
K	O
.	O
On	O
the	O
pivotal	O
role	O
of	O
PPARa	O
in	O
adaptation	O
of	O
the	O
heart	O
to	O
hypoxia	B-Disease
and	O
why	O
fat	O
in	O
the	O
diet	O
increases	O
hypoxic	B-Disease
injury	O
.	O
	
27491646	
Gartanin	O
induces	O
cell	O
cycle	O
arrest	O
and	O
autophagy	O
and	O
suppresses	O
migration	O
involving	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
and	O
MAPK	O
signalling	O
pathway	O
in	O
human	O
glioma	B-Disease
cells	O
.	O
	
In	O
central	O
nervous	O
system	O
","	O
glioma	B-Disease
is	O
the	O
most	O
common	O
primary	B-Disease
brain	I-Disease
tumour	I-Disease
.	O
	
The	O
diffuse	O
migration	O
and	O
rapid	O
proliferation	O
are	O
main	O
obstacles	O
for	O
successful	O
treatment	O
.	O
	
Gartanin	O
","	O
a	O
natural	O
xanthone	O
of	O
mangosteen	O
","	O
suppressed	O
proliferation	O
","	O
migration	O
and	O
colony	O
formation	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
in	O
T98G	O
glioma	B-Disease
cells	O
but	O
not	O
in	O
mouse	O
normal	O
neuronal	O
HT22	O
cells	O
.	O
	
Gartanin	O
","	O
at	O
low	O
micromole	O
","	O
led	O
to	O
cell	O
cycle	O
arrest	O
in	O
G1	O
phase	O
accompanied	O
by	O
inhibited	O
expression	O
level	O
of	O
G1	O
cell	O
cycle	O
regulatory	O
proteins	O
cyclin	O
D1	O
","	O
while	O
increased	O
expression	O
level	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p27Kip1	O
.	O
	
In	O
addition	O
","	O
the	O
secretion	O
and	O
activity	O
of	O
matrix	O
metalloproteinases	O
2	O
/	O
9	O
(	O
MMP	O
-	O
2	O
/-	O
9	O
)	O
were	O
significantly	O
suppressed	O
in	O
T98G	O
cells	O
treated	O
with	O
gartanin	O
","	O
and	O
it	O
might	O
result	O
from	O
modulating	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPK	O
)	O
signalling	O
pathway	O
in	O
T98G	O
glioma	B-Disease
cells	O
.	O
	
Moreover	O
","	O
gartanin	O
significantly	O
induced	O
autophagy	O
in	O
T98G	O
cells	O
and	O
increased	O
GFP	O
-	O
LC3	O
punctate	O
fluorescence	O
accompanied	O
by	O
the	O
increased	O
expression	O
level	O
of	O
Beclin	O
1	O
and	O
LC3	O
-	O
II	O
","	O
while	O
suppressed	O
expression	O
level	O
of	O
p62	O
.	O
	
Gartanin	O
treatment	O
resulted	O
in	O
obvious	O
inhibition	O
of	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
signalling	O
pathway	O
","	O
which	O
is	O
important	O
in	O
modulating	O
autophagy	O
.	O
	
Notably	O
","	O
gartanin	O
-	O
mediated	O
anti	O
-	O
viability	O
was	O
significantly	O
abrogated	O
by	O
autophagy	O
inhibitors	O
including	O
3	O
-	O
methyladenine	O
(	O
3	O
-	O
MA	O
)	O
and	O
chloroquine	O
(	O
CQ	O
).	O
	
These	O
results	O
indicate	O
that	O
anti	O
-	O
proliferation	O
effect	O
of	O
gartanin	O
in	O
T98G	O
cells	O
is	O
most	O
likely	O
via	O
cell	O
cycle	O
arrest	O
modulated	O
by	O
autophagy	O
","	O
which	O
is	O
regulated	O
by	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
signalling	O
pathway	O
","	O
while	O
anti	O
-	O
migration	O
effect	O
is	O
most	O
likely	O
via	O
suppression	O
of	O
MMP	O
-	O
2	O
/-	O
9	O
activity	O
which	O
is	O
involved	O
in	O
MAPK	O
signalling	O
pathway	O
.	O
	
16611040	
Gene	O
therapy	O
for	O
cystic	B-Disease
fibrosis	I-Disease
airway	O
disease	O
-	O
is	O
clinical	O
success	O
imminent	O
?	O
	
Cystic	B-Disease
fibrosis	I-Disease
(	O
CF	B-Disease
)	O
was	O
one	O
of	O
the	O
first	O
inherited	B-Disease
disorders	I-Disease
for	O
which	O
gene	O
therapy	O
was	O
seriously	O
considered	O
as	O
a	O
realistic	O
option	O
for	O
treatment	O
","	O
and	O
as	O
such	O
","	O
it	O
has	O
long	O
provided	O
a	O
paradigm	O
for	O
gene	O
therapy	O
of	O
inherited	B-Disease
diseases	I-Disease
.	O
	
However	O
","	O
despite	O
the	O
cloning	O
of	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
gene	O
in	O
1989	O
","	O
over	O
15	O
years	O
later	O
a	O
practical	O
gene	O
therapy	O
for	O
CF	B-Disease
has	O
not	O
eventuated	O
.	O
	
There	O
are	O
a	O
number	O
of	O
reasons	O
for	O
this	O
","	O
and	O
analysis	O
of	O
the	O
specific	O
issues	O
that	O
have	O
delayed	O
the	O
successful	O
development	O
of	O
gene	O
therapy	O
for	O
CF	B-Disease
also	O
provides	O
general	O
insights	O
into	O
the	O
practical	O
complexities	O
involved	O
in	O
the	O
development	O
of	O
gene	O
therapy	O
for	O
inherited	B-Disease
disorders	I-Disease
.	O
	
The	O
issues	O
which	O
have	O
prevented	O
the	O
application	O
of	O
gene	O
therapy	O
for	O
CF	B-Disease
to	O
date	O
include	O
the	O
lack	O
of	O
suitable	O
gene	O
delivery	O
technologies	O
","	O
the	O
complexities	O
of	O
the	O
interactions	O
between	O
the	O
host	O
and	O
vector	O
","	O
the	O
biology	O
of	O
the	O
lung	O
airways	O
","	O
and	O
the	O
nature	O
of	O
the	O
pathology	O
found	O
in	O
individuals	O
with	O
CF	B-Disease
.	O
	
We	O
will	O
discuss	O
the	O
history	O
of	O
CF	B-Disease
gene	O
therapy	O
with	O
specific	O
reference	O
to	O
these	O
and	O
other	O
issues	O
that	O
pre	O
-	O
occupy	O
the	O
field	O
at	O
present	O
:	O
namely	O
","	O
the	O
question	O
of	O
what	O
vectors	O
appear	O
to	O
be	O
suitable	O
for	O
airway	O
gene	O
delivery	O
in	O
CF	B-Disease
","	O
what	O
cells	O
must	O
be	O
targeted	O
","	O
how	O
airway	O
epithelium	O
defences	O
can	O
be	O
overcome	O
or	O
eluded	O
to	O
allow	O
efficient	O
gene	O
delivery	O
","	O
how	O
to	O
ensure	O
safe	O
and	O
long	O
-	O
term	O
transgene	O
expression	O
and	O
the	O
need	O
to	O
identify	O
relevant	O
surrogate	O
success	O
measures	O
that	O
can	O
be	O
used	O
to	O
assess	O
the	O
outcome	O
of	O
gene	O
therapy	O
in	O
CF	B-Disease
patients	O
.	O
	
17033974	
Mutation	O
in	O
the	O
auxiliary	O
calcium	O
-	O
channel	O
subunit	O
CACNA2D4	O
causes	O
autosomal	O
recessive	O
cone	B-Disease
dystrophy	I-Disease
.	O
	
Retinal	O
signal	O
transmission	O
depends	O
on	O
the	O
activity	O
of	O
high	O
voltage	O
-	O
gated	O
l	O
-	O
type	O
calcium	O
channels	O
in	O
photoreceptor	O
ribbon	O
synapses	O
.	O
	
We	O
recently	O
identified	O
a	O
truncating	O
frameshift	O
mutation	O
in	O
the	O
Cacna2d4	O
gene	O
in	O
a	O
spontaneous	O
mouse	O
mutant	O
with	O
profound	O
loss	O
of	O
retinal	O
signaling	O
and	O
an	O
abnormal	O
morphology	O
of	O
ribbon	O
synapses	O
in	O
rods	O
and	O
cones	O
.	O
	
The	O
Cacna2d4	O
gene	O
encodes	O
an	O
l	O
-	O
type	O
calcium	O
-	O
channel	O
auxiliary	O
subunit	O
of	O
the	O
alpha	O
(	O
2	O
)	O
delta	O
type	O
.	O
	
Mutations	O
in	O
its	O
human	O
orthologue	O
","	O
CACNA2D4	O
","	O
were	O
not	O
yet	O
known	O
to	O
be	O
associated	O
with	O
a	O
disease	O
.	O
	
We	O
performed	O
mutation	O
analyses	O
of	O
34	O
patients	O
who	O
received	O
an	O
initial	O
diagnosis	O
of	O
night	B-Disease
blindness	I-Disease
","	O
and	O
","	O
in	O
two	O
affected	O
siblings	O
","	O
we	O
detected	O
a	O
homozygous	O
nucleotide	O
substitution	O
(	O
c	O
.	O
2406C	O
-->	O
A	O
)	O
in	O
CACNA2D4	O
.	O
	
The	O
mutation	O
introduces	O
a	O
premature	O
stop	O
codon	O
that	O
truncates	O
one	O
-	O
third	O
of	O
the	O
corresponding	O
open	O
reading	O
frame	O
.	O
	
Both	O
patients	O
share	O
symptoms	O
of	O
slowly	O
progressing	O
cone	B-Disease
dystrophy	I-Disease
.	O
	
These	O
findings	O
represent	O
the	O
first	O
report	O
of	O
a	O
mutation	O
in	O
the	O
human	O
CACNA2D4	O
gene	O
and	O
define	O
a	O
novel	O
gene	O
defect	O
that	O
causes	O
autosomal	O
recessive	O
cone	B-Disease
dystrophy	I-Disease
.	O
	
24014394	
A	O
homozygous	O
mutation	O
in	O
LYRM7	O
/	O
MZM1L	O
associated	O
with	O
early	O
onset	O
encephalopathy	B-Disease
","	O
lactic	B-Disease
acidosis	I-Disease
","	O
and	O
severe	O
reduction	B-Disease
of	I-Disease
mitochondrial	I-Disease
complex	I-Disease
III	I-Disease
activity	O
.	O
	
Mutations	O
in	O
nuclear	O
genes	O
associated	O
with	O
defective	B-Disease
complex	I-Disease
III	I-Disease
(	I-Disease
cIII	I-Disease
)	I-Disease
of	I-Disease
the	I-Disease
mitochondrial	I-Disease
respiratory	O
chain	O
are	O
rare	O
","	O
having	O
been	O
found	O
in	O
only	O
two	O
cIII	O
assembly	O
factors	O
and	O
","	O
as	O
private	O
changes	O
in	O
single	O
families	O
","	O
three	O
cIII	O
structural	O
subunits	O
.	O
	
Recently	O
","	O
human	O
LYRM7	O
/	O
MZM1L	O
","	O
the	O
ortholog	O
of	O
yeast	O
MZM1	O
","	O
has	O
been	O
identified	O
as	O
a	O
new	O
assembly	O
factor	O
for	O
cIII	O
.	O
	
In	O
a	O
baby	O
patient	O
with	O
early	O
onset	O
","	O
severe	O
encephalopathy	B-Disease
","	O
lactic	B-Disease
acidosis	I-Disease
and	O
profound	O
","	O
isolated	O
cIII	B-Disease
deficiency	I-Disease
in	O
skeletal	O
muscle	O
","	O
we	O
identified	O
a	O
disease	O
-	O
segregating	O
homozygous	O
mutation	O
(	O
c	O
.	O
73G	O
>	O
A	O
)	O
in	O
LYRM7	O
/	O
MZM1L	O
","	O
predicting	O
a	O
drastic	O
change	O
in	O
a	O
highly	O
conserved	O
amino	O
-	O
acid	O
residue	O
(	O
p	O
.	O
Asp25Asn	O
).	O
	
In	O
a	O
mzm1D	O
yeast	O
strain	O
","	O
the	O
expression	O
of	O
a	O
mzm1	O
(	O
D25N	O
)	O
mutant	O
allele	O
caused	O
temperature	O
-	O
sensitive	O
respiratory	B-Disease
growth	I-Disease
defect	I-Disease
","	O
decreased	O
oxygen	O
consumption	O
","	O
impaired	O
maturation	O
/	O
stabilization	O
of	O
the	O
Rieske	O
Fe	O
-	O
S	O
protein	O
","	O
and	O
reduced	O
complex	O
III	O
activity	O
and	O
amount	O
.	O
	
LYRM7	O
/	O
MZM1L	O
is	O
a	O
novel	O
disease	O
gene	O
","	O
causing	O
cIII	B-Disease
-	I-Disease
defective	I-Disease
","	O
early	O
onset	O
","	O
severe	O
mitochondrial	B-Disease
encephalopathy	I-Disease
.	O
	
15018851	
Comparison	O
of	O
sequential	O
cytomegalovirus	O
isolates	O
in	O
a	O
patient	O
with	O
lymphoma	B-Disease
and	O
failing	O
antiviral	O
therapy	O
.	O
	
BACKGROUND	O
:	O
Long	B-Disease
-	I-Disease
term	I-Disease
anti	I-Disease
-	I-Disease
cytomegalovirus	I-Disease
(	O
CMV	B-Disease
)	O
treatments	O
in	O
immunocompromised	O
patients	O
are	O
hampered	O
by	O
resistance	O
to	O
antiviral	O
drugs	O
.	O
	
Longitudinal	O
changes	O
in	O
the	O
resistance	O
genotype	O
may	O
depend	O
on	O
changes	O
in	O
selective	O
pressure	O
and	O
the	O
complexity	O
of	O
CMV	B-Disease
isolates	O
.	O
	
OBJECTIVE	O
:	O
To	O
evaluate	O
longitudinal	O
changes	O
in	O
the	O
CMV	B-Disease
resistance	O
genotype	O
and	O
phenotype	O
along	O
with	O
strain	O
-	O
specific	O
variability	O
in	O
a	O
patient	O
with	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
'	I-Disease
s	I-Disease
lymphoma	I-Disease
in	O
whom	O
successive	O
anti	O
-	O
CMV	B-Disease
treatments	O
failed	O
.	O
	
STUDY	O
DESIGN	O
:	O
The	O
resistance	O
phenotype	O
and	O
genotype	O
of	O
seven	O
CMV	B-Disease
isolates	O
collected	O
from	O
one	O
patient	O
during	O
a	O
2	O
-	O
year	O
follow	O
-	O
up	O
period	O
were	O
retrospectively	O
analysed	O
.	O
	
In	O
parallel	O
","	O
we	O
used	O
glycoprotein	O
B	O
(	O
gB	O
)	O
genotyping	O
","	O
and	O
a	O
-	O
and	O
UL10	O
-	O
13	O
-	O
sequence	O
analysis	O
to	O
study	O
CMV	B-Disease
interstrain	O
variability	O
.	O
	
RESULTS	O
:	O
The	O
patient	O
was	O
infected	O
by	O
at	O
least	O
three	O
CMV	B-Disease
strains	O
plus	O
variants	O
of	O
the	O
parental	O
strains	O
.	O
	
Resistance	O
to	O
ganciclovir	O
","	O
cidofovir	O
and	O
foscarnet	O
was	O
successively	O
detected	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O
	
UL97	O
protein	O
kinase	O
changes	O
responsible	O
for	O
resistance	O
to	O
ganciclovir	O
were	O
initially	O
detected	O
at	O
residues	O
591	O
and	O
592	O
","	O
and	O
then	O
at	O
position	O
594	O
.	O
	
Decreased	O
sensitivity	O
to	O
foscarnet	O
coincided	O
with	O
the	O
appearance	O
of	O
amino	O
acid	O
substitution	O
N495K	O
in	O
DNA	O
polymerase	O
","	O
whereas	O
cross	O
-	O
resistance	O
to	O
ganciclovir	O
and	O
cidofovir	O
was	O
due	O
to	O
the	O
L501I	O
substitution	O
.	O
	
CONCLUSIONS	O
:	O
The	O
CMV	B-Disease
isolates	O
obtained	O
from	O
our	O
patient	O
were	O
complex	O
mixtures	O
of	O
strains	O
.	O
	
Changes	O
in	O
resistance	O
genotypes	O
depended	O
on	O
resistance	O
selective	O
pressure	O
and	O
were	O
not	O
linked	O
to	O
interstrain	O
variation	O
.	O
	
17671735	
Coincidence	O
of	O
mutations	O
in	O
different	O
connexin	O
genes	O
in	O
Hungarian	O
patients	O
.	O
	
Mutations	O
in	O
the	O
GJB2	O
gene	O
are	O
the	O
most	O
common	O
cause	O
of	O
hereditary	O
prelingual	O
sensorineural	B-Disease
hearing	I-Disease
impairment	I-Disease
in	O
Europe	O
.	O
	
Several	O
studies	O
indicate	O
that	O
different	O
members	O
of	O
the	O
connexin	O
protein	O
family	O
interact	O
to	O
form	O
gap	O
junctions	O
in	O
the	O
inner	O
ear	O
.	O
	
Mutations	O
in	O
different	O
connexin	O
genes	O
may	O
accumulate	O
and	O
","	O
consequently	O
lead	O
to	O
hearing	B-Disease
impairment	I-Disease
.	O
	
Therefore	O
","	O
we	O
screened	O
47	O
Hungarian	O
GJB2	O
-	O
heterozygous	O
(	O
one	O
mutation	O
in	O
coding	O
exon	O
of	O
the	O
GJB2	O
gene	O
)	O
patients	O
with	O
hearing	B-Disease
impairment	I-Disease
for	O
DNA	O
changes	O
in	O
two	O
further	O
connexin	O
genes	O
(	O
GJB6	O
and	O
GJB3	O
)	O
and	O
in	O
the	O
5	O
'	O
non	O
-	O
coding	O
region	O
of	O
GJB2	O
including	O
the	O
splice	O
sites	O
.	O
	
Eleven	O
out	O
of	O
47	O
GJB2	O
-	O
heterozygous	O
patients	O
analyzed	O
carried	O
the	O
splice	O
site	O
mutation	O
-	O
3170G	O
>	O
A	O
in	O
the	O
5	O
'	O
UTR	O
region	O
of	O
GJB2	O
.	O
	
One	O
out	O
of	O
these	O
11	O
patients	O
showed	O
homozygous	O
-	O
3170G	O
>	O
A	O
genotype	O
in	O
combination	O
with	O
p	O
.	O
R127H	O
.	O
	
Next	O
to	O
the	O
GJB2	O
mutations	O
we	O
noted	O
2	O
cases	O
of	O
deletion	O
in	O
GJB6	O
[	O
Delta	O
(	O
GJB6	O
-	O
D13S1830	O
)]	O
and	O
3	O
(	O
2	O
new	O
and	O
1	O
described	O
)	O
base	O
substitutions	O
in	O
GJB3	O
[	O
c	O
.	O
357C	O
>	O
T	O
","	O
c	O
.	O
798C	O
>	O
T	O
and	O
c	O
.	O
94C	O
>	O
T	O
(	O
p	O
.	O
R32W	O
)]	O
which	O
are	O
unlikely	O
disease	O
-	O
causing	O
.	O
	
Our	O
results	O
suggest	O
the	O
importance	O
of	O
routine	O
screening	O
for	O
the	O
rather	O
frequent	O
-	O
3170G	O
>	O
A	O
mutation	O
(	O
in	O
addition	O
to	O
c	O
.	O
35delG	O
)	O
in	O
patients	O
with	O
hearing	B-Disease
impairment	I-Disease
.	O
	
28518143	
Calcium	O
sensing	O
receptor	O
protects	O
high	O
glucose	O
-	O
induced	O
energy	O
metabolism	B-Disease
disorder	I-Disease
via	O
blocking	O
gp78	O
-	O
ubiquitin	O
proteasome	O
pathway	O
.	O
	
Diabetic	B-Disease
cardiomyopathy	I-Disease
(	O
DCM	B-Disease
)	O
is	O
a	O
major	O
complication	O
and	O
fatal	O
cause	O
of	O
the	O
patients	O
with	O
diabetes	B-Disease
.	O
	
The	O
calcium	O
sensing	O
receptor	O
(	O
CaSR	O
)	O
is	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
","	O
which	O
is	O
involved	O
in	O
maintaining	O
calcium	O
homeostasis	O
","	O
regulating	O
cell	O
proliferation	O
and	O
apoptosis	O
","	O
and	O
so	O
on	O
.	O
	
In	O
our	O
previous	O
study	O
","	O
we	O
found	O
that	O
CaSR	O
expression	O
","	O
intracellular	O
calcium	O
levels	O
and	O
cardiac	O
function	O
were	O
all	O
significantly	O
decreased	O
in	O
DCM	B-Disease
rats	O
;	O
however	O
","	O
the	O
exact	O
mechanism	O
are	O
not	O
clear	O
yet	O
.	O
	
The	O
present	O
study	O
revealed	O
the	O
protective	O
role	O
of	O
CaSR	O
in	O
myocardial	B-Disease
energy	I-Disease
metabolism	I-Disease
disorder	I-Disease
induced	O
by	O
high	O
glucose	O
(	O
HG	O
)	O
as	O
well	O
as	O
the	O
underlying	O
mechanism	O
.	O
	
Here	O
","	O
we	O
demonstrated	O
that	O
HG	O
decreased	O
the	O
expression	O
of	O
CaSR	O
","	O
mitochondrial	O
fusion	O
proteins	O
(	O
Mfn1	O
","	O
Mfn2	O
"),"	O
cell	O
gap	O
junction	O
related	O
proteins	O
(	O
Cx43	O
","	O
beta	O
-	O
catenin	O
","	O
N	O
-	O
cadherin	O
"),"	O
and	O
intracellular	O
ATP	O
concentration	O
.	O
	
In	O
contrast	O
","	O
HG	O
increased	O
extracellular	O
ATP	O
concentration	O
","	O
the	O
expression	O
of	O
gp78	O
","	O
mitochondrial	O
fission	O
proteins	O
(	O
Fis1	O
","	O
Drp1	O
"),"	O
and	O
the	O
ubiquitination	O
levels	O
of	O
Mfn1	O
","	O
Mfn2	O
and	O
Cx43	O
.	O
	
Moreover	O
","	O
CaSR	O
agonist	O
and	O
gp78	O
-	O
siRNA	O
significantly	O
reduced	O
the	O
above	O
changes	O
.	O
	
Taken	O
together	O
","	O
these	O
results	O
suggest	O
that	O
HG	O
induces	O
myocardial	B-Disease
energy	I-Disease
metabolism	I-Disease
disorder	I-Disease
via	O
decrease	O
of	O
CaSR	O
expression	O
","	O
and	O
activation	O
of	O
gp78	O
-	O
ubiquitin	O
proteasome	O
system	O
.	O
	
In	O
turn	O
","	O
these	O
effects	O
disrupt	O
the	O
structure	O
and	O
function	O
of	O
the	O
mitochondria	O
and	O
the	O
cell	O
gap	O
junction	O
","	O
result	O
in	O
the	O
reduced	O
ATP	O
synthesis	O
and	O
the	O
increased	O
ATP	O
leakage	O
.	O
	
Stimulation	O
of	O
CaSR	O
significantly	O
attenuates	O
HG	O
-	O
induced	O
abnormal	B-Disease
myocardial	I-Disease
energy	I-Disease
metabolism	I-Disease
","	O
suggesting	O
CaSR	O
would	O
be	O
a	O
promising	O
potential	O
therapeutic	O
target	O
for	O
DCM	B-Disease
.	O
	
17600377	
A	O
novel	O
compound	O
","	O
maltolyl	O
p	O
-	O
coumarate	O
","	O
attenuates	O
cognitive	B-Disease
deficits	I-Disease
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	B-Disease
models	O
.	O
	
To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
","	O
we	O
newly	O
synthesized	O
maltolyl	O
p	O
-	O
coumarate	O
by	O
the	O
esterification	O
of	O
maltol	O
and	O
p	O
-	O
coumaric	O
acid	O
.	O
	
In	O
the	O
present	O
study	O
","	O
we	O
investigated	O
whether	O
maltolyl	O
p	O
-	O
coumarate	O
could	O
improve	O
cognitive	B-Disease
decline	I-Disease
in	O
scopolamine	O
-	O
injected	O
rats	O
and	O
in	O
amyloid	O
beta	O
peptide	O
(	O
1	O
-	O
42	O
)-	O
infused	O
rats	O
.	O
	
Maltolyl	O
p	O
-	O
coumarate	O
was	O
found	O
to	O
attenuate	O
cognitive	B-Disease
deficits	I-Disease
in	O
both	O
rat	O
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	O
beta	O
peptide	O
(	O
1	O
-	O
42	O
)-	O
infused	O
rats	O
.	O
	
We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	O
p	O
-	O
coumarate	O
in	O
vitro	O
using	O
SH	O
-	O
SY5Y	O
cells	O
.	O
	
Cells	O
were	O
pretreated	O
with	O
maltolyl	O
p	O
-	O
coumarate	O
","	O
before	O
exposed	O
to	O
amyloid	O
beta	O
peptide	O
(	O
1	O
-	O
42	O
"),"	O
glutamate	O
or	O
H2O2	O
.	O
	
We	O
found	O
that	O
maltolyl	O
p	O
-	O
coumarate	O
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	O
oxygen	O
species	O
","	O
cytochrome	O
c	O
release	O
","	O
and	O
caspase	O
3	O
activation	O
.	O
	
Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
","	O
our	O
study	O
suggests	O
that	O
maltolyl	O
p	O
-	O
coumarate	O
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	B-Disease
death	I-Disease
and	O
progressive	O
decline	B-Disease
of	I-Disease
cognitive	I-Disease
function	I-Disease
.	O
	
16181814	
Mono	O
-	O
allelic	O
POLG	O
expression	O
resulting	O
from	O
nonsense	O
-	O
mediated	O
decay	O
and	O
alternative	O
splicing	O
in	O
a	O
patient	O
with	O
Alpers	B-Disease
syndrome	I-Disease
.	O
	
Alpers	B-Disease
syndrome	I-Disease
is	O
an	O
autosomal	O
recessive	O
mitochondrial	B-Disease
DNA	I-Disease
depletion	I-Disease
disorder	O
that	O
affects	O
children	O
and	O
young	O
adults	O
.	O
	
It	O
is	O
characterized	O
by	O
a	O
progressive	O
","	O
fatal	O
brain	O
and	O
liver	B-Disease
disease	I-Disease
.	O
	
This	O
syndrome	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
POLG	O
","	O
the	O
gene	O
encoding	O
the	O
mitochondrial	O
DNA	O
polymerase	O
(	O
pol	O
gamma	O
).	O
	
Most	O
patients	O
with	O
Alpers	B-Disease
syndrome	I-Disease
have	O
been	O
found	O
to	O
be	O
compound	O
heterozygotes	O
","	O
carrying	O
two	O
pathogenic	O
mutations	O
in	O
trans	O
at	O
the	O
POLG	O
locus	O
.	O
	
POLG	O
is	O
a	O
nuclear	O
-	O
encoded	O
gene	O
whose	O
protein	O
product	O
is	O
imported	O
into	O
mitochondria	O
","	O
where	O
it	O
is	O
essential	O
for	O
mtDNA	O
replication	O
and	O
repair	O
.	O
	
We	O
studied	O
the	O
skin	O
fibroblasts	O
of	O
a	O
patient	O
with	O
Alpers	B-Disease
syndrome	I-Disease
having	O
the	O
genotype	O
E873stop	O
/	O
A467T	O
.	O
	
The	O
E873stop	O
mutation	O
produces	O
a	O
premature	O
termination	O
codon	O
(	O
TAG	O
)	O
in	O
exon	O
17	O
.	O
	
The	O
A467T	O
mutation	O
produces	O
a	O
threonine	O
to	O
alanine	O
substitution	O
at	O
a	O
highly	O
conserved	O
site	O
in	O
exon	O
7	O
.	O
	
The	O
allele	O
bearing	O
the	O
stop	O
codon	O
(	O
E873	O
-	O
TAG	O
)	O
is	O
predicted	O
to	O
produce	O
a	O
truncated	O
","	O
catalytically	O
inactive	O
polymerase	O
.	O
	
However	O
","	O
only	O
full	O
-	O
length	O
pol	O
gamma	O
protein	O
was	O
detected	O
by	O
Western	O
blot	O
analysis	O
.	O
	
Here	O
","	O
we	O
show	O
that	O
transcripts	O
containing	O
this	O
stop	O
codon	O
undergo	O
nonsense	O
-	O
associated	O
alternative	O
splicing	O
and	O
nonsense	O
-	O
mediated	O
decay	O
.	O
	
More	O
than	O
95	O
%	O
of	O
the	O
functional	O
POLG	O
mRNA	O
was	O
derived	O
from	O
the	O
allele	O
bearing	O
the	O
A467T	O
mutation	O
and	O
less	O
than	O
5	O
%	O
contained	O
the	O
E873stop	O
mutation	O
.	O
	
These	O
events	O
ensured	O
that	O
virtually	O
all	O
POLG	O
protein	O
in	O
the	O
cell	O
was	O
expressed	O
from	O
the	O
A467T	O
allele	O
.	O
	
Therefore	O
","	O
the	O
Alpers	O
phenotype	O
in	O
this	O
patient	O
was	O
a	O
consequence	O
of	O
a	O
single	O
-	O
copy	O
gene	O
dose	O
of	O
the	O
A467T	O
allele	O
","	O
and	O
selective	O
elimination	O
of	O
transcripts	O
bearing	O
the	O
E873stop	O
mutation	O
.	O
	
20143913	
Large	O
deletion	O
involving	O
exon	O
5	O
of	O
the	O
arylsulfatase	O
B	O
gene	O
caused	O
apparent	O
homozygosity	O
in	O
a	O
mucopolysaccharidosis	B-Disease
type	I-Disease
VI	I-Disease
patient	O
.	O
	
Apparent	O
homozygosity	O
for	O
the	O
mutation	O
p	O
.	O
R315X	O
present	O
on	O
exon	O
5	O
of	O
the	O
arylsulfatase	O
B	O
(	O
ARSB	O
)	O
gene	O
in	O
a	O
mucopolysaccharidosis	B-Disease
type	I-Disease
VI	I-Disease
patient	O
was	O
solved	O
in	O
this	O
study	O
by	O
further	O
testing	O
for	O
a	O
second	O
mutation	O
.	O
	
Patient	O
cDNA	O
analysis	O
revealed	O
that	O
the	O
entire	O
exon	O
5	O
of	O
the	O
ARSB	O
gene	O
was	O
lacking	O
;	O
this	O
new	O
mutation	O
was	O
identified	O
as	O
c	O
.	O
899	O
-	O
1142del	O
.	O
	
As	O
the	O
genomic	O
DNA	O
sequencing	O
excluded	O
the	O
presence	O
of	O
splicing	O
mutations	O
","	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
performed	O
for	O
polymorphisms	O
listed	O
in	O
the	O
NCBI	O
SNP	O
database	O
for	O
the	O
ARSB	O
gene	O
.	O
	
This	O
allowed	O
the	O
mutation	O
at	O
the	O
genomic	O
DNA	O
level	O
to	O
be	O
identified	O
as	O
g	O
.	O
99367	O
-	O
102002del	O
;	O
this	O
gross	O
deletion	O
","	O
involving	O
the	O
entire	O
exon	O
5	O
of	O
the	O
gene	O
and	O
parts	O
of	O
introns	O
4	O
and	O
5	O
led	O
to	O
a	O
frameshift	O
starting	O
at	O
amino	O
acid	O
300	O
and	O
resulting	O
in	O
a	O
protein	O
with	O
39	O
%	O
amino	O
acids	O
different	O
from	O
the	O
normal	O
enzyme	O
.	O
	
We	O
stress	O
that	O
extensive	O
DNA	O
analysis	O
needs	O
to	O
be	O
performed	O
in	O
case	O
of	O
apparent	O
homozygosity	O
to	O
avoid	O
potential	O
errors	O
in	O
genetic	O
counseling	O
.	O
	
15579441	
Hypoxia	B-Disease
in	O
renal	B-Disease
disease	I-Disease
with	O
proteinuria	B-Disease
and	O
/	O
or	O
glomerular	O
hypertension	B-Disease
.	O
	
Despite	O
the	O
increasing	O
need	O
to	O
identify	O
and	O
quantify	O
tissue	O
oxygenation	O
at	O
the	O
cellular	O
level	O
","	O
relatively	O
few	O
methods	O
have	O
been	O
available	O
.	O
	
In	O
this	O
study	O
","	O
we	O
developed	O
a	O
new	O
hypoxia	B-Disease
-	O
responsive	O
reporter	O
vector	O
using	O
a	O
hypoxia	B-Disease
-	O
responsive	O
element	O
of	O
the	O
5	O
'	O
vascular	O
endothelial	O
growth	O
factor	O
untranslated	O
region	O
and	O
generated	O
a	O
novel	O
hypoxia	B-Disease
-	O
sensing	O
transgenic	O
rat	O
.	O
	
We	O
then	O
applied	O
this	O
animal	O
model	O
to	O
the	O
detection	O
of	O
tubulointerstitial	O
hypoxia	B-Disease
in	O
the	O
diseased	B-Disease
kidney	I-Disease
.	O
	
With	O
this	O
model	O
","	O
we	O
were	O
able	O
to	O
identify	O
diffuse	O
cortical	O
hypoxia	B-Disease
in	O
the	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
and	O
focal	O
and	O
segmental	O
hypoxia	B-Disease
in	O
the	O
remnant	O
kidney	O
model	O
.	O
	
Expression	O
of	O
the	O
hypoxia	B-Disease
-	O
responsive	O
transgene	O
increased	O
throughout	O
the	O
observation	O
period	O
","	O
reaching	O
2	O
.	O
2	O
-	O
fold	O
at	O
2	O
weeks	O
in	O
the	O
puromycin	O
aminonucleoside	O
model	O
and	O
2	O
.	O
6	O
-	O
fold	O
at	O
4	O
weeks	O
in	O
the	O
remnant	O
kidney	O
model	O
","	O
whereas	O
that	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
showed	O
a	O
mild	O
decrease	O
","	O
reflecting	O
distinct	O
behaviors	O
of	O
the	O
two	O
genes	O
.	O
	
The	O
degree	O
of	O
hypoxia	B-Disease
showed	O
a	O
positive	O
correlation	O
with	O
microscopic	O
tubulointerstitial	B-Disease
injury	I-Disease
in	O
both	O
models	O
.	O
	
Finally	O
","	O
we	O
identified	O
the	O
localization	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
","	O
ED	O
-	O
1	O
-	O
positive	O
","	O
and	O
terminal	O
dUTP	O
nick	O
-	O
end	O
labeled	O
-	O
positive	O
cells	O
in	O
the	O
hypoxic	B-Disease
cortical	O
area	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O
	
We	O
propose	O
here	O
a	O
possible	O
pathological	O
tie	O
between	O
chronic	O
tubulointerstitial	O
hypoxia	B-Disease
and	O
progressive	O
glomerular	B-Disease
diseases	I-Disease
.	O
	
15754732	
Novel	O
somatic	O
MEN1	O
gene	O
alterations	O
in	O
sporadic	O
primary	B-Disease
hyperparathyroidism	I-Disease
and	O
correlation	O
with	O
clinical	O
characteristics	O
.	O
	
Primary	B-Disease
hyperparathyroidism	I-Disease
(	O
pHPT	B-Disease
)	O
is	O
a	O
common	O
endocrine	B-Disease
disease	I-Disease
that	O
in	O
more	O
than	O
95	O
%	O
of	O
cases	O
is	O
sporadic	O
and	O
only	O
in	O
some	O
cases	O
is	O
caused	O
by	O
inherited	B-Disease
disorders	I-Disease
","	O
isolated	O
or	O
as	O
part	O
of	O
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
(	O
MEN1	B-Disease
and	I-Disease
2	I-Disease
).	O
	
Somatic	O
mutations	O
of	O
MEN1	O
gene	O
have	O
also	O
been	O
described	O
in	O
sporadic	O
parathyroid	B-Disease
tumors	I-Disease
.	O
	
In	O
our	O
study	O
","	O
we	O
examined	O
the	O
presence	O
of	O
alterations	O
in	O
MEN1	O
gene	O
in	O
a	O
series	O
of	O
39	O
patients	O
who	O
had	O
undergone	O
surgery	O
for	O
sporadic	O
pHPT	B-Disease
(	O
35	O
with	O
parathyroid	B-Disease
adenoma	I-Disease
or	I-Disease
hyperplasia	I-Disease
","	O
4	O
with	O
a	O
carcinoma	B-Disease
).	O
	
A	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
also	O
analysed	O
.	O
	
After	O
DNA	O
extraction	O
from	O
paraffin	O
-	O
embedded	O
tissues	O
","	O
we	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
the	O
exons	O
2	O
-	O
10	O
of	O
the	O
MEN1	O
gene	O
.	O
	
Somatic	O
MEN1	O
mutations	O
were	O
detected	O
in	O
6	O
of	O
the	O
35	O
patients	O
with	O
a	O
benign	B-Disease
parathyroid	I-Disease
lesion	I-Disease
examined	O
(	O
17	O
.	O
1	O
"%),"	O
whereas	O
no	O
alterations	O
were	O
found	O
in	O
the	O
carcinomas	B-Disease
.	O
	
Four	O
novel	O
MEN1	O
gene	O
mutations	O
were	O
identified	O
as	O
follows	O
:	O
one	O
frameshift	O
mutation	O
(	O
222insT	O
","	O
exon	O
2	O
"),"	O
one	O
frameshift	O
deletion	O
(	O
912delTA	O
","	O
exon	O
5	O
"),"	O
one	O
in	O
-	O
frame	O
deletion	O
(	O
835del18	O
","	O
exon	O
4	O
)	O
and	O
one	O
missense	O
mutation	O
(	O
P291A	O
","	O
exon	O
6	O
).	O
	
In	O
addition	O
","	O
one	O
missense	O
mutation	O
(	O
L89R	O
","	O
exon	O
2	O
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
Q536X	O
","	O
exon	O
10	O
)	O
were	O
previously	O
reported	O
.	O
	
Moreover	O
","	O
two	O
polymorphisms	O
were	O
also	O
found	O
:	O
one	O
allele	O
carried	O
a	O
R171Q	O
polymorphism	O
(	O
1	O
/	O
39	O
tumors	B-Disease
"),"	O
while	O
a	O
D418D	O
polymorphism	O
(	O
GAC	O
/	O
GAT	O
)	O
was	O
found	O
in	O
15	O
and	O
8	O
tumors	B-Disease
in	O
hetero	O
(	O
CT	O
)	O
and	O
homozygosity	O
(	O
TT	O
"),"	O
respectively	O
.	O
	
In	O
no	O
case	O
(	O
mutations	O
and	O
/	O
or	O
polymorphisms	O
)	O
did	O
we	O
find	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O
	
In	O
conclusion	O
","	O
our	O
data	O
demonstrate	O
the	O
presence	O
of	O
somatic	O
alterations	O
of	O
the	O
MEN1	O
tumor	B-Disease
suppressor	O
gene	O
in	O
about	O
one	O
fifth	O
of	O
benign	O
sporadic	O
parathyroid	B-Disease
tumors	I-Disease
.	O
	
The	O
absence	O
of	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
","	O
however	O
","	O
suggests	O
the	O
involvement	O
of	O
other	O
genetic	O
/	O
epigenetic	O
factors	O
for	O
the	O
full	O
expression	O
of	O
the	O
disease	O
.	O
	
18385794	
Identification	O
of	O
novel	O
mutations	O
and	O
sequence	O
variants	O
in	O
the	O
SOX2	O
and	O
CHX10	O
genes	O
in	O
patients	O
with	O
anophthalmia	B-Disease
/	O
microphthalmia	B-Disease
.	O
	
PURPOSE	O
:	O
Mutations	O
in	O
the	O
SOX2	O
and	O
CHX10	O
genes	O
have	O
been	O
reported	O
in	O
patients	O
with	O
anophthalmia	B-Disease
and	O
/	O
or	O
microphthalmia	B-Disease
.	O
	
In	O
this	O
study	O
","	O
we	O
evaluated	O
34	O
anophthalmic	B-Disease
/	O
microphthalmic	B-Disease
patient	O
DNA	O
samples	O
(	O
two	O
sets	O
of	O
siblings	O
included	O
)	O
for	O
mutations	O
and	O
sequence	O
variants	O
in	O
SOX2	O
and	O
CHX10	O
.	O
	
METHODS	O
:	O
Conformational	O
sensitive	O
gel	O
electrophoresis	O
(	O
CSGE	O
)	O
was	O
used	O
for	O
the	O
initial	O
SOX2	O
and	O
CHX10	O
screening	O
of	O
34	O
affected	O
individuals	O
(	O
two	O
sets	O
of	O
siblings	O
"),"	O
five	O
unaffected	O
family	O
members	O
","	O
and	O
80	O
healthy	O
controls	O
.	O
	
Patient	O
samples	O
containing	O
heteroduplexes	O
were	O
selected	O
for	O
sequence	O
analysis	O
.	O
	
Base	O
pair	O
changes	O
in	O
SOX2	O
and	O
CHX10	O
were	O
confirmed	O
by	O
sequencing	O
bidirectionally	O
in	O
patient	O
samples	O
.	O
	
RESULTS	O
:	O
Two	O
novel	O
heterozygous	O
mutations	O
and	O
two	O
sequence	O
variants	O
(	O
one	O
known	O
)	O
in	O
SOX2	O
were	O
identified	O
in	O
this	O
cohort	O
.	O
	
Mutation	O
c	O
.	O
310	O
G	O
>	O
T	O
(	O
p	O
.	O
Glu104X	O
"),"	O
found	O
in	O
one	O
patient	O
","	O
was	O
in	O
the	O
region	O
encoding	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
DNA	O
-	O
binding	O
domain	O
and	O
resulted	O
in	O
a	O
change	O
from	O
glutamic	O
acid	O
to	O
a	O
stop	O
codon	O
.	O
	
The	O
second	O
mutation	O
","	O
noted	O
in	O
two	O
affected	O
siblings	O
","	O
was	O
a	O
single	O
nucleotide	O
deletion	O
c	O
.	O
549delC	O
(	O
p	O
.	O
Pro184ArgfsX19	O
)	O
in	O
the	O
region	O
encoding	O
the	O
activation	O
domain	O
","	O
resulting	O
in	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
the	O
coding	O
sequence	O
.	O
	
The	O
shortened	O
protein	O
products	O
may	O
result	O
in	O
the	O
loss	O
of	O
function	O
.	O
	
In	O
addition	O
","	O
a	O
novel	O
nucleotide	O
substitution	O
c	O
.*	O
557G	O
>	O
A	O
was	O
identified	O
in	O
the	O
3	O
'-	O
untranslated	O
region	O
in	O
one	O
patient	O
.	O
	
The	O
relationship	O
between	O
the	O
nucleotide	O
change	O
and	O
the	O
protein	O
function	O
is	O
indeterminate	O
.	O
	
A	O
known	O
single	O
nucleotide	O
polymorphism	O
(	O
c	O
.	O
*	O
469	O
C	O
>	O
A	O
","	O
SNP	O
rs11915160	O
)	O
was	O
also	O
detected	O
in	O
2	O
of	O
the	O
34	O
patients	O
.	O
	
Screening	O
of	O
CHX10	O
identified	O
two	O
synonymous	O
sequence	O
variants	O
","	O
c	O
.	O
471	O
C	O
>	O
T	O
(	O
p	O
.	O
Ser157Ser	O
","	O
rs35435463	O
)	O
and	O
c	O
.	O
579	O
G	O
>	O
A	O
(	O
p	O
.	O
Gln193Gln	O
","	O
novel	O
SNP	O
"),"	O
and	O
one	O
non	O
-	O
synonymous	O
sequence	O
variant	O
","	O
c	O
.	O
871	O
G	O
>	O
A	O
(	O
p	O
.	O
Asp291Asn	O
","	O
novel	O
SNP	O
).	O
	
The	O
non	O
-	O
synonymous	O
polymorphism	O
was	O
also	O
present	O
in	O
healthy	O
controls	O
","	O
suggesting	O
non	O
-	O
causality	O
.	O
	
CONCLUSIONS	O
:	O
These	O
results	O
support	O
the	O
role	O
of	O
SOX2	O
in	O
ocular	O
development	O
.	O
	
Loss	O
of	O
SOX2	O
function	O
results	O
in	O
severe	O
eye	B-Disease
malformation	I-Disease
.	O
	
CHX10	O
was	O
not	O
implicated	O
with	O
microphthalmia	B-Disease
/	O
anophthalmia	B-Disease
in	O
our	O
patient	O
cohort	O
.	O
	
25589620	
Pharmacogenetic	O
Analysis	O
of	O
INT	O
144	O
Trial	O
:	O
Association	O
of	O
Polymorphisms	O
with	O
Survival	O
and	O
Toxicity	B-Disease
in	O
Rectal	B-Disease
Cancer	I-Disease
Patients	O
Treated	O
with	O
5	O
-	O
FU	O
and	O
Radiation	O
.	O
	
PURPOSE	O
:	O
We	O
tested	O
whether	O
18	O
polymorphisms	O
in	O
16	O
genes	O
(	O
GSTP1	O
","	O
COX2	O
","	O
IL10	O
","	O
EGFR	O
","	O
EGF	O
","	O
FGFR4	O
","	O
CCDN1	O
","	O
VEGFR2	O
","	O
VEGF	O
","	O
CXCR2	O
","	O
IL8	O
","	O
MMP3	O
","	O
ICAM1	O
","	O
ERCC1	O
","	O
RAD51	O
","	O
and	O
XRCC3	O
)	O
would	O
predict	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
"),"	O
overall	O
survival	O
(	O
OS	O
"),"	O
and	O
toxicity	B-Disease
in	O
the	O
INT0144	O
trial	O
","	O
which	O
was	O
designed	O
to	O
investigate	O
different	O
postoperative	O
regimens	O
of	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)-	O
based	O
chemoradiation	O
(	O
CRT	O
)	O
in	O
locally	O
advanced	O
rectal	B-Disease
cancers	I-Disease
:	O
Arm	O
1	O
consisted	O
of	O
bolus	O
5	O
-	O
FU	O
followed	O
by	O
5	O
-	O
FU	O
protracted	O
venous	O
infusion	O
(	O
PVI	O
)	O
with	O
radiotherapy	O
;	O
arm	O
2	O
was	O
induction	O
and	O
concomitant	O
PVI	O
5	O
-	O
FU	O
with	O
radiotherapy	O
and	O
arm	O
3	O
was	O
induction	O
and	O
concomitant	O
bolus	O
5	O
-	O
FU	O
with	O
radiotherapy	O
.	O
	
EXPERIMENTAL	O
DESIGN	O
:	O
DNA	O
from	O
746	O
stage	O
II	O
/	O
III	O
rectal	O
patients	O
enrolled	O
in	O
the	O
Southwest	O
Oncology	O
Group	O
(	O
SWOG	O
)	O
S9304	O
phase	O
III	O
trial	O
was	O
analyzed	O
.	O
	
Genomic	O
DNA	O
was	O
extracted	O
from	O
formalin	O
-	O
fixed	O
","	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
tumor	B-Disease
tissue	O
.	O
	
The	O
polymorphisms	O
were	O
analyzed	O
using	O
direct	O
DNA	O
-	O
sequencing	O
or	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
).	O
	
RESULTS	O
:	O
GSTP1	O
-	O
Ile105Val	O
(	O
rs1695	O
)	O
was	O
significantly	O
associated	O
with	O
DFS	O
and	O
OS	O
and	O
its	O
effect	O
did	O
not	O
vary	O
by	O
treatment	O
arm	O
.	O
	
The	O
five	O
-	O
year	O
DFS	O
and	O
OS	O
were	O
53	O
%	O
and	O
58	O
"%,"	O
respectively	O
","	O
for	O
G	O
/	O
G	O
","	O
66	O
%	O
and	O
72	O
%	O
for	O
G	O
/	O
A	O
","	O
and	O
57	O
%	O
and	O
66	O
%	O
for	O
A	O
/	O
A	O
patients	O
.	O
	
In	O
arm	O
2	O
","	O
IL8	O
-	O
251A	O
/	O
A	O
genotype	O
(	O
rs4073	O
)	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
toxicities	B-Disease
(	O
P	O
=	O
0	O
.	O
4	O
).	O
	
The	O
VEGFR2	O
H472Q	O
Q	O
/	O
Q	O
genotype	O
(	O
rs1870377	O
)	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
grade	O
3	O
-	O
5	O
proximal	O
upper	O
gastrointestinal	O
tract	O
(	O
PUGIT	O
)	O
mucositis	B-Disease
(	O
P	O
=	O
0	O
.	O
4	O
)	O
in	O
arm	O
2	O
.	O
	
However	O
","	O
in	O
arm	O
1	O
","	O
this	O
genotype	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
PUGIT	O
mucositis	B-Disease
(	O
P	O
=	O
0	O
.	O
4	O
).	O
	
CONCLUSION	O
:	O
rs1695	O
may	O
be	O
prognostic	O
in	O
patients	O
with	O
rectal	B-Disease
cancer	I-Disease
treated	O
with	O
adjuvant	O
CRT	O
.	O
	
rs4073	O
and	O
rs1870377	O
may	O
exhibit	O
different	O
associations	O
with	O
toxicity	B-Disease
","	O
according	O
to	O
the	O
5	O
-	O
FU	O
schedule	O
.	O
	
15086325	
Identification	O
of	O
three	O
F5	O
gene	O
mutations	O
associated	O
with	O
inherited	B-Disease
coagulation	I-Disease
factor	I-Disease
V	I-Disease
deficiency	I-Disease
in	O
two	O
Chinese	O
pedigrees	O
.	O
	
To	O
investigate	O
the	O
molecular	O
defects	O
in	O
two	O
Chinese	O
pedigrees	O
with	O
inherited	B-Disease
factor	I-Disease
V	I-Disease
(	I-Disease
FV	I-Disease
)	I-Disease
deficiency	I-Disease
.	O
	
A	O
37	O
-	O
year	O
-	O
old	O
male	O
(	O
proband	O
1	O
)	O
and	O
an	O
18	O
-	O
month	O
-	O
old	O
boy	O
(	O
proband	O
2	O
)	O
were	O
diagnosed	O
as	O
inherited	B-Disease
coagulation	I-Disease
FV	I-Disease
deficiency	I-Disease
by	O
severely	O
reduced	O
plasma	O
levels	O
of	O
FV	O
activity	O
and	O
antigen	O
.	O
	
All	O
25	O
exons	O
and	O
their	O
flanking	O
sequence	O
of	O
F5	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
both	O
probands	O
and	O
the	O
PCR	O
products	O
were	O
directly	O
sequenced	O
.	O
	
Total	O
RNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
lymphocytes	O
of	O
proband	O
1	O
for	O
detecting	O
the	O
changes	O
at	O
mRNA	O
level	O
.	O
	
The	O
homozygous	O
deletion	O
IVS8	O
-	O
2A	O
>	O
G	O
was	O
identified	O
in	O
the	O
F5	O
gene	O
of	O
proband	O
1	O
and	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
analysis	O
revealed	O
the	O
abolishment	O
of	O
the	O
canonical	O
splicing	O
site	O
by	O
the	O
mutation	O
and	O
the	O
activation	O
of	O
the	O
cryptic	O
acceptor	O
site	O
24	O
bp	O
upstream	O
instead	O
.	O
	
The	O
insertion	O
introduced	O
eight	O
additional	O
amino	O
acids	O
(	O
AA	O
)	O
into	O
the	O
FV	O
protein	O
.	O
	
Two	O
heterozygous	O
mutations	O
of	O
F5	O
gene	O
were	O
discovered	O
in	O
proband	O
2	O
.	O
	
The	O
2238	O
-	O
9del	O
AG	O
in	O
exon	O
13	O
introduced	O
a	O
premature	O
termination	O
code	O
at	O
689	O
AA	O
and	O
the	O
substitution	O
of	O
G6410	O
by	O
T	O
in	O
exon	O
23	O
lead	O
to	O
the	O
missense	O
mutation	O
Gly2079Val	O
.	O
	
Three	O
F5	O
gene	O
mutations	O
","	O
IVS8	O
-	O
2A	O
>	O
G	O
","	O
2238	O
-	O
9del	O
AG	O
and	O
G6410T	O
","	O
have	O
been	O
identified	O
in	O
two	O
Chinese	O
pedigree	O
with	O
congenital	B-Disease
FV	I-Disease
deficiency	I-Disease
","	O
respectively	O
.	O
	
19300402	
Bradykinin	O
receptors	O
antagonists	O
and	O
nitric	O
oxide	O
synthase	O
inhibitors	O
in	O
vincristine	O
and	O
streptozotocin	O
induced	O
hyperalgesia	B-Disease
in	O
chemotherapy	O
and	O
diabetic	B-Disease
neuropathy	I-Disease
rat	O
model	O
.	O
	
PURPOSE	O
:	O
The	O
influence	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
constitutive	O
NO	O
synthase	O
(	O
L	O
-	O
NOArg	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
"),"	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	O
NO	O
synthase	O
(	O
L	O
-	O
NIL	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	O
NO	O
synthase	O
(	O
7	O
-	O
NI	O
;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
ip	O
"),"	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	O
and	O
B1	O
receptors	O
:	O
D	O
-	O
Arg	O
-[	O
Hyp3	O
","	O
Thi5	O
","	O
D	O
-	O
Tic7	O
","	O
Oic8	O
]	O
bradykinin	O
(	O
HOE	O
140	O
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	O
Arg10	O
HOE	O
140	O
(	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
respectively	O
","	O
in	O
model	O
of	O
diabetic	B-Disease
(	I-Disease
streptozotocin	I-Disease
-	I-Disease
induced	I-Disease
)	I-Disease
and	I-Disease
toxic	I-Disease
(	I-Disease
vincristine	I-Disease
-	I-Disease
induced	I-Disease
)	I-Disease
neuropathy	I-Disease
was	O
investigated	O
.	O
	
METHODS	O
:	O
The	O
changes	O
in	O
pain	B-Disease
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli	O
--	O
the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall	O
-	O
Selitto	O
.	O
	
RESULTS	O
:	O
The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	O
receptors	O
and	O
inducible	O
NO	O
synthase	O
but	O
not	O
neuronal	O
NO	O
synthase	O
activity	O
reduces	O
diabetic	B-Disease
hyperalgesia	I-Disease
.	O
	
Pretreatment	O
with	O
L	O
-	O
NOArg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
","	O
significantly	O
increases	O
antihyperalgesic	O
activity	O
both	O
HOE	O
140	O
and	O
des	O
Arg10	O
HOE	O
140	O
.	O
	
It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	O
NO	O
synthase	O
and	O
neuronal	O
NO	O
synthase	O
activation	O
as	O
well	O
as	O
bradykinin	O
are	O
involved	O
in	O
hyperalgesia	B-Disease
produced	O
by	O
vincristine	O
.	O
	
Moreover	O
","	O
L	O
-	O
NOArg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	O
140	O
or	O
des	O
-	O
Arg10HOE	O
140	O
in	O
toxic	B-Disease
neuropathy	I-Disease
.	O
	
CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B-Disease
and	I-Disease
toxic	I-Disease
neuropathy	I-Disease
.	O
	
In	O
streptozotocin	O
-	O
induced	O
hyperalgesia	B-Disease
","	O
inducible	O
NO	O
synthase	O
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	O
","	O
whereas	O
in	O
vincristine	O
-	O
induced	O
hyperalgesia	B-Disease
bradykinin	O
seemed	O
to	O
activate	O
neuronal	O
NO	O
synthase	O
pathway	O
.	O
	
Therefore	O
","	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	O
receptor	O
antagonists	O
and	O
NO	O
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B-Disease
pain	I-Disease
","	O
even	O
in	O
hospital	O
care	O
.	O
	
24288432	
Association	O
of	O
a	O
FGFR	O
-	O
4	O
gene	O
polymorphism	O
with	O
bronchopulmonary	B-Disease
dysplasia	I-Disease
and	O
neonatal	B-Disease
respiratory	I-Disease
distress	I-Disease
.	O
	
BACKGROUND	O
:	O
Bronchopulmonary	B-Disease
dysplasia	I-Disease
(	O
BPD	B-Disease
)	O
is	O
the	O
most	O
common	O
chronic	O
lung	B-Disease
disease	I-Disease
of	O
premature	B-Disease
birth	I-Disease
","	O
characterized	O
by	O
impaired	B-Disease
alveolar	I-Disease
development	I-Disease
and	O
inflammation	B-Disease
.	O
	
Pathomechanisms	O
contributing	O
to	O
BPD	B-Disease
are	O
poorly	O
understood	O
.	O
	
However	O
","	O
it	O
is	O
assumed	O
that	O
genetic	O
factors	O
predispose	O
to	O
BPD	B-Disease
and	O
other	O
pulmonary	B-Disease
diseases	I-Disease
of	O
preterm	O
neonates	O
","	O
such	O
as	O
neonatal	B-Disease
respiratory	I-Disease
distress	I-Disease
syndrome	I-Disease
(	O
RDS	B-Disease
).	O
	
For	O
association	O
studies	O
","	O
genes	O
upregulated	O
during	O
alveolarization	O
are	O
major	O
candidates	O
for	O
genetic	O
analysis	O
","	O
for	O
example	O
","	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
and	O
their	O
receptors	O
(	O
FGFR	O
).	O
	
OBJECTIVE	O
:	O
Determining	O
genetic	O
risk	O
variants	O
in	O
a	O
Caucasian	O
population	O
of	O
premature	O
neonates	O
with	O
BPD	B-Disease
and	O
RDS	B-Disease
.	O
	
Methods	O
.	O
	
We	O
genotyped	O
27	O
polymorphisms	O
within	O
14	O
candidate	O
genes	O
via	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
):	O
MMP	O
-	O
1	O
","	O
-	O
2	O
","	O
-	O
9	O
","	O
and	O
-	O
12	O
","	O
-	O
16	O
","	O
FGF	O
receptors	O
2	O
and	O
4	O
","	O
FGF	O
-	O
2	O
","	O
-	O
3	O
","	O
-	O
4	O
","	O
-	O
7	O
","	O
and	O
-	O
18	O
","	O
Signal	O
-	O
Regulatory	O
Protein	O
a	O
(	O
SIRPA	O
)	O
and	O
Thyroid	O
Transcription	O
Factor	O
-	O
1	O
(	O
TTF	O
-	O
1	O
).	O
	
RESULTS	O
:	O
Five	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
MMP	O
-	O
9	O
","	O
MMP	O
-	O
12	O
","	O
FGFR	O
-	O
4	O
","	O
FGF	O
-	O
3	O
","	O
and	O
FGF	O
-	O
7	O
are	O
associated	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
with	O
RDS	B-Disease
","	O
defined	O
as	O
surfactant	O
application	O
within	O
the	O
first	O
24	O
hours	O
after	O
birth	O
.	O
	
One	O
of	O
them	O
","	O
in	O
FGFR	O
-	O
4	O
(	O
rs1966265	O
"),"	O
is	O
associated	O
with	O
both	O
RDS	B-Disease
(	O
P	O
=	O
0	O
.	O
3	O
)	O
and	O
BPD	B-Disease
(	O
P	O
=	O
0	O
.	O
23	O
).	O
	
CONCLUSION	O
:	O
rs1966265	O
in	O
FGF	O
receptor	O
4	O
is	O
a	O
possible	O
genetic	O
key	O
variant	O
in	O
alveolar	B-Disease
diseases	I-Disease
of	O
preterm	O
newborns	O
.	O
	
28259923	
Pleomorphic	O
adenoma	O
gene	O
like	O
-	O
2	O
induces	O
epithelial	O
-	O
mesenchymal	O
transition	O
via	O
Wnt	O
/	O
b	O
-	O
catenin	O
signaling	O
pathway	O
in	O
human	O
colorectal	B-Disease
adenocarcinoma	I-Disease
.	O
	
Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
a	O
critical	O
step	O
in	O
the	O
acquisition	O
of	O
metastatic	O
and	O
invasive	O
power	O
for	O
tumor	B-Disease
cells	O
.	O
	
Colorectal	B-Disease
adenocarcinoma	I-Disease
(	O
CRC	B-Disease
)	O
is	O
a	O
common	O
cancer	B-Disease
where	O
metastasis	B-Disease
is	O
directly	O
linked	O
to	O
patient	O
survival	O
.	O
	
Recent	O
studies	O
show	O
that	O
pleomorphic	O
adenoma	O
gene	O
like	O
-	O
2	O
(	O
PLAGL2	O
)	O
could	O
induce	O
tumor	B-Disease
EMT	O
and	O
is	O
an	O
independent	O
predictive	O
factor	O
associated	O
with	O
poor	O
prognosis	O
in	O
cancer	B-Disease
.	O
	
In	O
the	O
present	O
study	O
","	O
we	O
confirmed	O
the	O
role	O
of	O
PLAGL2	O
in	O
the	O
prognosis	O
of	O
CRC	B-Disease
patients	O
and	O
provide	O
molecular	O
evidence	O
of	O
PLAGL2	O
promoted	O
EMT	O
in	O
CRC	B-Disease
cell	O
line	O
SW480	O
.	O
	
We	O
found	O
that	O
PLAGL2	O
expression	O
was	O
upregulated	O
in	O
the	O
paraffin	O
-	O
embedded	O
CRC	B-Disease
tissues	O
compared	O
to	O
borderline	O
or	O
benign	O
tissues	O
.	O
	
Experimental	O
EMT	O
induced	O
by	O
PLAGL2	O
plasmid	O
transfection	O
proved	O
PLAGL2	O
protein	O
overexpression	O
could	O
enhance	O
the	O
cell	O
scratch	O
wound	O
-	O
healing	O
and	O
transwell	O
ability	O
and	O
significantly	O
upregulated	O
mesenchymal	O
marker	O
proteins	O
","	O
N	O
-	O
cadherin	O
and	O
vimentin	O
and	O
concurrently	O
downregulated	O
epithelial	O
marker	O
of	O
E	O
-	O
cadherin	O
.	O
	
Subsequently	O
","	O
through	O
western	O
blot	O
assay	O
","	O
we	O
found	O
that	O
PLAGL2	O
could	O
activate	O
the	O
wnt	O
-	O
signaling	O
component	O
b	O
-	O
catenin	O
in	O
the	O
nuclei	O
.	O
	
More	O
CRC	B-Disease
cell	O
metastasis	B-Disease
to	O
the	O
lungs	O
was	O
observed	O
when	O
the	O
PLAGL2	O
overexpressing	O
SW480	O
cells	O
were	O
injected	O
into	O
the	O
tail	O
vein	O
of	O
rats	O
","	O
compared	O
with	O
the	O
cell	O
control	O
and	O
PLAGL2	O
silence	O
group	O
.	O
	
Our	O
findings	O
indicated	O
that	O
PLAGL2	O
might	O
be	O
a	O
very	O
upstream	O
key	O
molecule	O
regulating	O
EMT	O
involved	O
in	O
Wnt	O
/	O
b	O
-	O
catenin	O
signaling	O
pathway	O
.	O
	
16000134	
Successful	O
therapy	O
with	O
argatroban	O
for	O
superior	O
mesenteric	O
vein	B-Disease
thrombosis	I-Disease
in	O
a	O
patient	O
with	O
congenital	B-Disease
antithrombin	I-Disease
deficiency	I-Disease
.	O
	
A	O
38	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
with	O
superior	B-Disease
mesenteric	I-Disease
vein	I-Disease
(	I-Disease
SMV	I-Disease
)	I-Disease
thrombosis	I-Disease
","	O
which	O
was	O
refractory	O
to	O
anticoagulation	O
therapy	O
.	O
	
The	O
plasma	O
antithrombin	O
activity	O
was	O
decreased	O
and	O
hardly	O
compensated	O
by	O
concentrated	O
antithrombin	O
preparation	O
due	O
to	O
high	O
consumption	O
rate	O
.	O
	
However	O
","	O
successful	O
anticoagulation	O
was	O
achieved	O
by	O
administration	O
of	O
direct	O
thrombin	O
inhibitor	O
","	O
argatroban	O
.	O
	
Family	O
studies	O
of	O
antithrombin	O
activity	O
revealed	O
that	O
she	O
had	O
type	B-Disease
I	I-Disease
congenital	I-Disease
antithrombin	I-Disease
deficiency	I-Disease
.	O
	
A	O
novel	O
heterozygous	O
mutation	O
in	O
the	O
gene	O
for	O
antithrombin	O
(	O
single	O
nucleotide	O
T	O
insertion	O
at	O
7916	O
and	O
7917	O
","	O
Glu	O
272	O
to	O
stop	O
in	O
exon	O
4	O
)	O
was	O
identified	O
.	O
	
Argatroban	O
administration	O
would	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
congenital	B-Disease
antithrombin	I-Disease
deficiency	I-Disease
with	O
SMV	B-Disease
thrombosis	I-Disease
.	O
	
16225977	
Amisulpride	O
related	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
in	O
an	O
adolescent	O
schizophrenic	B-Disease
.	O
	
Tic	B-Disease
disorders	I-Disease
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	O
such	O
as	O
risperidone	O
","	O
olanzapine	O
and	O
ziprasidone	O
.	O
	
However	O
","	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
","	O
including	O
motor	O
and	O
phonic	O
variants	O
","	O
occurring	O
during	O
treatment	O
with	O
quetiapine	O
or	O
clozapine	O
.	O
	
We	O
present	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
schizophrenic	B-Disease
who	O
developed	O
frequent	O
involuntary	B-Disease
eye	I-Disease
-	I-Disease
blinking	I-Disease
movements	I-Disease
after	O
5	O
months	O
of	O
amisulpride	O
treatment	O
(	O
1000	O
mg	O
per	O
day	O
).	O
	
The	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	O
down	O
to	O
800	O
mg	O
per	O
day	O
.	O
	
However	O
","	O
her	O
psychosis	B-Disease
recurred	O
after	O
the	O
dose	O
reduction	O
.	O
	
We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	O
.	O
	
She	O
has	O
been	O
in	O
complete	O
remission	O
under	O
the	O
combined	O
medications	O
for	O
more	O
than	O
one	O
year	O
and	O
maintains	O
a	O
fair	O
role	O
function	O
.	O
	
No	O
more	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O
	
Together	O
with	O
previously	O
reported	O
cases	O
","	O
our	O
patient	O
suggests	O
that	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
such	O
as	O
quetiapine	O
","	O
clozapine	O
","	O
or	O
amisulpride	O
.	O
	
20859899	
Syncope	B-Disease
caused	O
by	O
hyperkalemia	B-Disease
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
and	O
spironolactone	O
.	O
	
A	O
76	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	B-Disease
infarction	I-Disease
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	B-Disease
of	I-Disease
consciousness	I-Disease
due	O
to	O
marked	O
bradycardia	B-Disease
caused	O
by	O
hyperkalemia	B-Disease
.	O
	
The	O
concentration	O
of	O
serum	O
potassium	O
was	O
high	O
","	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	O
level	O
.	O
	
The	O
cause	O
of	O
hyperkalemia	B-Disease
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	O
","	O
an	O
aldosterone	O
antagonist	O
","	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
intake	O
of	O
ramipril	O
","	O
an	O
ACE	O
inhibitor	O
.	O
	
This	O
case	O
is	O
a	O
good	O
example	O
of	O
electrolyte	O
imbalance	O
causing	O
acute	O
life	O
-	O
threatening	O
cardiac	O
events	O
.	O
	
Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	B-Disease
","	O
especially	O
in	O
elderly	O
patients	O
using	O
ACE	O
/	O
ARB	O
in	O
combination	O
with	O
potassium	O
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	B-Disease
disturbance	I-Disease
.	O
	
15041272	
A	O
first	O
Taiwanese	O
Chinese	O
family	O
of	O
type	B-Disease
2B	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
with	O
R1306W	O
mutation	O
.	O
	
Clinical	O
","	O
laboratory	O
and	O
genetic	B-Disease
defect	I-Disease
of	O
a	O
Taiwanese	O
family	O
with	O
type	B-Disease
2B	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
(	O
VWD	B-Disease
)	O
were	O
studied	O
.	O
	
The	O
proband	O
was	O
a	O
55	O
-	O
year	O
-	O
old	O
woman	O
who	O
gave	O
birth	O
to	O
two	O
daughters	O
and	O
one	O
son	O
aged	O
30	O
","	O
29	O
and	O
27	O
","	O
respectively	O
.	O
	
All	O
had	O
abnormal	O
mucocutaneous	O
bleedings	B-Disease
since	O
their	O
childhood	O
.	O
	
In	O
proband	O
","	O
PT	O
","	O
PTT	O
and	O
platelet	O
count	O
were	O
normal	O
;	O
template	O
bleeding	B-Disease
time	O
was	O
14	O
min	O
;	O
VIII	O
:	O
C	O
was	O
51	O
"%,"	O
von	O
Willebrand	O
factor	O
antigen	O
(	O
VWF	O
:	O
Ag	O
"),"	O
42	O
%	O
and	O
von	O
Willerand	O
factor	O
ristocetin	O
-	O
cofactor	O
(	O
VWF	O
:	O
RCo	O
","	O
15	O
%);	O
ristocetin	B-Disease
-	I-Disease
induced	I-Disease
platelet	I-Disease
aggregation	I-Disease
(	O
RIPA	B-Disease
)	O
at	O
0	O
.	O
3	O
and	O
0	O
.	O
6	O
mg	O
/	O
ml	O
of	O
ristocetin	O
was	O
16	O
%	O
and	O
68	O
"%,"	O
respectively	O
.	O
	
The	O
enhanced	O
response	O
to	O
ristocetin	O
was	O
identified	O
to	O
be	O
in	O
plasma	O
","	O
not	O
in	O
platelet	O
itself	O
","	O
by	O
mixing	O
studies	O
.	O
	
Analysis	O
of	O
von	O
Willebrand	O
factor	O
(	O
VWF	O
)	O
multimer	O
of	O
plasma	O
but	O
not	O
of	O
platelets	O
showed	O
absence	O
of	O
high	O
-	O
molecular	O
weight	O
(	O
HMW	O
)	O
multimer	O
.	O
	
All	O
three	O
children	O
had	O
similar	O
laboratory	O
findings	O
.	O
	
Exon	O
28	O
of	O
VWF	O
gene	O
was	O
amplified	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
sequenced	O
.	O
	
The	O
proband	O
and	O
three	O
children	O
were	O
all	O
found	O
to	O
be	O
heterozygous	O
for	O
C	O
to	O
T	O
transition	O
at	O
nucleotide	O
3916	O
resulting	O
in	O
Arg	O
1306	O
Trp	O
(	O
R1306W	O
)	O
substitution	O
.	O
	
This	O
mutation	O
in	O
the	O
glycoprotein	O
Ib	O
(	O
GPIb	O
)-	O
binding	O
site	O
has	O
been	O
found	O
to	O
increase	O
the	O
affinity	O
of	O
plasma	O
VWF	O
for	O
platelets	O
","	O
and	O
thus	O
cause	O
loss	O
of	O
HMW	O
multimers	O
and	O
often	O
thrombocytopenia	B-Disease
.	O
	
In	O
conclusion	O
","	O
a	O
first	O
report	O
of	O
type	B-Disease
2B	I-Disease
VWD	I-Disease
in	O
a	O
Taiwanese	O
Chinese	O
family	O
who	O
show	O
R1306W	O
mutation	O
in	O
VWF	O
gene	O
was	O
described	O
.	O
	
17395743	
Identification	O
of	O
PVT1	O
as	O
a	O
candidate	O
gene	O
for	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
in	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
using	O
a	O
pooling	O
-	O
based	O
genome	O
-	O
wide	O
single	O
nucleotide	O
polymorphism	O
association	O
study	O
.	O
	
To	O
identify	O
genetic	O
variants	O
contributing	O
to	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
in	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
","	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
analysis	O
of	O
115	O
","	O
352	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
pools	O
of	O
105	O
unrelated	O
case	O
subjects	O
with	O
ESRD	B-Disease
and	O
102	O
unrelated	O
control	O
subjects	O
who	O
have	O
had	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
for	O
>	O
or	O
=	O
10	O
years	O
without	O
macroalbuminuria	O
.	O
	
Using	O
a	O
sliding	O
window	O
statistic	O
of	O
ranked	O
SNPs	O
","	O
we	O
identified	O
a	O
200	O
-	O
kb	O
region	O
on	O
8q24	O
harboring	O
three	O
SNPs	O
showing	O
substantial	O
differences	O
in	O
allelic	O
frequency	O
between	O
case	O
and	O
control	O
pools	O
.	O
	
These	O
SNPs	O
were	O
genotyped	O
in	O
individuals	O
comprising	O
each	O
pool	O
","	O
and	O
strong	O
evidence	O
for	O
association	O
was	O
found	O
with	O
rs2720709	O
(	O
P	O
=	O
0	O
.	O
21	O
;	O
odds	O
ratio	O
2	O
.	O
57	O
[	O
95	O
%	O
CI	O
1	O
.	O
66	O
-	O
3	O
.	O
96	O
"]),"	O
which	O
is	O
located	O
in	O
the	O
plasmacytoma	O
variant	O
translocation	O
gene	O
PVT1	O
.	O
	
We	O
sequenced	O
all	O
exons	O
","	O
exon	O
-	O
intron	O
boundaries	O
","	O
and	O
the	O
promoter	O
of	O
PVT1	O
and	O
identified	O
47	O
variants	O
","	O
11	O
of	O
which	O
represented	O
nonredundant	O
markers	O
with	O
minor	O
allele	O
frequency	O
>	O
or	O
=	O
0	O
.	O
5	O
.	O
	
We	O
subsequently	O
genotyped	O
these	O
11	O
variants	O
and	O
an	O
additional	O
87	O
SNPs	O
identified	O
through	O
public	O
databases	O
in	O
319	O
-	O
kb	O
flanking	O
rs2720709	O
(	O
approximately	O
1	O
SNP	O
/	O
3	O
.	O
5	O
kb	O
);	O
23	O
markers	O
were	O
associated	O
with	O
ESRD	B-Disease
at	O
P	O
<	O
0	O
.	O
1	O
.	O
	
The	O
strongest	O
evidence	O
for	O
association	O
was	O
found	O
for	O
rs2648875	O
(	O
P	O
=	O
0	O
.	O
18	O
;	O
2	O
.	O
97	O
[	O
1	O
.	O
90	O
-	O
4	O
.	O
65	O
"]),"	O
which	O
maps	O
to	O
intron	O
8	O
of	O
PVT1	O
.	O
	
Together	O
","	O
these	O
results	O
suggest	O
that	O
PVT1	O
may	O
contribute	O
to	O
ESRD	B-Disease
susceptibility	O
in	O
diabetes	B-Disease
.	O
	
27729412	
Reduced	O
adiponectin	O
expression	O
after	O
high	O
-	O
fat	O
diet	O
is	O
associated	O
with	O
selective	O
up	O
-	O
regulation	O
of	O
ALDH1A1	O
and	O
further	O
retinoic	O
acid	O
receptor	O
signaling	O
in	O
adipose	O
tissue	O
.	O
	
Adiponectin	O
is	O
an	O
adipocyte	O
-	O
derived	O
adipokine	O
with	O
potent	O
antidiabetic	O
","	O
anti	O
-	O
inflammatory	B-Disease
","	O
and	O
antiatherogenic	O
activity	O
.	O
	
Long	O
-	O
term	O
","	O
high	O
-	O
fat	O
diet	O
results	O
in	O
gain	O
of	O
body	O
weight	O
","	O
adiposity	B-Disease
","	O
further	O
inflammatory	B-Disease
-	O
based	O
cardiovascular	B-Disease
diseases	I-Disease
","	O
and	O
reduced	O
adiponectin	O
secretion	O
.	O
	
Vitamin	O
A	O
derivatives	O
/	O
retinoids	O
are	O
involved	O
in	O
several	O
of	O
these	O
processes	O
","	O
which	O
mainly	O
take	O
place	O
in	O
white	O
adipose	O
tissue	O
(	O
WAT	O
).	O
	
In	O
this	O
study	O
","	O
we	O
examined	O
adiponectin	O
expression	O
as	O
a	O
function	O
of	O
dietary	O
high	O
-	O
fat	O
and	O
high	O
-	O
vitamin	O
A	O
conditions	O
in	O
mice	O
.	O
	
A	O
decrease	O
of	O
adiponectin	O
expression	O
in	O
addition	O
to	O
an	O
up	O
-	O
regulation	O
of	O
aldehyde	O
dehydrogenase	O
A1	O
(	O
ALDH1A1	O
"),"	O
retinoid	O
signaling	O
","	O
and	O
retinoic	O
acid	O
response	O
element	O
signaling	O
was	O
selectively	O
observed	O
in	O
WAT	O
of	O
mice	O
fed	O
a	O
normal	O
-	O
vitamin	O
A	O
","	O
high	O
-	O
fat	O
diet	O
.	O
	
Reduced	O
adiponectin	O
expression	O
in	O
WAT	O
was	O
also	O
observed	O
in	O
mice	O
fed	O
a	O
high	O
-	O
vitamin	O
A	O
diet	O
.	O
	
Adipocyte	O
cell	O
culture	O
revealed	O
that	O
endogenous	O
and	O
synthetic	O
retinoic	O
acid	O
receptor	O
(	O
RAR	O
)	O
a	O
-	O
and	O
RARg	O
-	O
selective	O
agonists	O
","	O
as	O
well	O
as	O
a	O
synthetic	O
retinoid	O
X	O
receptor	O
agonist	O
","	O
efficiently	O
reduced	O
adiponectin	O
expression	O
","	O
whereas	O
ALDH1A1	O
expression	O
only	O
increased	O
with	O
RAR	O
agonists	O
.	O
	
We	O
conclude	O
that	O
reduced	O
adiponectin	O
expression	O
under	O
high	O
-	O
fat	O
dietary	O
conditions	O
is	O
dependent	O
on	O
1	O
)	O
increased	O
ALDH1A1	O
expression	O
in	O
adipocytes	O
","	O
which	O
does	O
not	O
increase	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
levels	O
;	O
2	O
)	O
further	O
RAR	O
ligand	O
-	O
induced	O
","	O
WAT	O
-	O
selective	O
","	O
increased	O
retinoic	O
acid	O
response	O
element	O
-	O
mediated	O
signaling	O
;	O
and	O
3	O
)	O
RAR	O
ligand	O
-	O
dependent	O
reduction	O
of	O
adiponectin	O
expression	O
.-	O
Landrier	O
","	O
J	O
.-	O
F	O
".,"	O
Kasiri	O
","	O
E	O
".,"	O
Karkeni	O
","	O
E	O
".,"	O
Mihaly	O
","	O
J	O
".,"	O
Beke	O
","	O
G	O
".,"	O
Weiss	O
","	O
K	O
".,"	O
Lucas	O
","	O
R	O
".,"	O
Aydemir	O
","	O
G	O
".,"	O
Salles	O
","	O
J	O
".,"	O
Walrand	O
","	O
S	O
".,"	O
de	O
Lera	O
","	O
A	O
.	O
R	O
".,"	O
Ruhl	O
","	O
R	O
.	O
Reduced	O
adiponectin	O
expression	O
after	O
high	O
-	O
fat	O
diet	O
is	O
associated	O
with	O
selective	O
up	O
-	O
regulation	O
of	O
ALDH1A1	O
and	O
further	O
retinoic	O
acid	O
receptor	O
signaling	O
in	O
adipose	O
tissue	O
.	O
	
29183288	
Arginase	O
1	O
deletion	O
in	O
myeloid	O
cells	O
affects	O
the	O
inflammatory	B-Disease
response	O
in	O
allergic	O
asthma	B-Disease
","	O
but	O
not	O
lung	O
mechanics	O
","	O
in	O
female	O
mice	O
.	O
	
BACKGROUND	O
:	O
(	O
Over	O
-)	O
expression	O
of	O
arginase	O
may	O
limit	O
local	O
availability	O
of	O
arginine	O
for	O
nitric	O
oxide	O
synthesis	O
.	O
	
We	O
investigated	O
the	O
significance	O
of	O
arginase1	O
(	O
ARG1	O
)	O
for	O
the	O
development	O
of	O
airway	O
hyperresponsiveness	O
(	O
AHR	O
)	O
and	O
lung	B-Disease
inflammation	I-Disease
in	O
female	O
mice	O
with	O
ovalbumin	O
(	O
OVA	O
)-	O
induced	O
allergic	O
asthma	B-Disease
.	O
	
METHODS	O
:	O
Arg1	O
was	O
ablated	O
in	O
the	O
lung	O
by	O
crossing	O
Arg1	O
fl	O
/	O
fl	O
and	O
Tie2Cre	O
tg	O
/-	O
mice	O
.	O
	
OVA	O
sensitization	O
and	O
challenge	O
were	O
conducted	O
","	O
and	O
AHR	O
to	O
methacholine	O
was	O
determined	O
using	O
the	O
Flexivent	O
system	O
.	O
	
Changes	O
in	O
gene	O
expression	O
","	O
chemokine	O
and	O
cytokine	O
secretion	O
","	O
plasma	O
IgE	O
","	O
and	O
lung	O
histology	O
were	O
quantified	O
using	O
RT	O
-	O
qPCR	O
","	O
ELISA	O
","	O
and	O
immunohistochemistry	O
","	O
respectively	O
.	O
	
RESULTS	O
:	O
Arg1	O
ablation	O
had	O
no	O
influence	O
on	O
the	O
development	O
of	O
OVA	O
-	O
induced	O
AHR	O
","	O
but	O
attenuated	O
OVA	O
-	O
induced	O
increases	O
in	O
expression	O
of	O
Arg2	O
and	O
Nos2	O
","	O
Slc7a1	O
","	O
Slc7a2	O
","	O
and	O
Slc7a7	O
(	O
arginine	O
transporters	O
"),"	O
Il4	O
","	O
Il5	O
and	O
Il13	O
(	O
TH2	O
-	O
type	O
cytokines	O
"),"	O
Ccl2	O
and	O
Ccl11	O
(	O
chemokines	O
"),"	O
Ifng	O
(	O
TH1	O
-	O
type	O
cytokine	O
"),"	O
Clca3	O
and	O
Muc5ac	O
(	O
goblet	O
cell	O
markers	O
"),"	O
and	O
OVA	O
-	O
specific	O
IgE	O
.	O
	
Pulmonary	O
IL	O
-	O
10	O
protein	O
content	O
increased	O
","	O
but	O
IL	O
-	O
4	O
","	O
IL	O
-	O
5	O
","	O
IL	O
-	O
13	O
","	O
TNFalpha	O
and	O
IFNgamma	O
content	O
","	O
and	O
lung	O
histopathology	O
","	O
were	O
not	O
affected	O
.	O
	
Arg1	O
elimination	O
also	O
decreased	O
number	O
and	O
tightness	O
of	O
correlations	O
between	O
adaptive	O
changes	O
in	O
lung	O
function	O
and	O
inflammatory	B-Disease
parameters	O
in	O
OVA	O
/	O
OVA	O
-	O
treated	O
female	O
mice	O
.	O
	
OVA	O
/	O
OVA	O
-	O
treated	O
female	O
mice	O
mounted	O
a	O
higher	O
OVA	O
-	O
IgE	O
response	O
than	O
males	O
","	O
but	O
the	O
correlation	O
between	O
lung	O
function	O
and	O
inflammation	B-Disease
was	O
lower	O
.	O
	
Arg1	O
-	O
deficient	O
OVA	O
/	O
OVA	O
-	O
treated	O
females	O
differed	O
from	O
males	O
in	O
a	O
more	O
pronounced	O
decline	O
of	O
arginine	O
-	O
metabolizing	O
and	O
-	O
transporting	O
genes	O
","	O
higher	O
plasma	O
arginine	O
levels	O
","	O
a	O
smaller	O
OVA	O
-	O
specific	O
IgE	O
response	O
","	O
and	O
no	O
improvement	O
of	O
peripheral	O
lung	O
function	O
.	O
	
CONCLUSION	O
:	O
Complete	O
ablation	O
of	O
Arg1	O
in	O
the	O
lung	O
affects	O
mRNA	O
abundance	O
of	O
arginine	O
-	O
transporting	O
and	O
-	O
metabolizing	O
genes	O
","	O
and	O
pro	O
-	O
inflammatory	B-Disease
genes	O
","	O
but	O
not	O
methacholine	O
responsiveness	O
or	O
accumulation	O
of	O
inflammatory	B-Disease
cells	O
.	O
	
20959502	
Cerebrospinal	O
fluid	O
penetration	O
of	O
high	O
-	O
dose	O
daptomycin	O
in	O
suspected	O
Staphylococcus	O
aureus	O
meningitis	B-Disease
.	O
	
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
methicillin	O
-	O
sensitive	O
Staphylococcus	O
aureus	O
(	O
MSSA	O
)	O
bacteremia	B-Disease
with	O
suspected	O
MSSA	O
meningitis	B-Disease
treated	O
with	O
high	O
-	O
dose	O
daptomycin	O
assessed	O
with	O
concurrent	O
serum	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
.	O
	
CASE	O
SUMMARY	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	B-Disease
and	O
presumed	O
health	O
-	O
care	O
-	O
associated	O
pneumonia	B-Disease
shown	O
on	O
chest	O
radiograph	O
.	O
	
Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	O
","	O
levofloxacin	O
","	O
and	O
piperacillin	O
/	O
tazobactam	O
.	O
	
Blood	O
cultures	O
revealed	O
S	O
.	O
aureus	O
susceptible	O
to	O
oxacillin	O
.	O
	
Empiric	O
antibiotic	O
treatment	O
was	O
narrowed	O
to	O
nafcillin	O
on	O
day	O
4	O
.	O
	
On	O
day	O
8	O
","	O
the	O
patient	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
serum	O
creatinine	O
1	O
.	O
9	O
mg	O
/	O
dL	O
","	O
increased	O
from	O
1	O
.	O
2	O
mg	O
/	O
dL	O
the	O
previous	O
day	O
and	O
0	O
.	O
8	O
mg	O
/	O
dL	O
on	O
admission	O
).	O
	
The	O
patient	O
'	O
s	O
Glasgow	O
Coma	B-Disease
Score	O
was	O
3	O
","	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	B-Disease
arrest	I-Disease
on	O
day	O
10	O
.	O
	
The	O
patient	O
experienced	O
relapsing	O
MSSA	O
bacteremia	B-Disease
on	O
day	O
9	O
","	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	B-Disease
nervous	I-Disease
system	I-Disease
(	I-Disease
CNS	I-Disease
)	I-Disease
infection	I-Disease
.	O
	
Nafcillin	O
was	O
discontinued	O
and	O
daptomycin	O
9	O
mg	O
/	O
kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	B-Disease
and	O
was	O
continued	O
until	O
the	O
patient	O
'	O
s	O
death	B-Disease
on	O
day	O
16	O
.	O
	
Daptomycin	O
serum	O
and	O
CSF	O
trough	O
concentrations	O
were	O
11	O
.	O
21	O
ug	O
/	O
mL	O
and	O
0	O
.	O
52	O
ug	O
/	O
mL	O
","	O
respectively	O
","	O
prior	O
to	O
the	O
third	O
dose	O
.	O
	
Lumbar	O
puncture	O
results	O
were	O
inconclusive	O
and	O
no	O
further	O
blood	O
cultures	O
were	O
positive	O
for	O
MSSA	O
.	O
	
Creatine	O
kinase	O
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	O
therapy	O
and	O
were	O
not	O
reassessed	O
.	O
	
DISCUSSION	O
:	O
Daptomycin	O
was	O
initiated	O
in	O
our	O
patient	O
secondary	O
to	O
possible	O
nafcillin	O
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
and	O
relapsing	O
bacteremia	B-Disease
.	O
	
At	O
a	O
dose	O
of	O
9	O
mg	O
/	O
kg	O
","	O
resultant	O
penetration	O
of	O
5	O
%	O
was	O
higher	O
than	O
in	O
previous	O
reports	O
","	O
more	O
consistent	O
with	O
inflamed	O
meninges	O
.	O
	
CONCLUSIONS	O
:	O
High	O
-	O
dose	O
daptomycin	O
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	B-Disease
with	O
or	O
without	O
a	O
CNS	O
source	O
in	O
patients	O
who	O
have	O
failed	O
or	O
cannot	O
tolerate	O
standard	O
therapy	O
.	O
	
Further	O
clinical	O
evaluation	O
in	O
patients	O
with	O
confirmed	O
meningitis	B-Disease
is	O
warranted	O
.	O
	
20682662	
Lack	O
of	O
association	O
of	O
C	O
-	O
C	O
chemokine	O
receptor	O
5	O
DD32	O
deletion	O
status	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
","	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
","	O
lupus	B-Disease
nephritis	I-Disease
","	O
and	O
disease	O
severity	O
.	O
	
OBJECTIVE	O
:	O
C	O
-	O
C	O
chemokine	O
receptor	O
5	O
(	O
CCR5	O
)	O
plays	O
an	O
important	O
role	O
in	O
inflammation	B-Disease
.	O
	
A	O
32	O
base	O
-	O
pair	O
(	O
DD32	O
)	O
deletion	O
in	O
the	O
CCR5	O
gene	O
leads	O
to	O
a	O
nonfunctional	O
receptor	O
.	O
	
This	O
deletion	O
has	O
been	O
reported	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
development	O
and	O
progression	O
of	O
several	O
autoimmune	B-Disease
diseases	I-Disease
.	O
	
We	O
investigated	O
whether	O
the	O
DD32	O
deletion	O
is	O
associated	O
with	O
disease	O
susceptibility	O
in	O
a	O
population	O
of	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
"),"	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
"),"	O
and	O
lupus	B-Disease
nephritis	I-Disease
(	O
LN	B-Disease
);	O
and	O
whether	O
it	O
is	O
associated	O
with	O
disease	O
severity	O
.	O
	
METHODS	O
:	O
DNA	O
samples	O
from	O
405	O
RA	B-Disease
patients	O
","	O
97	O
SLE	B-Disease
patients	O
","	O
113	O
LN	B-Disease
patients	O
","	O
and	O
431	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
CCR5	O
DD32	O
deletion	O
.	O
	
Differences	O
in	O
genotype	O
frequencies	O
were	O
tested	O
between	O
patients	O
and	O
controls	O
.	O
	
Association	O
of	O
genotypes	O
with	O
disease	O
severity	O
was	O
analyzed	O
.	O
	
RESULTS	O
:	O
Genotype	O
frequencies	O
of	O
each	O
group	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O
	
The	O
genotype	O
frequencies	O
of	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
controls	O
(	O
CCR5	O
/	O
DD32	O
","	O
DD32	O
/	O
DD32	O
:	O
RA	B-Disease
18	O
.	O
3	O
%	O
and	O
1	O
.	O
2	O
"%,"	O
respectively	O
;	O
SLE	B-Disease
17	O
.	O
5	O
%	O
and	O
2	O
.	O
1	O
%;	O
LN	B-Disease
13	O
.	O
3	O
%	O
and	O
1	O
.	O
8	O
%;	O
controls	O
20	O
.	O
0	O
%	O
and	O
2	O
.	O
8	O
%).	O
	
However	O
","	O
there	O
was	O
a	O
trend	O
for	O
lower	O
DD32	O
deletion	O
allele	O
frequency	O
in	O
LN	B-Disease
patients	O
compared	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
8	O
).	O
	
There	O
was	O
no	O
significant	O
association	O
between	O
the	O
CCR5	O
status	O
and	O
disease	O
severity	O
in	O
RA	B-Disease
","	O
SLE	B-Disease
","	O
or	O
LN	B-Disease
.	O
	
CONCLUSION	O
:	O
Although	O
an	O
association	O
with	O
LN	B-Disease
cannot	O
be	O
excluded	O
","	O
the	O
CCR5	O
DD32	O
deletion	O
does	O
not	O
seem	O
to	O
be	O
a	O
disease	O
susceptibility	O
genotype	O
for	O
RA	B-Disease
","	O
SLE	B-Disease
","	O
or	O
LN	B-Disease
.	O
	
No	O
significant	O
effect	O
of	O
the	O
DD32	O
deletion	O
on	O
disease	O
severity	O
was	O
demonstrated	O
.	O
	
23285048	
Context	O
-	O
and	O
cell	O
-	O
dependent	O
effects	O
of	O
Delta	O
-	O
like	O
4	O
targeting	O
in	O
the	O
bone	O
marrow	O
microenvironment	O
.	O
	
Delta	O
-	O
like	O
4	O
(	O
Dll4	O
)	O
is	O
a	O
ligand	O
of	O
the	O
Notch	O
pathway	O
family	O
which	O
has	O
been	O
widely	O
studied	O
in	O
the	O
context	O
of	O
tumor	B-Disease
angiogenesis	O
","	O
its	O
blockade	O
shown	O
to	O
result	O
in	O
non	O
-	O
productive	O
angiogenesis	O
and	O
halted	O
tumor	B-Disease
growth	O
.	O
	
As	O
Dll4	O
inhibitors	O
enter	O
the	O
clinic	O
","	O
there	O
is	O
an	O
emerging	O
need	O
to	O
understand	O
their	O
side	O
effects	O
","	O
namely	O
the	O
systemic	O
consequences	O
of	O
Dll4	O
:	O
Notch	O
blockade	O
in	O
tissues	O
other	O
than	O
tumors	B-Disease
.	O
	
The	O
present	O
study	O
focused	O
on	O
the	O
effects	O
of	O
systemic	O
anti	O
-	O
Dll4	O
targeting	O
in	O
the	O
bone	O
marrow	O
(	O
BM	O
)	O
microenvironment	O
.	O
	
Here	O
we	O
show	O
that	O
Dll4	O
blockade	O
with	O
monoclonal	O
antibodies	O
perturbs	O
the	O
BM	O
vascular	O
niche	O
of	O
sub	O
-	O
lethally	O
irradiated	O
mice	O
","	O
resulting	O
in	O
increased	O
CD31	O
"(+),"	O
VE	O
-	O
Cadherin	O
(+)	O
and	O
c	O
-	O
kit	O
(+)	O
vessel	O
density	O
","	O
and	O
also	O
increased	O
megakaryocytes	O
","	O
whereas	O
CD105	O
"(+),"	O
VEGFR3	O
"(+),"	O
SMA	O
(+)	O
and	O
lectin	O
(+)	O
vessel	O
density	O
remained	O
unaltered	O
.	O
	
We	O
investigated	O
also	O
the	O
expression	O
of	O
angiocrine	O
genes	O
upon	O
Dll4	O
treatment	O
in	O
vivo	O
","	O
and	O
demonstrate	O
that	O
IGFbp2	O
","	O
IGFbp3	O
","	O
Angpt2	O
","	O
Dll4	O
","	O
DHH	O
and	O
VEGF	O
-	O
A	O
are	O
upregulated	O
","	O
while	O
FGF1	O
and	O
CSF2	O
are	O
reduced	O
.	O
	
In	O
vitro	O
treatment	O
of	O
endothelial	O
cells	O
with	O
anti	O
-	O
Dll4	O
reduced	O
Akt	O
phosphorylation	O
while	O
maintaining	O
similar	O
levels	O
of	O
Erk	O
1	O
/	O
2	O
phosphorylation	O
.	O
	
Besides	O
its	O
effects	O
in	O
the	O
BM	O
vascular	O
niche	O
","	O
anti	O
-	O
Dll4	O
treatment	O
perturbed	O
hematopoiesis	O
","	O
as	O
evidenced	O
by	O
increased	O
myeloid	O
(	O
CD11b	O
"(+)),"	O
decreased	O
B	O
(	O
B220	O
(+))	O
and	O
T	O
(	O
CD3	O
(+))	O
lymphoid	O
BM	O
content	O
of	O
treated	O
mice	O
","	O
with	O
a	O
corresponding	O
increase	O
in	O
myeloid	O
circulating	O
cells	O
.	O
	
Moreover	O
","	O
anti	O
-	O
Dll4	O
treatment	O
also	O
increased	O
the	O
number	O
of	O
CFU	O
-	O
M	O
and	O
-	O
G	O
colonies	O
in	O
methylcellulose	O
assays	O
","	O
independently	O
of	O
Notch1	O
.	O
	
Finally	O
","	O
anti	O
-	O
Dll4	O
treatment	O
of	O
donor	O
BM	O
improved	O
the	O
hematopoietic	O
recovery	O
of	O
lethally	O
irradiated	O
recipients	O
in	O
a	O
transplant	O
setting	O
.	O
	
Together	O
","	O
our	O
data	O
reveals	O
the	O
hematopoietic	O
(	O
BM	O
)	O
effects	O
of	O
systemic	O
anti	O
-	O
Dll4	O
treatment	O
result	O
from	O
qualitative	O
vascular	O
changes	O
and	O
also	O
direct	O
hematopoietic	O
cell	O
modulation	O
","	O
which	O
may	O
be	O
favorable	O
in	O
a	O
transplant	O
setting	O
.	O
	
27663860	
Role	O
of	O
angiotensin	O
II	O
type	O
1a	O
receptor	O
in	O
renal	B-Disease
injury	I-Disease
induced	O
by	O
deoxycorticosterone	O
acetate	O
-	O
salt	O
hypertension	B-Disease
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
in	O
vivo	O
role	O
of	O
angiotensin	O
II	O
type	O
1a	O
(	O
AT1a	O
)	O
receptor	O
in	O
renal	B-Disease
damage	I-Disease
as	O
a	O
result	O
of	O
hypertension	B-Disease
by	O
using	O
transgenic	O
mice	O
with	O
AT1a	O
receptor	O
gene	O
disruption	O
.	O
	
Transgenic	O
mice	O
that	O
express	O
human	O
liver	O
-	O
type	O
fatty	O
acid	O
binding	O
protein	O
(	O
L	O
-	O
FABP	O
)	O
with	O
or	O
without	O
disruption	O
of	O
the	O
AT1a	O
receptor	O
gene	O
(	O
L	O
-	O
FABP	O
(+/-)	O
AT1a	O
"(-/-),"	O
and	O
L	O
-	O
FABP	O
(+/-)	O
AT1a	O
"(+/+),"	O
respectively	O
)	O
were	O
used	O
with	O
urinary	O
L	O
-	O
FABP	O
as	O
an	O
indicator	O
of	O
tubulointerstitial	B-Disease
damage	I-Disease
.	O
	
Those	O
female	O
mice	O
were	O
administered	O
subcutaneously	O
deoxycorticosterone	O
acetate	O
(	O
DOCA	O
)-	O
salt	O
tablets	O
plus	O
drinking	O
water	O
that	O
contained	O
1	O
%	O
saline	O
for	O
28	O
d	O
after	O
uninephrectomy	O
.	O
	
In	O
L	O
-	O
FABP	O
(+/-)	O
AT1a	O
(+/+)	O
mice	O
that	O
received	O
DOCA	O
-	O
salt	O
treatment	O
","	O
hypertension	B-Disease
was	O
induced	O
and	O
slight	O
expansion	O
of	O
glomerular	O
area	O
","	O
glomerular	B-Disease
sclerosis	I-Disease
","	O
and	O
tubulointerstitial	B-Disease
damage	I-Disease
were	O
observed	O
.	O
	
In	O
L	O
-	O
FABP	O
(+/-)	O
AT1a	O
(-/-)	O
mice	O
that	O
received	O
DOCA	O
-	O
salt	O
treatment	O
","	O
hypertension	B-Disease
was	O
similarly	O
induced	O
and	O
the	O
degree	O
of	O
glomerular	B-Disease
damage	I-Disease
was	O
significantly	O
more	O
severe	O
than	O
in	O
L	O
-	O
FABP	O
(+/-)	O
AT1a	O
(+/+)-	O
DOCA	O
mice	O
.	O
	
Urinary	O
L	O
-	O
FABP	O
levels	O
were	O
significantly	O
higher	O
in	O
L	O
-	O
FABP	O
(+/-)	O
AT1a	O
(-/-)-	O
DOCA	O
mice	O
compared	O
with	O
those	O
in	O
L	O
-	O
FABP	O
(+/-)	O
AT1a	O
(+/+)-	O
DOCA	O
mice	O
.	O
	
Hydralazine	O
treatment	O
significantly	O
attenuated	O
renal	B-Disease
damage	I-Disease
that	O
was	O
found	O
in	O
L	O
-	O
FABP	O
(+/-)	O
AT1a	O
(-/-)-	O
DOCA	O
mice	O
along	O
with	O
a	O
reduction	O
in	O
blood	O
pressure	O
.	O
	
In	O
summary	O
","	O
activation	O
of	O
the	O
AT1a	O
receptor	O
may	O
contribute	O
to	O
maintenance	O
of	O
the	O
glomerular	O
structure	O
against	O
hypertensive	B-Disease
renal	I-Disease
damage	I-Disease
.-	O
Hisamichi	O
","	O
M	O
".,"	O
Kamijo	O
-	O
Ikemori	O
","	O
A	O
".,"	O
Sugaya	O
","	O
T	O
".,"	O
Ichikawa	O
","	O
D	O
".,"	O
Natsuki	O
","	O
T	O
".,"	O
Hoshino	O
","	O
S	O
".,"	O
Kimura	O
","	O
K	O
".,"	O
Shibagaki	O
","	O
Y	O
.	O
Role	O
of	O
angiotensin	O
II	O
type	O
1a	O
receptor	O
in	O
renal	B-Disease
injury	I-Disease
induced	O
by	O
deoxycorticosterone	O
acetate	O
-	O
salt	O
hypertension	B-Disease
.	O
	
27807193	
PTPN22	O
Is	O
a	O
Critical	O
Regulator	O
of	O
Fcg	O
Receptor	O
-	O
Mediated	O
Neutrophil	O
Activation	O
.	O
	
Neutrophils	O
act	O
as	O
a	O
first	O
line	O
of	O
defense	O
against	O
bacterial	O
and	O
fungal	B-Disease
infections	I-Disease
","	O
but	O
they	O
are	O
also	O
important	O
effectors	O
of	O
acute	B-Disease
and	I-Disease
chronic	I-Disease
inflammation	I-Disease
.	O
	
Genome	O
-	O
wide	O
association	O
studies	O
have	O
established	O
that	O
the	O
gene	O
encoding	O
the	O
protein	O
tyrosine	O
phosphatase	O
nonreceptor	O
22	O
(	O
PTPN22	O
)	O
makes	O
an	O
important	O
contribution	O
to	O
susceptibility	O
to	O
autoimmune	B-Disease
disease	I-Disease
","	O
notably	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O
	
Although	O
PTPN22	O
is	O
most	O
highly	O
expressed	O
in	O
neutrophils	O
","	O
its	O
function	O
in	O
these	O
cells	O
remains	O
poorly	O
characterized	O
.	O
	
We	O
show	O
in	O
this	O
article	O
that	O
neutrophil	O
effector	O
functions	O
","	O
including	O
adhesion	O
","	O
production	O
of	O
reactive	O
oxygen	O
species	O
","	O
and	O
degranulation	O
induced	O
by	O
immobilized	O
immune	O
complexes	O
","	O
were	O
reduced	O
in	O
Ptpn22	O
(-/-)	O
neutrophils	O
.	O
	
Tyrosine	O
phosphorylation	O
of	O
Lyn	O
and	O
Syk	O
was	O
altered	O
in	O
Ptpn22	O
(-/-)	O
neutrophils	O
.	O
	
On	O
stimulation	O
with	O
immobilized	O
immune	O
complexes	O
","	O
Ptpn22	O
(-/-)	O
neutrophils	O
manifested	O
reduced	O
activation	O
of	O
key	O
signaling	O
intermediates	O
.	O
	
Ptpn22	O
(-/-)	O
mice	O
were	O
protected	O
from	O
immune	O
complex	O
-	O
mediated	O
arthritis	B-Disease
","	O
induced	O
by	O
the	O
transfer	O
of	O
arthritogenic	O
serum	O
.	O
	
In	O
contrast	O
","	O
in	O
vivo	O
neutrophil	O
recruitment	O
following	O
thioglycollate	O
-	O
induced	O
peritonitis	B-Disease
and	O
in	O
vitro	O
chemotaxis	O
were	O
not	O
affected	O
by	O
lack	O
of	O
PTPN22	O
.	O
	
Our	O
data	O
suggest	O
an	O
important	O
role	O
for	O
PTPN22	O
-	O
dependent	O
dephosphorylation	O
events	O
","	O
which	O
are	O
required	O
to	O
enable	O
full	O
FcgR	O
-	O
induced	O
activation	O
","	O
pointing	O
to	O
an	O
important	O
role	O
for	O
this	O
molecule	O
in	O
neutrophil	O
function	O
.	O
	
15069170	
Four	O
novel	O
mutations	O
in	O
the	O
thiazide	O
-	O
sensitive	O
Na	O
-	O
Cl	O
co	O
-	O
transporter	O
gene	O
in	O
Japanese	O
patients	O
with	O
Gitelman	B-Disease
'	I-Disease
s	I-Disease
syndrome	I-Disease
.	O
	
BACKGROUND	O
:	O
Gitelman	B-Disease
'	I-Disease
s	I-Disease
syndrome	I-Disease
(	O
GS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
resulting	O
from	O
inactivating	O
mutations	O
in	O
the	O
thiazide	O
-	O
sensitive	O
Na	O
-	O
Cl	O
co	O
-	O
transporter	O
(	O
NCCT	O
)	O
gene	O
.	O
	
To	O
date	O
","	O
almost	O
90	O
mutations	O
have	O
been	O
identified	O
.	O
	
It	O
is	O
possible	O
that	O
there	O
is	O
a	O
population	O
-	O
specific	O
distribution	O
of	O
mutations	O
.	O
	
In	O
this	O
study	O
","	O
we	O
analysed	O
mutations	O
in	O
the	O
NCCT	O
gene	O
of	O
seven	O
Japanese	O
patients	O
with	O
GS	B-Disease
.	O
	
METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
patients	O
with	O
GS	B-Disease
","	O
their	O
family	O
members	O
and	O
healthy	O
control	O
subjects	O
.	O
	
A	O
mutation	O
analysis	O
of	O
the	O
NCCT	O
gene	O
was	O
performed	O
completely	O
by	O
direct	O
automated	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
DNA	O
products	O
.	O
	
In	O
patients	O
with	O
a	O
deletion	O
or	O
splice	O
site	O
mutation	O
","	O
we	O
undertook	O
cDNA	O
sequence	O
analysis	O
.	O
	
RESULTS	O
:	O
We	O
identified	O
nine	O
mutations	O
.	O
	
Five	O
of	O
them	O
[	O
c	O
.	O
185C	O
>	O
T	O
(	O
Thr60Met	O
"),"	O
c	O
.	O
1712C	O
>	O
T	O
(	O
Ala569Val	O
"),"	O
c	O
.	O
1930C	O
>	O
T	O
(	O
Arg642Cys	O
"),"	O
c	O
.	O
2552T	O
>	O
A	O
(	O
Leu849His	O
)	O
and	O
c	O
.	O
1932delC	O
]	O
have	O
been	O
reported	O
in	O
Japanese	O
patients	O
","	O
but	O
not	O
in	O
GS	B-Disease
patients	O
from	O
other	O
ethnic	O
groups	O
.	O
	
The	O
remaining	O
four	O
mutations	O
[	O
c	O
.	O
7A	O
>	O
T	O
(	O
Met1Leu	O
"),"	O
c	O
.	O
1181_1186	O
+	O
20del26	O
","	O
c	O
.	O
1811_1812delAT	O
and	O
IVS16	O
+	O
1G	O
>	O
A	O
]	O
were	O
novel	O
.	O
	
In	O
cDNA	O
derived	O
from	O
a	O
patient	O
with	O
c	O
.	O
1181_1186	O
+	O
20del26	O
","	O
a	O
deletion	O
of	O
exon	O
9	O
and	O
a	O
frameshift	O
at	O
the	O
start	O
of	O
exon	O
10	O
were	O
observed	O
.	O
	
In	O
cDNA	O
derived	O
from	O
patients	O
with	O
IVS16	O
+	O
1G	O
>	O
A	O
","	O
an	O
additional	O
96	O
bp	O
insertion	O
between	O
exons	O
16	O
and	O
17	O
was	O
observed	O
.	O
	
Six	O
out	O
of	O
seven	O
patients	O
were	O
compound	O
heterozygotes	O
","	O
and	O
the	O
remaining	O
one	O
carried	O
a	O
single	O
heterozygous	O
mutation	O
.	O
	
CONCLUSIONS	O
:	O
We	O
found	O
four	O
novel	O
mutations	O
in	O
the	O
NCCT	O
gene	O
in	O
seven	O
Japanese	O
patients	O
with	O
GS	B-Disease
.	O
	
Moreover	O
","	O
our	O
study	O
suggests	O
that	O
the	O
distribution	O
of	O
mutations	O
in	O
the	O
NCCT	O
gene	O
in	O
Japanese	O
GS	B-Disease
patients	O
potentially	O
differs	O
from	O
that	O
in	O
other	O
populations	O
.	O
	
17397547	
Regulatory	O
network	O
of	O
inflammation	B-Disease
downstream	O
of	O
proteinase	O
-	O
activated	O
receptors	O
.	O
	
BACKGROUND	O
:	O
Protease	O
-	O
activated	O
receptors	O
(	O
PAR	O
)	O
are	O
present	O
in	O
the	O
urinary	O
bladder	O
","	O
and	O
their	O
expression	O
is	O
altered	O
in	O
response	O
to	O
inflammation	B-Disease
.	O
	
PARs	O
are	O
a	O
unique	O
class	O
of	O
G	O
protein	O
-	O
coupled	O
that	O
carry	O
their	O
own	O
ligands	O
","	O
which	O
remain	O
cryptic	O
until	O
unmasked	O
by	O
proteolytic	O
cleavage	O
.	O
	
Although	O
the	O
canonical	O
signal	O
transduction	O
pathway	O
downstream	O
of	O
PAR	O
activation	O
and	O
coupling	O
with	O
various	O
G	O
proteins	O
is	O
known	O
and	O
leads	O
to	O
the	O
rapid	O
transcription	O
of	O
genes	O
involved	O
in	O
inflammation	B-Disease
","	O
the	O
effect	O
of	O
PAR	O
activation	O
on	O
the	O
downstream	O
transcriptome	O
is	O
unknown	O
.	O
	
We	O
have	O
shown	O
that	O
intravesical	O
administration	O
of	O
PAR	O
-	O
activating	O
peptides	O
leads	O
to	O
an	O
inflammatory	B-Disease
reaction	O
characterized	O
by	O
edema	B-Disease
and	O
granulocyte	O
infiltration	O
.	O
	
Moreover	O
","	O
the	O
inflammatory	B-Disease
response	O
to	O
intravesical	O
instillation	O
of	O
known	O
pro	O
-	O
inflammatory	B-Disease
stimuli	O
such	O
as	O
E	O
.	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
"),"	O
substance	O
P	O
(	O
SP	O
"),"	O
and	O
antigen	O
was	O
strongly	O
attenuated	O
by	O
PAR1	O
-	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
PAR2	O
-	O
deficiency	O
.	O
	
RESULTS	O
:	O
Here	O
","	O
cDNA	O
array	O
experiments	O
determined	O
inflammatory	B-Disease
genes	O
whose	O
expression	O
is	O
dependent	O
on	O
PAR1	O
activation	O
.	O
	
For	O
this	O
purpose	O
","	O
we	O
compared	O
the	O
alteration	O
in	O
gene	O
expression	O
in	O
wild	O
type	O
and	O
PAR1	O
-/-	O
mice	O
induced	O
by	O
classical	O
pro	O
-	O
inflammatory	B-Disease
stimuli	O
(	O
LPS	O
","	O
SP	O
","	O
and	O
antigen	O
).	O
	
75	O
transcripts	O
were	O
considered	O
to	O
be	O
dependent	O
on	O
PAR	O
-	O
1	O
activation	O
and	O
further	O
annotated	O
in	O
silico	O
by	O
Ingenuity	O
Pathways	O
Analysis	O
(	O
IPA	O
)	O
and	O
gene	O
ontology	O
(	O
GO	O
).	O
	
Selected	O
transcripts	O
were	O
target	O
validated	O
by	O
quantitative	O
PCR	O
(	O
Q	O
-	O
PCR	O
).	O
	
Among	O
PAR1	O
-	O
dependent	O
transcripts	O
","	O
the	O
following	O
have	O
been	O
implicated	O
in	O
the	O
inflammatory	B-Disease
process	O
:	O
b2m	O
","	O
ccl7	O
","	O
cd200	O
","	O
cd63	O
","	O
cdbpd	O
","	O
cfl1	O
","	O
dusp1	O
","	O
fkbp1a	O
","	O
fth1	O
","	O
hspb1	O
","	O
marcksl1	O
","	O
mmp2	O
","	O
myo5a	O
","	O
nfkbia	O
","	O
pax1	O
","	O
plaur	O
","	O
ppia	O
","	O
ptpn1	O
","	O
ptprcap	O
","	O
s100a10	O
","	O
sim2	O
","	O
and	O
tnfaip2	O
.	O
	
However	O
","	O
a	O
balanced	O
response	O
to	O
signals	O
of	O
injury	O
requires	O
a	O
transient	O
cellular	O
activation	O
of	O
a	O
panel	O
of	O
genes	O
together	O
with	O
inhibitory	O
systems	O
that	O
temper	O
the	O
overwhelming	O
inflammation	B-Disease
.	O
	
In	O
this	O
context	O
","	O
the	O
activation	O
of	O
genes	O
such	O
as	O
dusp1	O
and	O
nfkbia	O
seems	O
to	O
counter	O
-	O
balance	O
the	O
inflammatory	B-Disease
response	O
to	O
PAR	O
activation	O
by	O
limiting	O
prolonged	O
activation	O
of	O
p38	O
MAPK	O
and	O
increased	O
cytokine	O
production	O
.	O
	
In	O
contrast	O
","	O
transcripts	O
such	O
as	O
arf6	O
and	O
dcnt1	O
that	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
PAR	O
re	O
-	O
sensitization	O
would	O
tend	O
to	O
perpetuate	O
the	O
inflammatory	B-Disease
reaction	O
in	O
response	O
to	O
common	O
pro	O
-	O
inflammatory	B-Disease
stimuli	O
.	O
	
CONCLUSION	O
:	O
The	O
combination	O
of	O
cDNA	O
array	O
results	O
and	O
genomic	O
networks	O
reveals	O
an	O
overriding	O
participation	O
of	O
PAR1	O
in	O
bladder	B-Disease
inflammation	I-Disease
","	O
provides	O
a	O
working	O
model	O
for	O
the	O
involvement	O
of	O
downstream	O
signaling	O
","	O
and	O
evokes	O
testable	O
hypotheses	O
regarding	O
the	O
transcriptome	O
downstream	O
of	O
PAR1	O
activation	O
.	O
	
It	O
remains	O
to	O
be	O
determined	O
whether	O
or	O
not	O
mechanisms	O
targeting	O
PAR1	O
gene	O
silencing	O
or	O
PAR1	O
blockade	O
will	O
ameliorate	O
the	O
clinical	O
manifestation	O
of	O
cystitis	B-Disease
.	O
	
17445520	
Caffeine	O
challenge	O
test	O
in	O
panic	B-Disease
disorder	I-Disease
and	O
depression	B-Disease
with	O
panic	B-Disease
attacks	I-Disease
.	O
	
Our	O
aim	O
was	O
to	O
observe	O
if	O
patients	O
with	O
panic	B-Disease
disorder	I-Disease
(	O
PD	B-Disease
)	O
and	O
patients	O
with	O
major	B-Disease
depression	I-Disease
with	O
panic	B-Disease
attacks	I-Disease
(	O
MDP	B-Disease
)	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B-Disease
Disorders	I-Disease
","	O
Fourth	O
Edition	O
criteria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
induction	O
of	O
panic	B-Disease
attacks	I-Disease
by	O
an	O
oral	O
caffeine	O
challenge	O
test	O
.	O
	
We	O
randomly	O
selected	O
29	O
patients	O
with	O
PD	B-Disease
","	O
27	O
with	O
MDP	B-Disease
","	O
25	O
with	O
major	B-Disease
depression	I-Disease
without	O
panic	B-Disease
attacks	I-Disease
(	O
MD	B-Disease
"),"	O
and	O
28	O
healthy	O
volunteers	O
.	O
	
The	O
patients	O
had	O
no	O
psychotropic	O
drug	O
for	O
at	O
least	O
a	O
4	O
-	O
week	O
period	O
.	O
	
In	O
a	O
randomized	O
double	O
-	O
blind	O
experiment	O
performed	O
in	O
2	O
occasions	O
7	O
days	O
apart	O
","	O
480	O
mg	O
caffeine	O
and	O
a	O
caffeine	O
-	O
free	O
(	O
placebo	O
)	O
solution	O
were	O
administered	O
in	O
a	O
coffee	O
form	O
and	O
anxiety	B-Disease
scales	O
were	O
applied	O
before	O
and	O
after	O
each	O
test	O
.	O
	
A	O
total	O
of	O
58	O
.	O
6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patients	O
with	O
PD	B-Disease
","	O
44	O
.	O
4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
patients	O
with	O
MDP	B-Disease
","	O
12	O
.	O
0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patients	O
with	O
MD	B-Disease
","	O
and	O
7	O
.	O
1	O
%	O
(	O
n	O
=	O
2	O
)	O
of	O
control	O
subjects	O
had	O
a	O
panic	B-Disease
attack	I-Disease
after	O
the	O
480	O
-	O
mg	O
caffeine	O
challenge	O
test	O
(	O
chi	O
(	O
2	O
)(	O
3	O
)	O
=	O
16	O
.	O
22	O
","	O
P	O
=	O
.	O
1	O
).	O
	
The	O
patients	O
with	O
PD	B-Disease
and	O
MDP	B-Disease
were	O
more	O
sensitive	O
to	O
caffeine	O
than	O
were	O
patients	O
with	O
MD	B-Disease
and	O
healthy	O
volunteers	O
.	O
	
No	O
panic	B-Disease
attack	I-Disease
was	O
observed	O
after	O
the	O
caffeine	O
-	O
free	O
solution	O
intake	O
.	O
	
The	O
patients	O
with	O
MD	B-Disease
had	O
a	O
lower	O
heart	O
rate	O
response	O
to	O
the	O
test	O
than	O
all	O
the	O
other	O
groups	O
(	O
2	O
-	O
way	O
analysis	O
of	O
variance	O
","	O
group	O
by	O
time	O
interaction	O
with	O
Greenhouse	O
-	O
Geisser	O
correction	O
:	O
F	O
(	O
3	O
","	O
762	O
)	O
=	O
2	O
.	O
85	O
","	O
P	O
=	O
.	O
26	O
).	O
	
Our	O
data	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
panic	B-Disease
attacks	I-Disease
","	O
no	O
matter	O
if	O
associated	O
with	O
PD	B-Disease
or	O
MDP	B-Disease
","	O
and	O
hyperreactivity	O
to	O
an	O
oral	O
caffeine	O
challenge	O
test	O
.	O
	
23651211	
Upregulation	O
of	O
T	O
-	O
cell	O
factor	O
-	O
4	O
isoform	O
-	O
responsive	O
target	O
genes	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
	
BACKGROUND	O
:	O
The	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signalling	O
pathway	O
regulates	O
genes	O
involved	O
in	O
cell	O
proliferation	O
","	O
survival	O
","	O
migration	O
and	O
invasion	O
through	O
regulation	O
by	O
T	O
-	O
cell	O
factor	O
(	O
TCF	O
)-	O
4	O
transcription	O
factor	O
proteins	O
.	O
	
However	O
","	O
the	O
role	O
of	O
TCF	O
-	O
4	O
isoforms	O
generated	O
by	O
alternative	O
splicing	O
events	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
(	O
HCC	B-Disease
)	O
is	O
unknown	O
.	O
	
AIM	O
:	O
Here	O
","	O
we	O
investigated	O
TCF	O
-	O
4	O
isoforms	O
(	O
TCF	O
-	O
4J	O
and	O
K	O
)-	O
responsive	O
target	O
genes	O
that	O
are	O
important	O
in	O
hepatic	B-Disease
oncogenesis	I-Disease
and	O
tumour	B-Disease
development	O
.	O
	
METHODS	O
:	O
Gene	O
expression	O
microarray	O
was	O
performed	O
on	O
HCC	B-Disease
cells	O
overexpressing	O
TCF	O
-	O
4J	O
and	O
K	O
isoforms	O
.	O
	
Expression	O
level	O
of	O
selected	O
target	O
genes	O
was	O
evaluated	O
and	O
correlations	O
were	O
made	O
between	O
their	O
expression	O
level	O
and	O
that	O
of	O
TCF	O
-	O
4	O
isoform	O
in	O
47	O
pairs	O
of	O
human	O
HCC	B-Disease
tumours	I-Disease
.	O
	
RESULTS	O
:	O
Comparison	O
by	O
gene	O
expression	O
microarray	O
revealed	O
that	O
447	O
genes	O
were	O
upregulated	O
and	O
343	O
downregulated	O
more	O
than	O
2	O
.	O
0	O
-	O
fold	O
in	O
TCF	O
-	O
4J	O
compared	O
with	O
TCF	O
-	O
4K	O
expressing	O
cells	O
.	O
	
We	O
validated	O
expression	O
of	O
18	O
selected	O
target	O
genes	O
involved	O
in	O
Wnt	O
/	O
beta	O
-	O
catenin	O
","	O
insulin	O
/	O
IGF	O
-	O
1	O
/	O
IRS1	O
and	O
Notch	O
signalling	O
pathways	O
in	O
47	O
pairs	O
of	O
human	O
HCCs	B-Disease
and	O
adjacent	O
uninvolved	O
liver	O
tissues	O
.	O
	
It	O
was	O
observed	O
that	O
13	O
genes	O
(	O
CLDN2	O
","	O
STK17B	O
","	O
SPP1	O
","	O
AXIN2	O
","	O
WISP2	O
","	O
MMP7	O
","	O
IRS1	O
","	O
ANXA1	O
","	O
CAMK2N1	O
","	O
ASPH	O
","	O
GPR56	O
","	O
CD24	O
and	O
JAG1	O
)	O
activated	O
by	O
TCF	O
-	O
4J	O
isoform	O
in	O
HCC	B-Disease
cells	O
","	O
were	O
also	O
upregulated	O
in	O
HCC	B-Disease
tumours	I-Disease
compared	O
with	O
adjacent	O
peritumour	O
tissue	O
;	O
more	O
importantly	O
","	O
10	O
genes	O
exhibited	O
a	O
significant	O
correlation	O
with	O
the	O
TCF	O
-	O
4J	O
expression	O
level	O
in	O
tumour	B-Disease
.	O
	
CONCLUSION	O
:	O
TCF	O
-	O
4	O
isoforms	O
(	O
TCF	O
-	O
4J	O
and	O
K	O
)	O
activated	O
different	O
downstream	O
target	O
genes	O
in	O
HCC	B-Disease
.	O
	
The	O
biological	O
consequence	O
of	O
TCF	O
-	O
4J	O
isoform	O
expression	O
was	O
upregulation	O
of	O
genes	O
associated	O
with	O
tripartite	O
Wnt	O
/	O
beta	O
-	O
catenin	O
","	O
insulin	O
/	O
IGF	O
-	O
1	O
/	O
IRS1	O
and	O
Notch	O
signal	O
transduction	O
pathway	O
activation	O
","	O
which	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
HCC	B-Disease
.	O
	
15991002	
Nicotine	O
antagonizes	O
caffeine	O
-	O
but	O
not	O
pentylenetetrazole	O
-	O
induced	O
anxiogenic	B-Disease
effect	I-Disease
in	O
mice	O
.	O
	
RATIONALE	O
:	O
Nicotine	O
and	O
caffeine	O
are	O
widely	O
consumed	O
licit	O
psychoactive	O
drugs	O
worldwide	O
.	O
	
Epidemiological	O
studies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O
	
Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
","	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	B-Disease
responses	O
.	O
	
OBJECTIVES	O
:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	O
on	O
anxiety	B-Disease
induced	O
by	O
caffeine	O
and	O
another	O
anxiogenic	O
drug	O
","	O
pentylenetetrazole	O
","	O
in	O
mice	O
.	O
	
The	O
elevated	O
plus	O
-	O
maze	O
(	O
EPM	O
)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	B-Disease
.	O
	
METHODS	O
:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	O
(	O
0	O
.	O
5	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.)	O
	
or	O
saline	O
10	O
min	O
before	O
caffeine	O
(	O
70	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.)	O
	
or	O
pentylenetetrazole	O
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.)	O
	
injections	O
.	O
	
After	O
15	O
min	O
","	O
mice	O
were	O
evaluated	O
for	O
their	O
open	O
-	O
and	O
closed	O
-	O
arm	O
time	O
and	O
entries	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
session	O
.	O
	
Locomotor	O
activity	O
was	O
recorded	O
for	O
individual	O
groups	O
by	O
using	O
the	O
same	O
treatment	O
protocol	O
with	O
the	O
EPM	O
test	O
.	O
	
RESULTS	O
:	O
Nicotine	O
(	O
0	O
.	O
5	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
","	O
whereas	O
caffeine	O
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	O
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenic	B-Disease
effect	I-Disease
","	O
apparent	O
with	O
decreases	O
in	O
open	O
-	O
arm	O
time	O
and	O
entry	O
.	O
	
Nicotine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine	O
-	O
but	O
not	O
pentylenetetrazole	O
-	O
induced	O
anxiety	B-Disease
.	O
	
Administration	O
of	O
each	O
drug	O
and	O
their	O
combinations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomotor	O
activity	O
.	O
	
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	O
on	O
caffeine	O
-	O
induced	O
anxiety	B-Disease
is	O
specific	O
to	O
caffeine	O
","	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiolytic	O
effect	O
.	O
	
Thus	O
","	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	O
and	O
caffeine	O
.	O
	
16565833	
The	O
influence	O
of	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
doxorubicin	O
administration	O
on	O
the	O
protection	O
against	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B-Disease
in	O
mice	O
.	O
	
PURPOSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
cardiotoxicity	B-Disease
","	O
the	O
anthracyclin	O
doxorubicin	O
(	O
DOX	O
)	O
continues	O
to	O
be	O
an	O
effective	O
and	O
widely	O
used	O
chemotherapeutic	O
agent	O
.	O
	
DOX	O
-	O
induced	O
cardiac	B-Disease
damage	I-Disease
presumably	O
results	O
from	O
the	O
formation	O
of	O
free	O
radicals	O
by	O
DOX	O
.	O
	
Reactive	O
oxygen	O
species	O
particularly	O
affect	O
the	O
cardiac	O
myocytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
antioxidant	O
defense	O
system	O
.	O
	
The	O
semisynthetic	O
flavonoid	O
monohydroxyethylrutoside	O
(	O
monoHER	O
)	O
showed	O
cardioprotection	O
against	O
DOX	O
-	O
induced	O
cardiotoxicity	B-Disease
through	O
its	O
radical	O
scavenging	O
and	O
iron	O
chelating	O
properties	O
.	O
	
Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
life	O
of	O
monoHER	O
(	O
about	O
30	O
min	O
"),"	O
it	O
is	O
expected	O
that	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
DOX	O
might	O
be	O
of	O
influence	O
on	O
the	O
cardioprotective	O
effect	O
of	O
monoHER	O
.	O
	
Therefore	O
","	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
this	O
possible	O
effect	O
.	O
	
METHODS	O
:	O
Six	O
groups	O
of	O
6	O
BALB	O
/	O
c	O
mice	O
were	O
treated	O
with	O
saline	O
","	O
DOX	O
alone	O
or	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.)	O
	
preceded	O
by	O
monoHER	O
(	O
500	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.)	O
	
with	O
an	O
interval	O
of	O
10	O
","	O
30	O
","	O
60	O
or	O
120	O
min	O
.	O
	
After	O
a	O
6	O
-	O
week	O
treatment	O
period	O
and	O
additional	O
observation	O
for	O
2	O
weeks	O
","	O
the	O
mice	O
were	O
sacrificed	O
.	O
	
Their	O
cardiac	O
tissues	O
were	O
processed	O
for	O
light	O
microscopy	O
","	O
after	O
which	O
cardiomyocyte	B-Disease
damage	I-Disease
was	O
evaluated	O
according	O
to	O
Billingham	O
(	O
in	O
Cancer	O
Treat	O
Rep	O
62	O
(	O
6	O
):	O
865	O
-	O
872	O
","	O
1978	O
).	O
	
Microscopic	O
evaluation	O
revealed	O
that	O
treatment	O
with	O
DOX	O
alone	O
induced	O
significant	O
cardiac	B-Disease
damage	I-Disease
in	O
comparison	O
to	O
the	O
saline	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O
	
RESULTS	O
:	O
The	O
number	O
of	O
damaged	O
cardiomyocytes	O
was	O
9	O
.	O
6	O
-	O
fold	O
(	O
95	O
%	O
CI	O
4	O
.	O
4	O
-	O
21	O
.	O
0	O
)	O
higher	O
in	O
mice	O
treated	O
with	O
DOX	O
alone	O
than	O
that	O
in	O
animals	O
of	O
the	O
control	O
group	O
.	O
	
The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	O
treated	O
with	O
DOX	O
preceded	O
by	O
monoHER	O
and	O
those	O
in	O
mice	O
treated	O
with	O
saline	O
ranged	O
from	O
1	O
.	O
6	O
to	O
2	O
.	O
8	O
(	O
mean	O
2	O
.	O
2	O
","	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
4	O
.	O
1	O
","	O
P	O
=	O
0	O
.	O
19	O
).	O
	
The	O
mean	O
protective	O
effect	O
by	O
adding	O
monoHER	O
before	O
DOX	O
led	O
to	O
a	O
significant	O
4	O
.	O
4	O
-	O
fold	O
reduction	O
(	O
P	O
<	O
0	O
.	O
1	O
","	O
95	O
%	O
CI	O
2	O
.	O
3	O
-	O
8	O
.	O
2	O
)	O
of	O
abnormal	O
cardiomyocytes	O
.	O
	
This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
time	O
interval	O
between	O
monoHER	O
and	O
DOX	O
administration	O
(	O
P	O
=	O
0	O
.	O
345	O
).	O
	
CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
in	O
an	O
outpatient	O
clinical	O
setting	O
monoHER	O
may	O
be	O
administered	O
shortly	O
before	O
DOX	O
.	O
	
16680561	
Pharmacokinetics	O
of	O
desipramine	O
HCl	O
when	O
administered	O
with	O
cinacalcet	O
HCl	O
.	O
	
OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	O
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O
	
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	O
on	O
CYP2D6	O
activity	O
","	O
using	O
desipramine	O
as	O
a	O
probe	O
substrate	O
","	O
in	O
healthy	O
subjects	O
.	O
	
METHODS	O
:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
","	O
open	O
-	O
label	O
","	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	O
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasions	O
","	O
once	O
alone	O
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	O
(	O
90	O
mg	O
for	O
7	O
days	O
).	O
	
Blood	O
samples	O
were	O
obtained	O
predose	O
and	O
up	O
to	O
72	O
h	O
postdose	O
.	O
	
RESULTS	O
:	O
Fourteen	O
subjects	O
completed	O
both	O
treatment	O
arms	O
.	O
	
Relative	O
to	O
desipramine	O
alone	O
","	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
desipramine	O
increased	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
coadministered	O
with	O
cinacalcet	O
.	O
	
The	O
t	O
(	O
1	O
/	O
2	O
","	O
z	O
)	O
of	O
desipramine	O
was	O
longer	O
when	O
desipramine	O
was	O
coadministered	O
with	O
cinacalcet	O
(	O
21	O
.	O
0	O
versus	O
43	O
.	O
3	O
hs	O
).	O
	
The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regimens	O
.	O
	
Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	O
alone	O
than	O
when	O
receiving	O
desipramine	O
with	O
cinacalcet	O
(	O
33	O
versus	O
86	O
"%),"	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	B-Disease
and	O
headache	B-Disease
)	O
have	O
been	O
reported	O
for	O
patients	O
treated	O
with	O
either	O
desipramine	O
or	O
cinacalcet	O
.	O
	
CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
cinacalcet	O
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6	O
.	O
	
These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	O
","	O
dose	O
adjustment	O
may	O
be	O
necessary	O
for	O
drugs	O
that	O
demonstrate	O
a	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
CYP2D6	O
.	O
	
16867021	
Antipsychotic	O
-	O
like	O
profile	O
of	O
thioperamide	O
","	O
a	O
selective	O
H3	O
-	O
receptor	O
antagonist	O
in	O
mice	O
.	O
	
Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B-Disease
.	O
	
The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	O
H	O
(	O
3	O
)-	O
receptor	O
ligands	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	B-Disease
","	O
apomorphine	O
-	O
induced	O
climbing	O
behavior	O
and	O
amphetamine	O
-	O
induced	O
locomotor	O
activities	O
in	O
mice	O
.	O
	
Catalepsy	B-Disease
was	O
induced	O
by	O
haloperidol	O
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
	
"),"	O
while	O
apomorphine	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.)	O
	
and	O
amphetamine	O
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.)	O
	
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities	O
","	O
respectively	O
.	O
	
(	O
R	O
)-	O
alpha	O
-	O
methylhistamine	O
(	O
RAMH	O
)	O
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.)	O
	
and	O
thioperamide	O
(	O
THP	O
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
	
"),"	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	B-Disease
.	O
	
Administration	O
of	O
THP	O
(	O
3	O
.	O
75	O
","	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.)	O
	
1	O
h	O
prior	O
to	O
haloperidol	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
catalepsy	B-Disease
times	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
However	O
","	O
pretreatment	O
with	O
RAMH	O
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.).	O
	
RAMH	O
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
","	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.)	O
	
per	O
se	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O
	
On	O
amphetamine	O
-	O
induced	O
hyperactivity	B-Disease
","	O
THP	O
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.)	O
	
reduced	O
locomotor	O
time	O
","	O
distance	O
traveled	O
and	O
average	O
speed	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
Pretreatment	O
with	O
RAMH	O
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.)	O
	
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	O
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.).	O
	
Climbing	O
behavior	O
induced	O
by	O
apomorphine	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	O
.	O
	
Such	O
an	O
effect	O
was	O
","	O
however	O
","	O
reversed	O
in	O
presence	O
of	O
RAMH	O
.	O
	
THP	O
exhibited	O
an	O
antipsychotic	O
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	O
-	O
induced	O
catalepsy	B-Disease
","	O
reducing	O
amphetamine	O
-	O
induced	O
hyperactivity	B-Disease
and	O
reducing	O
apomorphine	O
-	O
induced	O
climbing	O
in	O
mice	O
.	O
	
Such	O
effects	O
of	O
THP	O
were	O
reversed	O
by	O
RAMH	O
indicating	O
the	O
involvement	O
of	O
histamine	O
H	O
(	O
3	O
)-	O
receptors	O
.	O
	
Findings	O
suggest	O
a	O
potential	O
for	O
H	O
(	O
3	O
)-	O
receptor	O
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B-Disease
.	O
	
17042884	
Placebo	O
-	O
level	O
incidence	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
with	O
quetiapine	O
in	O
controlled	O
studies	O
of	O
patients	O
with	O
bipolar	B-Disease
mania	I-Disease
.	O
	
OBJECTIVES	O
:	O
To	O
evaluate	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
"),"	O
including	O
akathisia	B-Disease
","	O
with	O
quetiapine	O
in	O
patients	O
with	O
bipolar	B-Disease
mania	I-Disease
.	O
	
METHODS	O
:	O
Data	O
were	O
analyzed	O
from	O
four	O
similarly	O
designed	O
","	O
randomized	O
","	O
double	O
-	O
blind	O
","	O
3	O
-	O
to	O
12	O
-	O
week	O
studies	O
.	O
	
Two	O
studies	O
evaluated	O
quetiapine	O
monotherapy	O
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
(	O
n	O
=	O
209	O
)	O
versus	O
placebo	O
(	O
n	O
=	O
198	O
"),"	O
with	O
lithium	O
or	O
haloperidol	O
monotherapy	O
as	O
respective	O
active	O
controls	O
.	O
	
Two	O
studies	O
evaluated	O
quetiapine	O
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
in	O
combination	O
with	O
a	O
mood	O
stabilizer	O
(	O
lithium	O
or	O
divalproex	O
","	O
QTP	O
+	O
Li	O
/	O
DVP	O
)	O
(	O
n	O
=	O
196	O
)	O
compared	O
to	O
placebo	O
and	O
mood	O
stabilizer	O
(	O
PBO	O
+	O
Li	O
/	O
DVP	O
)	O
(	O
n	O
=	O
203	O
).	O
	
Extrapyramidal	B-Disease
symptoms	I-Disease
were	O
evaluated	O
using	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
(	O
SAS	O
"),"	O
the	O
Barnes	O
Akathisia	O
Rating	O
Scale	O
(	O
BARS	O
"),"	O
adverse	O
event	O
reports	O
and	O
anticholinergic	O
drug	O
usage	O
.	O
	
RESULTS	O
:	O
The	O
incidence	O
of	O
EPS	B-Disease
-	O
related	O
adverse	O
events	O
","	O
including	O
akathisia	B-Disease
","	O
was	O
no	O
different	O
with	O
quetiapine	O
monotherapy	O
(	O
12	O
.	O
9	O
%)	O
than	O
with	O
placebo	O
(	O
13	O
.	O
1	O
%).	O
	
Similarly	O
","	O
EPS	B-Disease
-	O
related	O
adverse	O
events	O
with	O
QTP	O
+	O
Li	O
/	O
DVP	O
(	O
21	O
.	O
4	O
%)	O
were	O
no	O
different	O
than	O
with	O
PBO	O
+	O
Li	O
/	O
DVP	O
(	O
19	O
.	O
2	O
%).	O
	
Adverse	O
events	O
related	O
to	O
EPS	B-Disease
occurred	O
in	O
59	O
.	O
6	O
%	O
of	O
patients	O
treated	O
with	O
haloperidol	O
(	O
n	O
=	O
99	O
)	O
monotherapy	O
","	O
whereas	O
26	O
.	O
5	O
%	O
of	O
patients	O
treated	O
with	O
lithium	O
(	O
n	O
=	O
98	O
)	O
monotherapy	O
experienced	O
adverse	O
events	O
related	O
to	O
EPS	B-Disease
.	O
	
The	O
incidence	O
of	O
akathisia	B-Disease
was	O
low	O
and	O
similar	O
with	O
quetiapine	O
monotherapy	O
(	O
3	O
.	O
3	O
%)	O
and	O
placebo	O
(	O
6	O
.	O
1	O
"%),"	O
and	O
with	O
QTP	O
+	O
Li	O
/	O
DVP	O
(	O
3	O
.	O
6	O
%)	O
and	O
PBO	O
+	O
Li	O
/	O
DVP	O
(	O
4	O
.	O
9	O
%).	O
	
Lithium	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
of	O
tremor	B-Disease
(	O
18	O
.	O
4	O
%)	O
than	O
quetiapine	O
(	O
5	O
.	O
6	O
%);	O
cerebellar	O
tremor	B-Disease
","	O
which	O
is	O
a	O
known	O
adverse	O
effect	O
of	O
lithium	O
","	O
may	O
have	O
contributed	O
to	O
the	O
elevated	O
rate	O
of	O
tremor	B-Disease
in	O
patients	O
receiving	O
lithium	O
therapy	O
.	O
	
Haloperidol	O
induced	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0	O
.	O
1	O
)	O
of	O
akathisia	B-Disease
(	O
33	O
.	O
3	O
%	O
versus	O
5	O
.	O
9	O
"%),"	O
tremor	B-Disease
(	O
30	O
.	O
3	O
%	O
versus	O
7	O
.	O
8	O
"%),"	O
and	O
extrapyramidal	B-Disease
syndrome	I-Disease
(	O
35	O
.	O
4	O
%	O
versus	O
5	O
.	O
9	O
%)	O
than	O
quetiapine	O
.	O
	
No	O
significant	O
differences	O
were	O
observed	O
between	O
quetiapine	O
and	O
placebo	O
on	O
SAS	O
and	O
BARS	O
scores	O
.	O
	
Anticholinergic	O
use	O
was	O
low	O
and	O
similar	O
with	O
quetiapine	O
or	O
placebo	O
.	O
	
CONCLUSIONS	O
:	O
In	O
bipolar	B-Disease
mania	I-Disease
","	O
the	O
incidence	O
of	O
EPS	B-Disease
","	O
including	O
akathisia	B-Disease
","	O
with	O
quetiapine	O
therapy	O
is	O
similar	O
to	O
that	O
with	O
placebo	O
.	O
	
17151160	
Randomized	O
comparison	O
of	O
olanzapine	O
versus	O
risperidone	O
for	O
the	O
treatment	O
of	O
first	O
-	O
episode	O
schizophrenia	B-Disease
:	O
4	O
-	O
month	O
outcomes	O
.	O
	
OBJECTIVE	O
:	O
The	O
authors	O
compared	O
4	O
-	O
month	O
treatment	O
outcomes	O
for	O
olanzapine	O
versus	O
risperidone	O
in	O
patients	O
with	O
first	O
-	O
episode	O
schizophrenia	B-Disease
spectrum	O
disorders	O
.	O
	
METHOD	O
:	O
One	O
hundred	O
twelve	O
subjects	O
(	O
70	O
%	O
male	O
;	O
mean	O
age	O
=	O
23	O
.	O
3	O
years	O
[	O
SD	O
=	O
5	O
.	O
1	O
])	O
with	O
first	O
-	O
episode	O
schizophrenia	B-Disease
(	O
75	O
"%),"	O
schizophreniform	B-Disease
disorder	I-Disease
(	O
17	O
"%),"	O
or	O
schizoaffective	B-Disease
disorder	I-Disease
(	O
8	O
%)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	O
(	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
risperidone	O
(	O
1	O
-	O
6	O
mg	O
/	O
day	O
).	O
	
RESULTS	O
:	O
Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	O
(	O
43	O
.	O
7	O
"%,"	O
95	O
%	O
CI	O
=	O
28	O
.	O
8	O
%-	O
58	O
.	O
6	O
%)	O
and	O
risperidone	O
(	O
54	O
.	O
3	O
"%,"	O
95	O
%	O
CI	O
=	O
39	O
.	O
9	O
%-	O
68	O
.	O
7	O
%).	O
	
Among	O
those	O
responding	O
to	O
treatment	O
","	O
more	O
subjects	O
in	O
the	O
olanzapine	O
group	O
(	O
40	O
.	O
9	O
"%,"	O
95	O
%	O
CI	O
=	O
16	O
.	O
8	O
%-	O
65	O
.	O
0	O
%)	O
than	O
in	O
the	O
risperidone	O
group	O
(	O
18	O
.	O
9	O
"%,"	O
95	O
%	O
CI	O
=	O
0	O
%-	O
39	O
.	O
2	O
%)	O
had	O
subsequent	O
ratings	O
not	O
meeting	O
response	O
criteria	O
.	O
	
Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	B-Disease
and	O
akathisia	B-Disease
did	O
not	O
differ	O
between	O
medications	O
.	O
	
Extrapyramidal	B-Disease
symptom	I-Disease
severity	O
scores	O
were	O
1	O
.	O
4	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
with	O
risperidone	O
and	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
)	O
with	O
olanzapine	O
.	O
	
Significantly	O
more	O
weight	B-Disease
gain	I-Disease
occurred	O
with	O
olanzapine	O
than	O
with	O
risperidone	O
:	O
the	O
increase	O
in	O
weight	O
at	O
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
.	O
2	O
%-	O
20	O
.	O
5	O
%)	O
with	O
olanzapine	O
and	O
11	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
8	O
.	O
4	O
%-	O
14	O
.	O
3	O
%)	O
with	O
risperidone	O
.	O
	
Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24	O
.	O
3	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanzapine	O
and	O
23	O
.	O
9	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95	O
%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
risperidone	O
.	O
	
CONCLUSIONS	O
:	O
Clinical	O
outcomes	O
with	O
risperidone	O
were	O
equal	O
to	O
those	O
with	O
olanzapine	O
","	O
and	O
response	O
may	O
be	O
more	O
stable	O
.	O
	
Olanzapine	O
may	O
have	O
an	O
advantage	O
for	O
motor	O
side	O
effects	O
.	O
	
Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	B-Disease
gain	I-Disease
","	O
but	O
weight	B-Disease
gain	I-Disease
was	O
greater	O
with	O
olanzapine	O
.	O
	
17255138	
Risks	O
and	O
benefits	O
of	O
COX	O
-	O
2	O
inhibitors	O
vs	O
non	O
-	O
selective	O
NSAIDs	O
:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit	O
?	O
	
A	O
retrospective	O
cohort	O
study	O
.	O
	
OBJECTIVES	O
:	O
The	O
risk	O
of	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
(	O
AMI	B-Disease
)	O
with	O
COX	O
-	O
2	O
inhibitors	O
may	O
offset	O
their	O
gastrointestinal	O
(	O
GI	O
)	O
benefit	O
compared	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
).	O
	
We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	B-Disease
and	O
GI	B-Disease
bleeding	I-Disease
among	O
elderly	O
patients	O
using	O
COX	O
-	O
2	O
inhibitors	O
","	O
NS	O
-	O
NSAIDs	O
and	O
acetaminophen	O
.	O
	
METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	O
or	O
acetaminophen	O
during	O
1999	O
-	O
2002	O
.	O
	
Outcomes	O
were	O
compared	O
using	O
Cox	O
regression	O
models	O
with	O
time	O
-	O
dependent	O
exposures	O
.	O
	
RESULTS	O
:	O
Person	O
-	O
years	O
of	O
exposure	O
among	O
non	O
-	O
users	O
of	O
aspirin	O
were	O
:	O
75	O
","	O
761	O
to	O
acetaminophen	O
","	O
42	O
","	O
671	O
to	O
rofecoxib	O
65	O
","	O
860	O
to	O
celecoxib	O
","	O
and	O
37	O
","	O
495	O
to	O
NS	O
-	O
NSAIDs	O
.	O
	
Among	O
users	O
of	O
aspirin	O
","	O
they	O
were	O
:	O
14	O
","	O
671	O
to	O
rofecoxib	O
","	O
22	O
","	O
875	O
to	O
celecoxib	O
","	O
9	O
","	O
832	O
to	O
NS	O
-	O
NSAIDs	O
and	O
38	O
","	O
48	O
to	O
acetaminophen	O
.	O
	
Among	O
non	O
-	O
users	O
of	O
aspirin	O
","	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI	B-Disease
/	O
GI	O
vs	O
the	O
acetaminophen	O
(	O
with	O
no	O
aspirin	O
)	O
group	O
were	O
:	O
rofecoxib	O
1	O
.	O
27	O
(	O
1	O
.	O
13	O
","	O
1	O
.	O
42	O
"),"	O
celecoxib	O
0	O
.	O
93	O
(	O
0	O
.	O
83	O
","	O
1	O
.	O
3	O
"),"	O
naproxen	O
1	O
.	O
59	O
(	O
1	O
.	O
31	O
","	O
1	O
.	O
93	O
"),"	O
diclofenac	O
1	O
.	O
17	O
(	O
0	O
.	O
99	O
","	O
1	O
.	O
38	O
)	O
and	O
ibuprofen	O
1	O
.	O
5	O
(	O
0	O
.	O
74	O
","	O
1	O
.	O
51	O
).	O
	
Among	O
users	O
of	O
aspirin	O
","	O
they	O
were	O
:	O
rofecoxib	O
1	O
.	O
73	O
(	O
1	O
.	O
52	O
","	O
1	O
.	O
98	O
"),"	O
celecoxib	O
1	O
.	O
34	O
(	O
1	O
.	O
19	O
","	O
1	O
.	O
52	O
"),"	O
ibuprofen	O
1	O
.	O
51	O
(	O
0	O
.	O
95	O
","	O
2	O
.	O
41	O
"),"	O
diclofenac	O
1	O
.	O
69	O
(	O
1	O
.	O
35	O
","	O
2	O
.	O
10	O
"),"	O
naproxen	O
1	O
.	O
35	O
(	O
0	O
.	O
97	O
","	O
1	O
.	O
88	O
)	O
and	O
acetaminophen	O
1	O
.	O
29	O
(	O
1	O
.	O
17	O
","	O
1	O
.	O
42	O
).	O
	
CONCLUSION	O
:	O
Among	O
non	O
-	O
users	O
of	O
aspirin	O
","	O
naproxen	O
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	B-Disease
/	O
GI	B-Disease
bleeding	I-Disease
.	O
	
The	O
AMI	B-Disease
/	O
GI	B-Disease
toxicity	I-Disease
of	O
celecoxib	O
was	O
similar	O
to	O
that	O
of	O
acetaminophen	O
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	O
and	O
NS	O
-	O
NSAIDs	O
.	O
	
Among	O
users	O
of	O
aspirin	O
","	O
both	O
celecoxib	O
and	O
naproxen	O
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O
	
17297207	
Quinine	O
-	O
induced	O
arrhythmia	B-Disease
in	O
a	O
patient	O
with	O
severe	B-Disease
malaria	I-Disease
.	O
	
It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	B-Disease
malaria	I-Disease
patient	O
with	O
jaundice	B-Disease
who	O
presented	O
with	O
arrhythmia	B-Disease
(	O
premature	B-Disease
ventricular	I-Disease
contraction	I-Disease
)	O
while	O
getting	O
quinine	O
infusion	O
was	O
reported	O
.	O
	
A	O
man	O
","	O
25	O
years	O
old	O
","	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	B-Disease
","	O
chill	B-Disease
","	O
vomiting	B-Disease
","	O
jaundice	B-Disease
.	O
	
The	O
patient	O
was	O
fully	O
conscious	O
","	O
blood	O
pressure	O
120	O
/	O
80	O
mmHg	O
","	O
pulse	O
rate	O
100	O
x	O
/	O
minute	O
","	O
regular	O
.	O
	
On	O
admission	O
","	O
laboratory	O
examination	O
showed	O
Plasmodium	O
falciparum	O
"(++++),"	O
total	O
bilirubin	O
8	O
.	O
25	O
mg	O
/	O
dL	O
","	O
conjugated	O
bilirubin	O
4	O
.	O
36	O
mg	O
/	O
dL	O
","	O
unconjugated	O
bilirubin	O
3	O
.	O
89	O
mg	O
/	O
dL	O
","	O
potassium	O
3	O
.	O
52	O
meq	O
/	O
L	O
Patient	O
was	O
diagnosed	O
as	O
severe	B-Disease
malaria	I-Disease
with	O
jaundice	B-Disease
and	O
got	O
quinine	O
infusion	O
in	O
dextrose	O
5	O
%	O
500	O
mg	O
/	O
8	O
hour	O
.	O
	
On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	B-Disease
","	O
diarrhea	B-Disease
","	O
tinnitus	B-Disease
","	O
loss	B-Disease
of	I-Disease
hearing	I-Disease
.	O
	
After	O
30	O
hours	O
of	O
quinine	O
infusion	O
the	O
patient	O
felt	O
palpitation	B-Disease
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	B-Disease
ventricular	I-Disease
contraction	I-Disease
(	O
PVC	B-Disease
)	O
>	O
5	O
x	O
/	O
minute	O
","	O
trigemini	O
","	O
constant	O
type	O
--	O
sinoatrial	B-Disease
block	I-Disease
","	O
positive	O
U	O
wave	O
.	O
	
He	O
was	O
treated	O
with	O
lidocaine	O
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	O
5	O
%/	O
24	O
hour	O
and	O
potassium	O
aspartate	O
tablet	O
.	O
	
Quinine	O
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	O
tablets	O
.	O
	
Three	O
hours	O
later	O
the	O
patient	O
felt	O
better	O
","	O
the	O
frequency	O
of	O
PVC	B-Disease
reduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
","	O
potassium	O
level	O
was	O
3	O
.	O
34	O
meq	O
/	O
L	O
.	O
	
He	O
was	O
discharged	O
on	O
7th	O
day	O
in	O
good	O
condition	O
.	O
	
Quinine	O
","	O
like	O
quinidine	O
","	O
is	O
a	O
chincona	O
alkaloid	O
that	O
has	O
anti	O
-	O
arrhythmic	B-Disease
property	O
","	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	B-Disease
that	O
can	O
cause	O
various	O
arrhythmias	B-Disease
","	O
including	O
severe	O
arrhythmia	B-Disease
such	O
as	O
multiple	O
PVC	B-Disease
.	O
	
Administration	O
of	O
parenteral	O
quinine	O
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro	O
-	O
arrhythmic	B-Disease
effect	O
","	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	B-Disease
diseases	I-Disease
or	O
patients	O
with	O
electrolyte	B-Disease
disorder	I-Disease
(	O
hypokalemia	B-Disease
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	B-Disease
and	O
or	O
diarrhea	B-Disease
in	O
malaria	B-Disease
cases	O
.	O
	
17384765	
Succimer	O
chelation	O
improves	O
learning	O
","	O
attention	O
","	O
and	O
arousal	O
regulation	O
in	O
lead	O
-	O
exposed	O
rats	O
but	O
produces	O
lasting	O
cognitive	B-Disease
impairment	I-Disease
in	O
the	O
absence	O
of	O
lead	O
exposure	O
.	O
	
BACKGROUND	O
:	O
There	O
is	O
growing	O
pressure	O
for	O
clinicians	O
to	O
prescribe	O
chelation	O
therapy	O
at	O
only	O
slightly	O
elevated	O
blood	O
lead	O
levels	O
.	O
	
However	O
","	O
very	O
few	O
studies	O
have	O
evaluated	O
whether	O
chelation	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	O
-	O
exposed	O
children	O
","	O
or	O
whether	O
these	O
agents	O
have	O
adverse	O
effects	O
that	O
may	O
affect	O
brain	O
development	O
in	O
the	O
absence	O
of	O
Pb	O
exposure	O
.	O
	
OBJECTIVES	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
answer	O
these	O
questions	O
","	O
using	O
a	O
rodent	O
model	O
of	O
early	O
childhood	O
Pb	O
exposure	O
and	O
treatment	O
with	O
succimer	O
","	O
a	O
widely	O
used	O
chelating	O
agent	O
for	O
the	O
treatment	O
of	O
Pb	B-Disease
poisoning	I-Disease
.	O
	
RESULTS	O
:	O
Pb	O
exposure	O
produced	O
lasting	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
","	I-Disease
attention	I-Disease
","	I-Disease
inhibitory	I-Disease
control	I-Disease
","	I-Disease
and	I-Disease
arousal	I-Disease
regulation	I-Disease
","	O
paralleling	O
the	O
areas	O
of	O
dysfunction	O
seen	O
in	O
Pb	O
-	O
exposed	O
children	O
.	O
	
Succimer	O
treatment	O
of	O
the	O
Pb	O
-	O
exposed	O
rats	O
significantly	O
improved	O
learning	O
","	O
attention	O
","	O
and	O
arousal	O
regulation	O
","	O
although	O
the	O
efficacy	O
of	O
the	O
treatment	O
varied	O
as	O
a	O
function	O
of	O
the	O
Pb	O
exposure	O
level	O
and	O
the	O
specific	O
functional	O
deficit	O
.	O
	
In	O
contrast	O
","	O
succimer	O
treatment	O
of	O
rats	O
not	O
previously	O
exposed	O
to	O
Pb	O
produced	O
lasting	O
and	O
pervasive	O
cognitive	B-Disease
and	I-Disease
affective	I-Disease
dysfunction	I-Disease
comparable	O
in	O
magnitude	O
to	O
that	O
produced	O
by	O
the	O
higher	O
Pb	O
exposure	O
regimen	O
.	O
	
CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
data	O
","	O
to	O
our	O
knowledge	O
","	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	B-Disease
deficits	I-Disease
due	O
to	O
Pb	O
exposure	O
.	O
	
These	O
findings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
succimer	O
treatment	O
protocol	O
that	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	O
-	O
exposed	O
children	O
.	O
	
However	O
","	O
they	O
also	O
suggest	O
that	O
succimer	O
treatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
children	O
who	O
do	O
not	O
have	O
elevated	O
tissue	O
levels	O
of	O
Pb	O
or	O
other	O
heavy	O
metals	O
.	O
	
17608141	
Attenuation	O
of	O
methamphetamine	O
-	O
induced	O
nigrostriatal	O
dopaminergic	O
neurotoxicity	B-Disease
in	O
mice	O
by	O
lipopolysaccharide	O
pretreatment	O
.	O
	
Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	B-Disease
terminal	I-Disease
damage	I-Disease
.	O
	
In	O
this	O
study	O
","	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	O
","	O
a	O
pro	O
-	O
inflammatory	B-Disease
and	O
inflammatory	B-Disease
factor	O
","	O
treatment	O
in	O
modulating	O
the	O
methamphetamine	O
-	O
induced	O
nigrostriatal	O
dopamine	O
neurotoxicity	B-Disease
.	O
	
Lipopolysaccharide	O
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine	O
-	O
elicited	O
hyperthermia	B-Disease
three	O
days	O
later	O
.	O
	
Such	O
systemic	O
lipopolysaccharide	O
treatment	O
mitigated	O
methamphetamine	O
-	O
induced	O
striatal	O
dopamine	O
and	O
3	O
","	O
4	O
-	O
dihydroxyphenylacetic	O
acid	O
depletions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
	
As	O
the	O
most	O
potent	O
dose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	O
was	O
administered	O
two	O
weeks	O
","	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	O
dosing	O
regimen	O
","	O
methamphetamine	O
-	O
induced	O
striatal	O
dopamine	O
and	O
3	O
","	O
4	O
-	O
dihydroxyphenylacetic	O
acid	O
depletions	O
remained	O
unaltered	O
.	O
	
Moreover	O
","	O
systemic	O
lipopolysaccharide	O
pretreatment	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenuated	O
local	O
methamphetamine	O
infusion	O
-	O
produced	O
dopamine	O
and	O
3	O
","	O
4	O
-	O
dihydroxyphenylacetic	O
acid	O
depletions	O
in	O
the	O
striatum	O
","	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	O
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	O
.	O
	
We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	O
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine	O
-	O
induced	O
nigrostriatal	O
dopamine	O
neurotoxicity	B-Disease
.	O
	
18162529	
Hypothalamic	O
prolactin	O
receptor	O
messenger	O
ribonucleic	O
acid	O
levels	O
","	O
prolactin	O
signaling	O
","	O
and	O
hyperprolactinemic	B-Disease
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	O
.	O
	
Hyperprolactinemia	B-Disease
can	O
reduce	O
fertility	O
and	O
libido	O
.	O
	
Although	O
central	O
prolactin	O
actions	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
","	O
the	O
mechanisms	O
are	O
poorly	O
understood	O
.	O
	
We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	B-Disease
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility	O
:	O
pulsatile	O
LH	O
secretion	O
and	O
the	O
estrogen	O
-	O
induced	O
LH	O
surge	O
.	O
	
Chronic	O
hyperprolactinemia	B-Disease
induced	O
by	O
the	O
dopamine	O
antagonist	O
sulpiride	O
caused	O
a	O
40	O
%	O
reduction	O
LH	O
pulse	O
frequency	O
in	O
ovariectomized	O
rats	O
","	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	O
.	O
	
Sulpiride	O
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid	O
-	O
induced	O
LH	O
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge	O
.	O
	
Estradiol	O
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	O
receptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
components	O
of	O
prolactin	O
'	O
s	O
signaling	O
pathway	O
.	O
	
To	O
test	O
the	O
hypothesis	O
that	O
estrogen	O
increases	O
PRL	O
-	O
R	O
expression	O
and	O
sensitivity	O
to	O
prolactin	O
","	O
we	O
next	O
demonstrated	O
that	O
estradiol	O
greatly	O
augments	O
prolactin	O
-	O
induced	O
STAT5	O
activation	O
.	O
	
Lastly	O
","	O
we	O
measured	O
PRL	O
-	O
R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
-	O
1	O
and	O
-	O
3	O
and	O
CIS	O
","	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	O
signaling	O
)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	O
and	O
estradiol	O
.	O
	
Sulpiride	O
induced	O
only	O
SOCS	O
-	O
1	O
in	O
the	O
medial	O
preoptic	O
area	O
","	O
where	O
GnRH	O
neurons	O
are	O
regulated	O
","	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus	O
","	O
PRL	O
-	O
R	O
","	O
SOCS	O
-	O
3	O
","	O
and	O
CIS	O
mRNA	O
levels	O
were	O
also	O
induced	O
.	O
	
Estradiol	O
enhanced	O
these	O
effects	O
on	O
SOCS	O
-	O
3	O
and	O
CIS	O
.	O
	
Interestingly	O
","	O
estradiol	O
also	O
induced	O
PRL	O
-	O
R	O
","	O
SOCS	O
-	O
3	O
","	O
and	O
CIS	O
mRNA	O
levels	O
independently	O
.	O
	
These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	B-Disease
in	O
a	O
steroid	O
-	O
dependent	O
manner	O
.	O
	
They	O
also	O
provide	O
evidence	O
for	O
estradiol	O
-	O
dependent	O
and	O
brain	O
region	O
-	O
specific	O
regulation	O
of	O
PRL	O
-	O
R	O
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	O
.	O
	
18308784	
Ginsenoside	O
Rg1	O
restores	O
the	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
induced	O
by	O
chronic	O
morphine	O
administration	O
in	O
rats	O
.	O
	
Rg1	O
","	O
as	O
a	O
ginsenoside	O
extracted	O
from	O
Panax	O
ginseng	O
","	O
could	O
ameliorate	O
spatial	O
learning	B-Disease
impairment	I-Disease
.	O
	
Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	O
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	O
on	O
learning	B-Disease
impairment	I-Disease
by	O
chronic	O
morphine	O
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect	O
.	O
	
Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
","	O
and	O
Rg1	O
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	O
once	O
a	O
day	O
for	O
10	O
days	O
.	O
	
Spatial	O
learning	O
capacity	O
was	O
assessed	O
in	O
the	O
Morris	O
water	O
maze	O
.	O
	
The	O
results	O
showed	O
that	O
rats	O
treated	O
with	O
Morphine	O
/	O
Rg1	O
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	O
.	O
	
By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo	O
","	O
the	O
results	O
showed	O
that	O
Rg1	O
restored	O
the	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
impaired	O
by	O
morphine	O
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats	O
.	O
	
The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	O
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	O
treated	O
with	O
morphine	O
","	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline	O
-	O
or	O
morphine	O
/	O
Rg1	O
-	O
treated	O
rats	O
;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
antagonist	O
MK801	O
.	O
	
We	O
conclude	O
that	O
Rg1	O
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	O
administration	O
and	O
restore	O
the	O
morphine	O
-	O
inhibited	O
LTP	O
.	O
	
This	O
effect	O
is	O
NMDA	O
receptor	O
dependent	O
.	O
	
18951540	
Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa	O
-	O
induced	O
dyskinesias	B-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
In	O
a	O
placebo	O
-	O
controlled	O
","	O
single	O
-	O
blinded	O
","	O
crossover	O
study	O
","	O
we	O
assessed	O
the	O
effect	O
of	O
"	186	187	O	
real	O
"	191	192	O	
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
"	252	253	O	
sham	O
"	257	258	O	
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
).	O
	
Ten	O
patients	O
with	O
PD	B-Disease
and	O
prominent	O
dyskinesias	B-Disease
had	O
rTMS	O
(	O
1	O
","	O
800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
","	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O
	
Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician	O
-	O
assessed	O
dyskinesia	B-Disease
severity	O
.	O
	
However	O
","	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	B-Disease
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo	O
.	O
	
The	O
major	O
effect	O
was	O
on	O
dystonia	B-Disease
subscore	O
.	O
	
Similarly	O
","	O
in	O
patient	O
diaries	O
","	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	B-Disease
scores	O
during	O
the	O
days	O
of	O
intervention	O
","	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only	O
.	O
	
Following	O
rTMS	O
","	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	B-Disease
symptoms	O
were	O
noted	O
.	O
	
The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low	O
-	O
frequency	O
rTMS	O
on	O
dyskinesias	B-Disease
in	O
PD	B-Disease
.	O
	
The	O
effects	O
may	O
be	O
further	O
exploited	O
for	O
potential	O
therapeutic	O
uses	O
.	O
	
19759529	
The	O
glycine	O
transporter	O
-	O
1	O
inhibitor	O
SSR103800	O
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	O
.	O
	
Schizophrenia	B-Disease
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	O
neurotransmission	O
.	O
	
However	O
","	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
produce	O
schizophrenic	B-Disease
-	O
like	O
symptoms	O
in	O
humans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	O
receptor	O
.	O
	
As	O
a	O
result	O
","	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	O
receptor	O
.	O
	
Among	O
them	O
are	O
glycine	O
transporter	O
-	O
1	O
(	O
GlyT1	O
)	O
inhibitors	O
such	O
as	O
SSR103800	O
","	O
which	O
indirectly	O
enhance	O
NMDA	O
receptor	O
function	O
by	O
increasing	O
the	O
glycine	O
(	O
a	O
co	O
-	O
agonist	O
for	O
the	O
NMDA	O
receptor	O
)	O
levels	O
in	O
the	O
synapse	O
.	O
	
This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	O
","	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B-Disease
","	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
","	O
amphetamine	O
and	O
MK	O
-	O
801	O
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
","	O
NMDA	O
Nr1	O
(	O
neo	O
-/-)	O
and	O
DAT	O
(-/-)).	O
	
Results	O
showed	O
that	O
SSR103800	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.)	O
	
blocked	O
hyperactivity	B-Disease
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	O
receptor	O
antagonist	O
","	O
MK	O
-	O
801	O
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	B-Disease
of	O
NMDA	O
Nr1	O
(	O
neo	O
-/-)	O
mice	O
.	O
	
In	O
contrast	O
","	O
SSR103800	O
failed	O
to	O
affect	O
hyperactivity	B-Disease
induced	O
by	O
amphetamine	O
or	O
naturally	O
observed	O
in	O
dopamine	O
transporter	O
(	O
DAT	O
(-/-))	O
knockout	O
mice	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.).	O
	
Importantly	O
","	O
both	O
classical	O
(	O
haloperidol	O
)	O
and	O
atypical	O
(	O
olanzapine	O
","	O
clozapine	O
and	O
aripiprazole	O
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	B-Disease
.	O
	
However	O
","	O
unlike	O
these	O
latter	O
","	O
SSR103800	O
did	O
not	O
produce	O
catalepsy	B-Disease
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
	
Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	O
inhibitor	O
","	O
SSR103800	O
","	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
","	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	O
system	O
","	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O
	
19914299	
Fluoxetine	O
improves	O
the	O
memory	B-Disease
deficits	I-Disease
caused	O
by	O
the	O
chemotherapy	O
agent	O
5	O
-	O
fluorouracil	O
.	O
	
Cancer	B-Disease
patients	O
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition	O
.	O
	
A	O
widely	O
used	O
chemotherapeutic	O
agent	O
","	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
"),"	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function	O
.	O
	
In	O
particular	O
this	O
anti	O
mitotic	O
drug	O
could	O
reduce	O
cell	O
proliferation	O
in	O
the	O
neurogenic	O
regions	O
of	O
the	O
adult	O
brain	O
.	O
	
In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	O
antidepressant	O
Fluoxetine	O
.	O
	
In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5	O
-	O
FU	O
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	O
either	O
separately	O
or	O
in	O
combination	O
with	O
5	O
-	O
FU	O
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats	O
.	O
	
Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5	O
-	O
FU	O
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O
	
A	O
separate	O
group	O
of	O
animals	O
was	O
tested	O
using	O
a	O
hippocampal	O
dependent	O
spatial	O
working	O
memory	O
test	O
","	O
the	O
object	O
location	O
recognition	O
test	O
(	O
OLR	O
).	O
	
Animals	O
treated	O
only	O
with	O
5	O
-	O
FU	O
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	O
improved	O
their	O
performance	O
.	O
	
5	O
-	O
FU	O
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls	O
.	O
	
This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	O
was	O
co	O
administered	O
with	O
5	O
-	O
FU	O
.	O
	
Fluoxetine	O
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour	O
.	O
	
These	O
findings	O
suggest	O
that	O
5	O
-	O
FU	O
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	O
.	O
	
20195852	
Risk	O
of	O
nephropathy	B-Disease
after	O
consumption	O
of	O
nonionic	O
contrast	O
media	O
by	O
children	O
undergoing	O
cardiac	O
angiography	O
:	O
a	O
prospective	O
study	O
.	O
	
Despite	O
increasing	O
reports	O
on	O
nonionic	O
contrast	O
media	O
-	O
induced	O
nephropathy	B-Disease
(	O
CIN	B-Disease
)	O
in	O
hospitalized	O
adult	O
patients	O
during	O
cardiac	O
procedures	O
","	O
the	O
studies	O
in	O
pediatrics	O
are	O
limited	O
","	O
with	O
even	O
less	O
focus	O
on	O
possible	O
predisposing	O
factors	O
and	O
preventive	O
measures	O
for	O
patients	O
undergoing	O
cardiac	O
angiography	O
.	O
	
This	O
prospective	O
study	O
determined	O
the	O
incidence	O
of	O
CIN	B-Disease
for	O
two	O
nonionic	O
contrast	O
media	O
(	O
CM	O
"),"	O
iopromide	O
and	O
iohexol	O
","	O
among	O
80	O
patients	O
younger	O
than	O
18	O
years	O
and	O
compared	O
the	O
rates	O
for	O
this	O
complication	O
in	O
relation	O
to	O
the	O
type	O
and	O
dosage	O
of	O
CM	O
and	O
the	O
presence	O
of	O
cyanosis	B-Disease
.	O
	
The	O
80	O
patients	O
in	O
the	O
study	O
consecutively	O
received	O
either	O
iopromide	O
(	O
group	O
A	O
","	O
n	O
=	O
40	O
)	O
or	O
iohexol	O
(	O
group	O
B	O
","	O
n	O
=	O
40	O
).	O
	
Serum	O
sodium	O
(	O
Na	O
"),"	O
potassium	O
(	O
K	O
"),"	O
and	O
creatinine	O
(	O
Cr	O
)	O
were	O
measured	O
24	O
h	O
before	O
angiography	O
as	O
baseline	O
values	O
","	O
then	O
measured	O
again	O
at	O
12	O
"-,"	O
24	O
"-,"	O
and	O
48	O
-	O
h	O
intervals	O
after	O
CM	O
use	O
.	O
	
Urine	O
samples	O
for	O
Na	O
and	O
Cr	O
also	O
were	O
checked	O
at	O
the	O
same	O
intervals	O
.	O
	
Risk	O
of	O
renal	B-Disease
failure	I-Disease
","	O
Injury	B-Disease
to	I-Disease
the	I-Disease
kidney	I-Disease
","	O
Failure	B-Disease
of	I-Disease
kidney	I-Disease
function	I-Disease
","	O
Loss	B-Disease
of	I-Disease
kidney	I-Disease
function	I-Disease
","	O
and	O
End	O
-	O
stage	O
renal	B-Disease
damage	I-Disease
(	O
RIFLE	O
criteria	O
)	O
were	O
used	O
to	O
define	O
CIN	B-Disease
and	O
its	O
incidence	O
in	O
the	O
study	O
population	O
.	O
	
Accordingly	O
","	O
among	O
the	O
15	O
CIN	B-Disease
patients	O
(	O
18	O
.	O
75	O
"%),"	O
7	O
.	O
5	O
%	O
of	O
the	O
patients	O
in	O
group	O
A	O
had	O
increased	O
risk	O
and	O
3	O
.	O
75	O
%	O
had	O
renal	B-Disease
injury	I-Disease
","	O
whereas	O
5	O
%	O
of	O
group	O
B	O
had	O
increased	O
risk	O
and	O
2	O
.	O
5	O
%	O
had	O
renal	B-Disease
injury	I-Disease
.	O
	
Whereas	O
33	O
.	O
3	O
%	O
of	O
the	O
patients	O
with	O
CIN	B-Disease
were	O
among	O
those	O
who	O
received	O
the	O
proper	O
dosage	O
of	O
CM	O
","	O
the	O
percentage	O
increased	O
to	O
66	O
.	O
6	O
%	O
among	O
those	O
who	O
received	O
larger	O
doses	O
","	O
with	O
a	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
CIN	B-Disease
related	O
to	O
the	O
different	O
dosages	O
of	O
CM	O
(	O
p	O
=	O
0	O
.	O
14	O
).	O
	
Among	O
the	O
15	O
patients	O
with	O
CIN	B-Disease
","	O
6	O
had	O
cyanotic	O
congenital	B-Disease
heart	I-Disease
diseases	I-Disease
","	O
but	O
the	O
incidence	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
for	O
the	O
noncyanotic	O
patients	O
(	O
p	O
=	O
0	O
.	O
243	O
).	O
	
Although	O
clinically	O
silent	O
","	O
CIN	B-Disease
is	O
not	O
rare	O
in	O
pediatrics	O
.	O
	
The	O
incidence	O
depends	O
on	O
dosage	O
but	O
not	O
on	O
the	O
type	O
of	O
consumed	O
nonionic	O
CM	O
","	O
nor	O
on	O
the	O
presence	O
of	O
cyanosis	B-Disease
","	O
and	O
although	O
CIN	B-Disease
usually	O
is	O
reversible	O
","	O
more	O
concern	O
is	O
needed	O
for	O
the	O
prevention	O
of	O
such	O
a	O
complication	O
in	O
children	O
.	O
	
20621845	
Elevation	O
of	O
ADAM10	O
","	O
ADAM17	O
","	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	O
-	O
induced	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
in	O
a	O
rat	O
model	O
.	O
	
PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
(	O
TAA	B-Disease
)	O
by	O
calcium	O
chloride	O
(	O
CaCl	O
(	O
2	O
))-	O
induced	O
arterial	B-Disease
injury	I-Disease
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
"),"	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B-Disease
formation	O
.	O
	
METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
was	O
exposed	O
to	O
0	O
.	O
5M	O
CaCl	O
(	O
2	O
)	O
or	O
normal	O
saline	O
(	O
NaCl	O
).	O
	
After	O
12weeks	O
","	O
animals	O
were	O
euthanized	O
","	O
and	O
CaCl	O
(	O
2	O
)-	O
treated	O
","	O
CaCl	O
(	O
2	O
)-	O
untreated	O
(	O
n	O
=	O
12	O
)	O
and	O
NaCl	O
-	O
treated	O
aortic	O
segments	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O
	
MMP	O
-	O
TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
semi	O
-	O
quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O
	
RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl	O
(	O
2	O
)-	O
treated	O
","	O
non	O
-	O
CaCl	O
(	O
2	O
)-	O
treated	O
and	O
NaCl	O
-	O
treated	O
segments	O
","	O
aneurymal	O
alteration	O
(	O
n	O
=	O
6	O
","	O
50	O
"%),"	O
media	O
degeneration	O
with	O
regional	O
disruption	O
","	O
fragmentation	O
of	O
elastic	O
fiber	O
","	O
and	O
increased	O
collagen	O
deposition	O
(	O
n	O
=	O
12	O
","	O
100	O
%)	O
were	O
demonstrated	O
in	O
CaCl	O
(	O
2	O
)-	O
treated	O
segments	O
.	O
	
MMP	O
-	O
2	O
","	O
MMP	O
-	O
9	O
","	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl	O
(	O
2	O
)-	O
treated	O
segments	O
(	O
all	O
p	O
<	O
0	O
.	O
1	O
"),"	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl	O
(	O
2	O
)-	O
untreated	O
segments	O
","	O
as	O
compared	O
with	O
NaCl	O
-	O
treated	O
segments	O
.	O
	
Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP	O
-	O
2	O
","	O
MMP	O
-	O
9	O
","	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
(	O
all	O
p	O
<	O
0	O
.	O
1	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl	O
(	O
2	O
)-	O
treated	O
segments	O
.	O
	
TIMP	O
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments	O
.	O
	
CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	B-Disease
model	O
by	O
periarterial	O
CaCl	O
(	O
2	O
)	O
exposure	O
in	O
rats	O
","	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP	O
-	O
2	O
","	O
MMP	O
-	O
9	O
","	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O
	
23872883	
Biochemical	O
effects	O
of	O
Solidago	O
virgaurea	O
extract	O
on	O
experimental	O
cardiotoxicity	B-Disease
.	O
	
Cardiovascular	B-Disease
diseases	I-Disease
(	O
CVDs	B-Disease
)	O
are	O
the	O
major	O
health	O
problem	O
of	O
advanced	O
as	O
well	O
as	O
developing	O
countries	O
of	O
the	O
world	O
.	O
	
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	O
virgaurea	O
extract	O
on	O
isoproterenol	O
-	O
induced	O
cardiotoxicity	B-Disease
in	O
rats	O
.	O
	
The	O
subcutaneous	O
injection	O
of	O
isoproterenol	O
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
","	O
for	O
two	O
consecutive	O
days	O
","	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	O
dehydrogenase	O
","	O
creatine	O
phosphokinase	O
","	O
alanine	O
transaminase	O
","	O
aspartate	O
transaminase	O
","	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
activities	O
","	O
total	O
cholesterol	O
","	O
triglycerides	O
","	O
free	O
serum	O
fatty	O
acid	O
","	O
cardiac	O
tissue	O
malondialdehyde	O
(	O
MDA	O
"),"	O
and	O
nitric	O
oxide	O
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	O
and	O
superoxide	O
dismutase	O
in	O
cardiac	O
tissue	O
as	O
compared	O
to	O
the	O
normal	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
Pretreatment	O
with	O
S	O
.	O
virgaurea	O
extract	O
for	O
5	O
weeks	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isoproterenol	O
injection	O
significantly	O
prevented	O
the	O
observed	O
alterations	O
.	O
	
Captopril	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
","	O
given	O
orally	O
"),"	O
an	O
inhibitor	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
used	O
as	O
a	O
standard	O
cardioprotective	O
drug	O
","	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
study	O
.	O
	
The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S	O
.	O
virgaurea	O
extract	O
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	O
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol	O
-	O
treated	O
rats	O
.	O
	
The	O
study	O
emphasizes	O
the	O
beneficial	O
action	O
of	O
S	O
.	O
virgaurea	O
extract	O
as	O
a	O
cardioprotective	O
agent	O
.	O
	
24333387	
Glial	O
activation	O
and	O
post	O
-	O
synaptic	O
neurotoxicity	B-Disease
:	O
the	O
key	O
events	O
in	O
Streptozotocin	O
(	O
ICV	O
)	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
rats	O
.	O
	
In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	B-Disease
in	O
ICV	O
Streptozotocin	O
(	O
STZ	O
)	O
induced	O
memory	B-Disease
impaired	I-Disease
rats	O
was	O
explored	O
.	O
	
In	O
experiment	O
set	O
up	O
1	O
:	O
Memory	B-Disease
deficit	I-Disease
was	O
found	O
in	O
Morris	O
water	O
maze	O
test	O
on	O
14	O
-	O
16	O
days	O
after	O
STZ	O
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
administration	O
.	O
	
STZ	O
causes	O
increased	O
expression	O
of	O
GFAP	O
","	O
CD11b	O
and	O
TNF	O
-	O
a	O
indicating	O
glial	O
activation	O
and	O
neuroinflammation	B-Disease
.	O
	
STZ	O
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS	O
","	O
nitrite	O
","	O
Ca	O
(	O
2	O
+)	O
and	O
reduced	O
the	O
mitochondrial	O
activity	O
in	O
synaptosomal	O
preparation	O
illustrating	O
free	O
radical	O
generation	O
and	O
excitotoxicity	B-Disease
.	O
	
Increased	O
expression	O
and	O
activity	O
of	O
Caspase	O
-	O
3	O
was	O
also	O
observed	O
in	O
STZ	O
treated	O
rat	O
which	O
specify	O
apoptotic	O
cell	O
death	O
in	O
hippocampus	O
and	O
cortex	O
.	O
	
STZ	O
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	O
and	O
PSD	O
-	O
95	O
","	O
while	O
","	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(	O
synaptophysin	O
and	O
SNAP	O
-	O
25	O
)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	B-Disease
.	O
	
Oral	O
treatment	O
with	O
Memantine	O
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuprofen	O
(	O
50	O
mg	O
/	O
kg	O
)	O
daily	O
for	O
13	O
days	O
attenuated	O
STZ	O
induced	O
glial	O
activation	O
","	O
apoptotic	O
cell	O
death	O
and	O
post	O
synaptic	O
neurotoxicity	B-Disease
in	O
rat	O
brain	O
.	O
	
Further	O
","	O
in	O
experiment	O
set	O
up	O
2	O
:	O
where	O
memory	O
function	O
was	O
not	O
affected	O
i	O
.	O
e	O
.	O
	
7	O
-	O
9	O
days	O
after	O
STZ	O
treatment	O
.	O
	
The	O
level	O
of	O
GFAP	O
","	O
CD11b	O
","	O
TNF	O
-	O
a	O
","	O
ROS	O
and	O
nitrite	O
levels	O
were	O
increased	O
.	O
	
On	O
the	O
other	O
hand	O
","	O
apoptotic	O
marker	O
","	O
synaptic	O
markers	O
","	O
mitochondrial	O
activity	O
and	O
Ca	O
(	O
2	O
+)	O
levels	O
remained	O
unaffected	O
.	O
	
Collective	O
data	O
indicates	O
that	O
neuroinflammatory	B-Disease
process	O
and	O
oxidative	O
stress	O
occurs	O
earlier	O
to	O
apoptosis	O
and	O
does	O
not	O
affect	O
memory	O
function	O
.	O
	
Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	B-Disease
are	O
the	O
key	O
factors	O
in	O
STZ	O
induced	O
memory	B-Disease
impairment	I-Disease
and	O
neuronal	O
cell	O
death	O
.	O
	
24438483	
Pre	O
-	O
treatment	O
of	O
bupivacaine	O
-	O
induced	O
cardiovascular	B-Disease
depression	I-Disease
using	O
different	O
lipid	O
formulations	O
of	O
propofol	O
.	O
	
BACKGROUND	O
:	O
Pre	O
-	O
treatment	O
with	O
lipid	O
emulsions	O
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	O
","	O
and	O
the	O
lipid	O
content	O
of	O
propofol	O
may	O
alleviate	O
bupivacaine	O
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	O
in	O
intralipid	O
or	O
medialipid	O
emulsions	O
on	O
bupivacaine	O
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
METHODS	O
:	O
Rats	O
were	O
anaesthetised	O
with	O
ketamine	O
and	O
were	O
given	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
min	O
propofol	O
in	O
intralipid	O
(	O
Group	O
P	O
"),"	O
propofol	O
in	O
medialipid	O
(	O
Group	O
L	O
"),"	O
or	O
saline	O
(	O
Group	O
C	O
)	O
over	O
20	O
min	O
.	O
	
Thereafter	O
","	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacaine	O
0	O
.	O
5	O
%	O
was	O
infused	O
.	O
	
We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	B-Disease
occurrence	O
","	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reduction	O
of	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	O
pressure	O
","	O
and	O
time	O
to	O
asystole	B-Disease
and	O
total	O
amount	O
of	O
bupivacaine	O
consumption	O
.	O
	
Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	B-Disease
.	O
	
RESULTS	O
:	O
The	O
time	O
to	O
first	O
dysrhythmia	B-Disease
occurrence	O
","	O
time	O
to	O
25	O
%	O
and	O
50	O
%	O
reductions	O
in	O
HR	O
","	O
and	O
time	O
to	O
asystole	B-Disease
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
groups	O
.	O
	
The	O
cumulative	O
bupivacaine	O
dose	O
given	O
at	O
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P	O
.	O
Plasma	O
bupivacaine	O
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C	O
.	O
Bupivacaine	O
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C	O
.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
treatment	O
with	O
propofol	O
in	O
intralipid	O
","	O
compared	O
with	O
propofol	O
in	O
medialipid	O
or	O
saline	O
","	O
delayed	O
the	O
onset	O
of	O
bupivacaine	O
-	O
induced	O
cardiotoxic	B-Disease
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	O
levels	O
.	O
	
Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	O
levels	O
of	O
propofol	O
in	O
medialipid	O
and	O
adapt	O
these	O
results	O
to	O
clinical	O
practice	O
.	O
	
25119790	
Curcumin	O
prevents	O
maleate	O
-	O
induced	O
nephrotoxicity	B-Disease
:	O
relation	O
to	O
hemodynamic	O
alterations	O
","	O
oxidative	O
stress	O
","	O
mitochondrial	O
oxygen	O
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I	O
.	O
	
The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	O
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
days	O
)	O
against	O
the	O
renal	B-Disease
injury	I-Disease
induced	O
by	O
maleate	O
was	O
evaluated	O
.	O
	
Tubular	O
proteinuria	B-Disease
and	O
oxidative	O
stress	O
were	O
induced	O
by	O
a	O
single	O
injection	O
of	O
maleate	O
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
rats	O
.	O
	
Maleate	O
-	O
induced	O
renal	B-Disease
injury	I-Disease
included	O
increase	O
in	O
renal	O
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein	O
","	O
glucose	O
","	O
sodium	O
","	O
neutrophil	O
gelatinase	O
-	O
associated	O
lipocalin	O
(	O
NGAL	O
)	O
and	O
N	O
-	O
acetyl	O
b	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
"),"	O
upregulation	O
of	O
kidney	O
injury	O
molecule	O
(	O
KIM	O
)-	O
1	O
","	O
decrease	O
in	O
renal	O
blood	O
flow	O
and	O
claudin	O
-	O
2	O
expression	O
besides	O
of	O
necrosis	B-Disease
and	I-Disease
apoptosis	I-Disease
of	I-Disease
tubular	I-Disease
cells	I-Disease
on	O
24	O
h	O
.	O
Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	O
and	O
proteins	O
and	O
diminution	O
in	O
renal	O
Nrf2	O
levels	O
.	O
	
Studies	O
were	O
also	O
conducted	O
in	O
renal	O
epithelial	O
LLC	O
-	O
PK1	O
cells	O
and	O
in	O
mitochondria	O
isolated	O
from	O
kidneys	O
of	O
all	O
the	O
experimental	O
groups	O
.	O
	
Maleate	O
induced	O
cell	O
damage	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
in	O
LLC	O
-	O
PK1	O
cells	O
in	O
culture	O
.	O
	
In	O
addition	O
","	O
maleate	O
treatment	O
reduced	O
oxygen	O
consumption	O
in	O
ADP	O
-	O
stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate	O
/	O
glutamate	O
as	O
substrate	O
.	O
	
The	O
activities	O
of	O
both	O
complex	O
I	O
and	O
aconitase	O
were	O
also	O
diminished	O
.	O
	
All	O
the	O
above	O
-	O
described	O
alterations	O
were	O
prevented	O
by	O
curcumin	O
.	O
	
It	O
is	O
concluded	O
that	O
curcumin	O
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate	O
-	O
induced	O
nephropathy	B-Disease
and	O
in	O
vitro	O
cell	O
damage	O
.	O
	
The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	O
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I	O
","	O
and	O
the	O
in	O
vitro	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
ROS	O
production	O
.	O
